UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
For the fiscal year ended December 31, 2014
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________ to _____________
Commission file number: 0-11635
PHOTOMEDEX, INC.FC GLOBAL REALTY INCORPORATED
(Exact name of registrant as specified in its charter)
Nevada | 59-2058100 | ||||||
| (State or Other Jurisdiction | (I.R.S. Employer | ||||||
| of incorporation or | Identification No.) | ||||||
100 Lakeside Drive,40 Ramland Road South, Suite 100, Horsham, Pennsylvania 19044200 Orangeburg, NY 10962
(Address of principal executive offices, including zip code)
(215) 619-3600
(Issuer'sIssuer’s telephone number, including area code)
Securities registered under Section 12(b) of the Exchange Act:
| Name of each exchange | |||||
| Title of each class | on which registered | ||||
| Common Stock | Nasdaq Capital Market, TASE | ||||
Securities registered under Section 12(g) of the Exchange Act:
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes☐ No [X]
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.
Yes☐ No [X]
Indicate by check mark whether the registrant: (i) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (ii) has been subject to such filing requirements for the past 90 days.
Yes [X]☒ No [__]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes [X]☒ No [__]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or emerging growth company. See the definitions of "large“large accelerated filer," "accelerated filer"” “accelerated filer,” “smaller reporting company,” and "smaller reporting company"“emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large Accelerated Filer ☐ | Accelerated | Filer ☐ | |
| Non-Accelerated Filer ☐ (Do not check if a smaller reporting company) | |||
Smaller reporting company | ☒ Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes []☐ No [X]
As of June 30, 2014, was 19,049,582 shares. The2017 (the last business day of the registrant’s most recently completed second fiscal quarter), the aggregate market value of the shares of the registrant’s common stock held by non-affiliates (11,790,039 shares), based on(based upon the closing marketsale price ($12.25)of such shares as reported on The Nasdaq Capital Market) was approximately $4.9 million. Shares of the registrant’s common stock asheld by each executive officer and director and by each person who owns 10% or more of June 30, 2014, was $144,427,978.
As of March 13, 2015,30, 2018, the number of shares outstanding of our common stock was 11,868,619.
22,101,718DOCUMENTS INCORPORATED BY REFERENCE. The closing market price of our common stock as of March 13, 2015 was $1.70.
None.
Table of Contents
| Part I | Page  | |||
| 3 | ||||
| Item 1A. | Risk Factors | |||
| Item 1B. | ||||
| Item 2. | ||||
| Item 3. | ||||
| Item 4 | ||||
| Item 5. | ||||
31 | ||||
| Item 6. | Selected Financial Data | |||
| Item 7. | ||||
| Item 7A. | ||||
| Item 8. | ||||
| Item 9. | ||||
| Item 9A. | ||||
| Item 9B. | ||||
| Item 10. | ||||
42 | ||||
| Item 11. | Executive Compensation | |||
| Item 12. | ||||
| Item 13. | ||||
| Item 14. | ||||
| Item 15. | ||||
56 | ||||
| 60 |
| i |
INTRODUCTORY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Use of Terms
Except as otherwise indicated by the context and for the purposes of this report only, references in this Annual Report on Form 10-K,report to “we,” “our” and “our company” refer to FC Global Realty Incorporated (Formerly: PhotoMedex, Inc.), a Nevada corporation, and its consolidated subsidiaries.
Special Note Regarding Forward Looking Statements
This report and the other materials we have filed or this Report, are "forward-looking statements." Thesewill file with the U.S. Securities and Exchange Commission, or the SEC, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including, but not limited to, statements regarding our business strategy, expectations and plans regarding our future operations and our future financial position. When used in this report or in the other materials we have filed or will file with the SEC, the words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “indicate,” “seek,” “project,” “plan,” “could,” “should” or “would” and similar expressions are intended to identify forward-looking statements. Among the factors that could cause or contribute to material differences between our actual results and those indicated from the forward-looking statements are risks and uncertainties inherent in our business, including, but not limited to:
| ● | our ability to successfully integrate the acquired real estate business; |
| ● | our ability to retain key employees; |
| ● | demand fluctuations in the real estate industry; |
| ● | adverse changes in economic conditions in markets where our real estate investments may be made; |
| ● | possible decreases in the market value of our future real estate investments; |
| ● | our ability to obtain adequate financing to fund our future property acquisitions and project developments; |
| ● | the possibility that we may not recover our advance costs in each real estate development project; |
| ● | our reliance on subcontractors to construct each property, and on building supply companies to provide components for each property’s construction; |
| ● | competition in the real estate industry; |
| ● | the possibility that legal challenges or governmental regulations may delay the start or completion of construction on our projected real estate ventures, increase our expenses, or limit our construction activities; |
| ● | the potential for increased costs or shortages of labor or components, or other circumstances beyond our control; |
| ● | our ability to continue as a going-concern; |
| ● | our ability to raise capital when needed; |
| ● | economic, political or other developments in foreign countries in which we do business; |
| ● | the international nature of our business; and |
| ● | results of existing or future litigation. |
Additional factors that could cause or contribute to such differences include, but are not limited to, statements about the plans, objectives, expectations and intentions of PhotoMedex, Inc., a Nevada corporation, (referred tothose discussed in this Report as "we," "us," "our", "registrant" or "the Company")report, and other statements contained in this Report that are not historical facts. Forward-looking statements in this Report or hereafter includedparticular, the risks discussed under Item 1A. “Risk Factors” and those discussed in other publicly available documents filedwe file with the Securities and Exchange Commission, or the Commission, reportsSEC. Except as required by law, we do not intend to our stockholders and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. When used in this Report, the words "will, " "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate" and similar expressions are generally intended to identify forward-looking statements, becauseupdate these forward-looking statements involve risks and uncertainties. There are important factors that could causepublicly or to update the reasons actual results tocould differ materially from those expressed or implied byanticipated in these forward-looking statements, including our plans, objectives, expectations and intentions and other factors discussed under "Risk Factors." We undertake no obligation to update such forward-looking statements. These forward-looking statements include, but are not limited to, statements about:
Stock Split
On September 7, 2016, we completed a 1-for-5 reverse stock split of our outstanding common stock. Accordingly, all share and per share information contained in this report has been restated to retroactively show the forward-looking statements,effect of that stock split.
| ii |
| ITEM 1. | BUSINESS. |
Our Company
Our company, founded in 1980, is transitioning from its former business as a skin health company to a company focused on real estate development and asset management, concentrating primarily on investments in high quality income producing assets, hotel and resort developments, residential developments and other opportunistic commercial properties.
Until the recent sale of our consumer products division, we were a global skin health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. Starting in 2014, we began to sell off certain business units and product lines and on January 23, 2017, we sold the last remaining major product line. Following this transaction, we had only minimal operations and assets remaining, of immaterial value to our company. We are in the process of liquidating the remaining legacy inventory and assets of this business line, after which speaktime we will no longer operate within the skin health business.
Following the Contribution Transaction described below, our focus is to build our company into a leading real estate, asset management and development company concentrating primarily on investments in high yield income producing assets and other opportunistic commercial properties via direct property ownership and asset management. Our objective is to generate long term net asset value growth while adhering to institutional best practices and a deep research process for all investments.
For income producing properties, we intend to acquire assets that provide recurring income with the potential for income growth over the long-term. We believe there can be an attractive risk/reward profile to such properties based on the location and the underlying creditworthiness of the tenants. We intend to use such income generation to fund additional acquisitions and development opportunities and general corporate purposes. In addition, we intend to invest in land assets that can be developed into income generating properties or properties for sale. We believe that our size and scale provide an opportunity to take advantage of smaller-tier assets that most traditional investors do not focus on due to size limitations, thus creating unique investment opportunities. In particular, we intend to target assets in secondary and tertiary markets that require minimal capital expenditures but generate initial unlevered cash flow yields that are higher than those in primary markets.
A second component of our investment strategy will revolve around sourcing asset management opportunities for which we would operate as an asset manager of real estate properties. We are not structured as a Real Estate Investment Trust “REIT”, thus we have the ability to retain earnings and to operate in real estate asset management, development and peripheral real estate activities, items that may be limited by REIT requirements. We will look to utilize our existing infrastructure to provide economies of scale to owners of real estate assets as we grow our portfolio over time.
Recent Developments
Contribution Transaction
On March 31, 2017, we entered into an Interest Contribution Agreement with First Capital Real Estate Operating Partnership, L.P., or the Contributor, First Capital Real Estate Trust Incorporated, or the Contributor Parent (the Contributor and the Contributor Parent are sometimes referred to in this report as the Contributor Parties), and FC Global Realty Operating Partnership, LLC, our wholly-owned subsidiary, or the Acquiror. The parties entered into amendments to the Interest Contribution Agreement on August 3, 2017, October 11, 2017 and December 22, 2017. Pursuant to the Interest Contribution Agreement, as amended (which we collectively refer to as the Contribution Agreement), the Contributor contributed certain real estate assets to the Acquiror. In exchange, the Contributor received shares of our common stock and newly designated Series A Convertible Preferred Stock as described below. We refer to this transaction as the Contribution Transaction.
On May 17, 2017 (referred to in this report as the Closing Date), the Contributor transferred $10 million of assets to the Acquiror, consisting of the following:
| ● | three vacant land sites intended for development as gas stations located in northern California, |
| ● | a 75% interest in a limited liability company that owns a vacant land site intended for development as a gas station, located in northern California; and |
| ● | a 100% interest in a limited liability company, which we refer to as the Avalon Interest, which owns a 17.9133% interest in a limited liability company called Avalon Jubilee LLC that owns property located in Los Lunas, New Mexico being developed as a single family residential development. As described below, the Contributor Parent agreed to transfer the Avalon Interest within 30 days following the Closing Date. |
Pursuant to the terms and conditions of an Agreement to Waive Closing Deliverables, dated as of May 17, 2017, the Contributor agreed to deliver the Avalon Interest to the Acquiror, in up to two installments, on or before the thirtieth (30th) calendar day following the Closing Date. The transfer of both installments of the Avalon Interest was completed on June 26, 2017. Notwithstanding that the Contributor did not complete the transfer of the Avalon Interest to the Acquiror on the Closing Date, the parties agreed that the Acquiror would be entitled to all economic benefits of ownership of the Avalon Interest from and after the date of the Closing Date.
On January 12, 2018, we received a copy of a complaint, dated November 17, 2017, that was filed by Alpha Alpha, LLC in the Thirteenth Judicial District Court in the County of Valencia in the State of New Mexico against Avalon Jubilee, LLC, the holding company that owns the property in Los Lunas, New Mexico, HiTex, LLC, MCBB, LLC, Land Strategies, LLC, Ronald R. Cobb and John Does 1 – 5. The suit asks the court to, among other things, determine whether there have been unauthorized transfers of interest in Avalon Jubilee LLC; and declare who are the holders of interests in Avalon Jubilee LLC. Although the complaint does not name our company or any of its subsidiaries or specifically question our interest in Avalon Jubilee LLC, it raises questions about whether the transfers of interest leading to our acquisition of our interest in Avalon Jubilee LLC were properly made in accordance with the Avalon Jubilee operating agreement. We have begun an internal investigation into this matter and will disclose the results of that investigation once it has been completed. Although neither our company nor any of its subsidiaries is a party to litigation regarding this matter, we recognized an impairment expense of $862 thousand to account for our estimate of the impact that such litigation may have on the operations and fair value of the underlying asset.
The proposed gas station sites are located in Atwater and Merced, California and had an agreed upon value of $2.6 million. We intend to explore our options for the development of these properties. We may (i) lease a property to a developer who will handle all further development of the property, with our company receiving monthly lease payments from the developer; (ii) engage a contractor to develop a property to a certain level, then lease it to a developer which will handle the final development and leasing of the property, with our company receiving monthly payments from the developer; or (iii) engage a contractor to completely develop a property, then lease it directly to a tenant who will remit monthly lease payments back to us. The option or options selected for these properties will depend upon the types of tenants interested in operating gas stations and/or related ventures on those properties, as well as our capitalization and available financial resources. In these arrangements, the construction and/or management of the properties are or will be handled by third-party firms which specialize in such work. Therefore, we anticipate that we will not need to hire significant additional personnel to develop, maintain and manage these properties. As for funding for any costs associated with these properties’ development, although we cannot provide any assurance that we will be able to obtain funding, we will seek funding from one or more of the following potential sources funding from third-party investors, funding as a result of loans secured by the properties, or joint-funding arrangements with developers and/or managers of these properties.
The residential development in New Mexico consists of approximately 250, non-contiguous, single family residential lots and a 10,000 square foot club house. The agreed upon value of this property was approximately $7.4 million. This property already has a management and construction arrangement in place. We are the minority holder in that property, holding a 17.9% interest.
In exchange for these assets, we issued to the Contributor 879,234 shares of our common stock, which represented approximately 19.9% of our issued and outstanding common stock immediately prior to the Closing Date, at a per share value of $2.5183, or $2.2 million in the aggregate. We issued the remaining $7.8 million of the approximately $10 million consideration to the Contributor in the form of 123,668 shares of our newly designated non-voting Series A Convertible Preferred Stock. Each share of the Series A Convertible Preferred Stock is convertible into 25 shares of our common stock, subject to the satisfaction of certain conditions, including stockholder approval of such conversion.
The number of shares of common stock issued to the Contributor and to be issued upon conversion of the Series A Convertible Preferred Stock was determined by dividing the $10 million value of the assets by $2.5183, a specified price per share value which represents a 7.5% premium above the volume-weighted average price of all on-exchange transactions in our common stock executed on The Nasdaq Capital Market, during the forty-three (43) trading days prior to the trading day immediately prior to the public announcement of the transaction by our company and the Contributor Parent on March 31, 2017, as reported by Bloomberg L.P. We believe that the trading price of our common stock at the time of the Contribution Transaction represented the value of our prior medical device business and not our new real estate development business. The value of the contributed assets was arrived at by the mutual agreement of the parties after analyzing each of the assets in comparison to historical sales of similar land parcels. We also assumed the obligations of the Contributor and its affiliates under certain agreements covering the delivered assets, including an Operating Agreement of Central Valley Gas Station Development, LLC, a Delaware limited liability company, dated January 28, 2013, and all amendments thereto; the Operating Agreement of Avalon Jubilee, LLC, a New Mexico limited liability company, dated as of May 16, 2012, and all amendments thereto; a Development Services Agreement, dated September 15, 2015, by and between UR-FC Contributed Assets, LLC, a Delaware limited liability company, as owner, and Land Strategies, LLC, a Nevada limited liability company, as developer, with respect to real property owned by Avalon Jubilee, LLC; and a Construction Contract dated, November 19, 2014, between Central Valley Gas Stations Development, LLC, as owner, and First Capital Builders, LLC, as contractor, with respect to the project known commonly as Green Sands and Buhach Rd., Atwater, CA. The Acquiror expects to enter into amended operating agreements with respect to some or all of these entities. As of the filing of this report, the agreements have not been amended.
Additionally, we assumed those ancillary agreements, commitments and obligations with respect to the delivered assets specified in that certain Assignment and Assumption Agreement, dated as of May 17, 2017.
Under the Contribution Agreement, on the Closing Date our Board was required to consist of seven (7) persons of whom three (3) would be designated by our company, three (3) would be designated by the Contributor Parent, and one (1) nonaffiliated director would be selected by the other six (6) directors; provided, however, that at least four (4) of the members of the Board as so designated would be independent directors. In accordance with the foregoing, on the Closing Date, Lewis C. Pell, Dr. Yoav Ben-Dror and Stephen P. Connelly resigned from our Board, Dr. Dolev Rafaeli, Dennis M. McGrath and Michael R. Stewart were designated by our company, and Suneet Singal, Richard J. Leider and Dr. Bob Froehlich were designated by the Contributor Parent to serve as members of the Board. The seventh director, Darrel C. Menthe, was designated and appointed to the Board by the other directors. On March 4, 2018, Suneet Singal resigned from the Company’s Board of Directors and on the following day, March 5, 2018, Darrel Menthe also resigned from the Company’s Board of Directors. Their resignations were not in connection with any known disagreement with the Company on any matter. Under the provisions of the Stock Purchase Agreement dated December 22, 2017, as reported in the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 29, 2017, Opportunity Fund I-SS, LLC, or “Opportunity Fund” has notified the Company that it may exercise its right to appoint two replacement directors to the Company’s Board of Directors, but it has not yet done so. The two directorships resulting from such resignations currently remain vacant. See “Private Placement” below.
Additionally, the following officer changes became effective as of the Closing Date:
| ● | Dr. Dolev Rafaeli, Dennis McGrath, and Dr. Yoav Ben-Dror resigned from their positions as officers of our company and its subsidiaries and we acknowledged and agreed that such resignations constituted valid terminations of their respective employment agreements for “Good Reason” (as that term is defined in their respective employment agreements) and the Board consented to the waiver of the notice requirements and cure periods as described in their respective resignation letters and confirmed that each of Messrs. Rafaeli and McGrath are entitled to all of the compensation described in Section 7(c) of their respective employment agreements for the remainder of the term of such employment agreements; |
| ● | Suneet Singal was appointed as Chief Executive Officer of our company and Stephen Johnson was appointed the Chief Financial Officer of our company (both of Messrs. Singal and Johnson have since resigned as officers of our company); and |
| ● | Dr. Ben-Dror resigned as managing director of our foreign subsidiaries, including Radiancy (Israel) Limited and Photo Therapeutics Limited in the United Kingdom, and agreed to enter into a non-compete agreement with our company and support the transition of his respective Board duties in lieu of his agreement for lock-up of his shares, and he will be entitled to all his compensation through a term that matches the term of Messrs. Rafaeli and McGrath. |
Closing of the Contribution Transaction was subject to customary closing conditions and certain other specific conditions, including the following: (i) the entry into a registration rights agreement requiring us to register for resale the shares being issued in connection with the Contribution Transaction; (ii) the entry into a lock up agreement that restricts the transfer of our shares that are held by certain of our affiliates and certain affiliates of the Contributor Parent; (iii) the restructuring of our Board as described above; (iv) the resignation of certain of our officers as described above; and (v) the entry into an employment agreement with Mr. Suneet Singal, who became our new Chief Executive Officer at the closing.
The Contribution Agreement contemplated that additional contributions would be made prior to December 31, 2017; however, the Contributor failed to satisfy the conditions precedent to those additional contributions before the December 31, 2017 deadline such that only the closing described above was completed.
We elected to early adopt ASU 2017-01,Business Combinations (Topic 805) Clarifying the Definition of a Business.Accordingly, the determination of whether the transaction represents a business combination was evaluated by applying ASU 2017-01 guidance. We have determined that the group of assets assumed do not include (and also, none of them on a stand-alone basis) include, an input and a substantive process that together significantly contribute to the ability to create output and thus it was determined that the contribution represents an acquisition of assets rather than a business combination. Accordingly, the total sum of the fair value of consideration given (i.e. the fair value of the equity interests issued) together with the transaction costs, was allocated to the individual assets acquired and liabilities assumed based on their relative fair values at the date of acquisition. Such allocation did not give rise to goodwill.
The terms of the Series A Convertible Preferred Stock are governed by a certificate of designation, or the Series A Certificate of Designation, filed by us with the Nevada Secretary of State on May 15, 2017. Pursuant to the Series A Certificate of Designation, we designated 3,000,000 shares of our preferred stock as Series A Convertible Preferred Stock. Following is a summary of the material terms of the Series A Convertible Preferred Stock:
| ● | Dividends. Except for stock dividends or distributions for which adjustments are made, holders of Series A Convertible Preferred Stock shall be entitled to receive dividends on shares of Series A Convertible Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock. No other dividends shall be paid on shares of Series A Convertible Preferred Stock. |
| ● | Liquidation. Upon any liquidation, dissolution or winding-up of our company, whether voluntary or involuntary, the holders of Series A Convertible Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of our company the same amount that a holder of common stock would receive if the Series A Convertible Preferred Stock were fully converted (disregarding for such purposes any conversion limitations) to common stock immediately prior to such liquidation, which amount shall be paidpari passuwith all holders of common stock. We must mail written notice of any such liquidation to each holder not less than 45 days prior to the payment date stated therein. |
| ● | Voting Rights. Except as otherwise provided in the Series A Certificate of Designation or as otherwise required by law, the Series A Convertible Preferred Stock shall have no voting rights. However, as long as any shares of Series A Convertible Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Convertible Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series A Convertible Preferred Stock or alter or amend the Series A Certificate of Designation, (b) amend our articles of incorporation or other charter documents in any manner that adversely affects any rights of the holders, (c) increase the number of authorized shares of Series A Convertible Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing. |
| ● | Conversion. Each share of Series A Convertible Preferred Stock shall be convertible, at any time and from time to time from at the option of the holder thereof, into that number of shares of common stock determined by dividing $62.9575 by the Conversion Price. The Conversion Price for the Series A Convertible Preferred Stock is equal to $2.5183, subject to adjustment as described in the Series A Certificate of Designation. |
Payout Notes and Stock Grant Agreement
Under the Contribution Agreement, amounts due to Dr. Dolev Rafaeli and Dennis M. McGrath under their employment agreements, as well as amounts due to Dr. Yoav Ben-Dror for his services as a board member and officer of our foreign subsidiaries, were converted to convertible secured notes in the principal amounts of approximately $3.1 million, $0.98 million and $1.5 million, respectively, following approval from our stockholders on October 12, 2017 (which we refer to as the Payout Notes). The Payout Notes were due on October 12, 2018, carried a ten percent (10%) interest rate, payable monthly in arrears commencing on December 1, 2017, and were secured by a security interest in all of our assets pursuant to a security agreement that we entered into with the holders of the Payout Notes on October 12, 2017. The Payout Notes were convertible into shares of our common stock and we agreed to register the shares underlying the Payout Notes within thirty (30) days of issuance with best efforts to cause the registration statement covering such shares to become effective within one-hundred twenty (120) days of issuance. On November 14, 2017, we filed a registration statement on Form S-3 (which we refer to as the First Registration Statement) to register all shares that may be issued upon conversion of the Payout Notes, which was subsequently amended to include the Payout Shares issued under the Stock Grant Agreement described below.
On December 22, 2017, we entered into a stock grant agreement, or the Stock Grant Agreement, with Dr. Dolev Rafaeli, Dennis M. McGrath and Dr. Yoav Ben-Dror (collectively referred to herein as the Note Holders) to (i) cause the early conversion of the Payout Notes into an aggregate of 5,628,291 shares of our common stock (which we refer to as the Payout Shares), (ii) effectuate the release of all security interests associated with the Payout Notes, (iii) provide for the issuance of an aggregate of 1,857,336 additional shares of common stock to the Note Holders as consideration for the various agreements of the Note Holders contained in the Stock Grant Agreement (which we refer to as the Additional Shares), (iv) provide for certain cash payments to the Note Holders in amounts equal to the interest payments that would have been made to the Note Holders absent the conversion of the Payout Notes, (v) obtain the agreement of the Note Holders to provide certain support services to our company, and (vi) obtain the conditional resignation of certain of the Note Holders from our Board of Directors. Accordingly, the Payout Notes were paid in full.
Pursuant to the Stock Grant Agreement, we agreed to make twelve (12) monthly payments on the first of each month commencing on January 1, 2018 in the amounts of approximately $21, $7, and $10 thousand, respectively, to Messrs. Rafaeli, McGrath, and Ben-Dror, respectively (which we refer to as the Cash Payments). The Cash Payments are consideration for certain consulting services to be provided by the Note Holders specified in the Stock Grant Agreement.
As promptly as possible following entry into the Stock Grant Agreement, we are required to file a proxy statement and hold a special meeting of our stockholders to authorize and approve the issuance of the Additional Shares. We are required to issue the Additional Shares promptly, but in any event within ten (10) days after we obtain stockholder approval of such issuance. As of the date of this Annual Reportreport, we have not yet filed such proxy statement.
In furtherance of obtaining such stockholder approval, on December 22, 2017, the Contributor, the Note Holders and certain other significant stockholders of our company, including OFI (as defined under “Private Placement” below), entered into a shareholder voting support and confidentiality agreement, or the Note Holder Voting Agreement, pursuant to which such stockholders agreed to vote their shares in favor of the transactions contemplated by the Stock Grant Agreement, including the issuance to the Note Holders or their designees of common stock equal to 20% or more of the common stock or 20% or more of the voting power outstanding before the issuance (which we refer to as the Note Holder 20% Proposal), and also agreed to certain transfer restrictions on the securities of our company owned by them. Under the Note Holder Voting Agreement, such stockholders may not transfer or otherwise dispose of any equity securities of our company until the earlier of: (i) the first business day following approval of the Note Holder 20% Proposal by our stockholders, (ii) the mutual written consent of the parties to the Note Holder Voting Agreement, or (iii) December 31, 2018. Such transfer restrictions do not apply to (y) the exercise of any option, warrant or other securities convertible or exchangeable for securities of our company or (z) to any transfer by the Contributor or the Contributor Parent, in each case, to any holder of a security issued by it. The Note Holder Voting Agreement also includes a power of attorney pursuant to which each stockholder designated and appointed our company and its duly authorized officers and agents as its agents and attorney in fact to act on the stockholder’s behalf to execute any proxy relating to any meeting of our stockholders for the purposes set forth in the Note Holder Voting Agreement.
On December 22, 2017, in connection with the Stock Grant Agreement, we entered into a registration rights agreement, or the Note Holder Registration Rights Agreement, with the Note Holders, pursuant to which we agreed to register the Additional Shares under the Securities Act. We agreed to file a registration statement covering the resale of the Additional Shares within 30 days of the Stock Grant Agreement and cause such registration statement to be declared effective under the Securities Act as soon as possible but, in any event, no later than 120 days following the filing date if such registration statement is filed on Form 10-K. WeS-3 or 150 days if such registration statement is filed on Form S-1. If such registration statement is not filed or declared effective by the SEC on or prior to such dates, or if after such registration statement is declared effective, without regard for the reason thereunder or efforts therefor, such registration statement ceases for any reason to be effective for more than an aggregate of 30 trading days during any 12-month period, which need not be consecutive, then in addition to any other rights the Note Holders may have under the Note Holder Registration Rights Agreement or under applicable law, we are required to pay to each Note Holder an amount in cash, as partial liquidated damages and not as a penalty, equal to 1.0% of the product obtained by multiplying (x) $1.00 by (y) the number of shares of common stock held by the Note Holder included in the registration statement (such product referred to as the Note Holder Investment Amount); provided that, in no event will we be liable for liquidated damages in excess of 1.0% of the Note Holder Investment Amount in any single month and that the maximum aggregate liquidated damages payable to the Note Holders under the Note Holder Registration Rights Agreement shall be ten percent (10%) of the Note Holder Investment Amount. The registration rights provision contained in the Payout Notes was incorporated by reference into the Note Holder Registration Rights Agreement, except that the Note Holders waived the breach by our company for failure to timely file the First Registration Statement and agreed that they are not under any obligation, and we expressly disclaim any obligation,entitled to update or alter any forward-looking statements, whetherliquidated damages as a result of new information, future eventssuch failure. Under the Note Holder Registration Rights Agreement, the Note Holders are entitled to liquidated damages if the First Registration Statement is not declared effective within 120 days following the date of the Payout Notes, but the Note Holders subsequently agreed to waive their rights to such liquidated damages until April 20, 2018. On January 23, 2018, we filed a registration statement on Form S-3 for the Additional Shares. The Note Holders waived their rights to liquidated damages in connection with the late filing of such registration statement and in connection with the effectiveness deadline for such registration statement until April 20, 2018.
Pursuant to the Stock Grant Agreement, Dr. Dolev Rafaeli and Dennis M. McGrath agreed to resign from our Board of Directors effective upon the last to occur of (i) receipt of all of the Payout Shares and all of the Additional Shares, (ii) receipt of all of the Cash Payments (either in accordance with the schedule provided in the Stock Grant Agreement or, otherwise. All subsequent forward-looking statements attributableat our option, in one lump sum on an accelerated basis), and (ii) the date that the Payout Shares and the Additional Shares have been registered for re-sale in accordance with the Note Holder Registration Rights Agreement.
Private Placement
On December 22, 2017, we entered into a securities purchase agreement, or the Purchase Agreement, with Opportunity Fund I-SS, LLC, a Delaware limited liability company, or OFI, under which OFI may invest up to $15 million in our company in a series of closings, in exchange for which OFI will receive shares of our newly designated Series B Preferred Stock at a purchase price of $1.00 per share.
On December 22, 2017, we completed the first closing under the Purchase Agreement, pursuant to which OFI provided $1.5 million to us in exchange for 1,500,000 shares of Series B Preferred Stock. On January 24, 2018, we completed a second closing under the Purchase Agreement, pursuant to which OFI provided approximately $2.2 million to us in exchange for 2,225,000 shares of Series B Preferred Stock. Under the Purchase Agreement, OFI may, but is not obligated to, make additional investments in one or more subsequent closings until an aggregate amount of $15 million has been invested or the Purchase Agreement has been terminated in accordance with its terms.
Under the Purchase Agreement, the proceeds from the first closing were to be used for working capital and general corporate purposes, the proceeds from the second closing were to be used to perform due diligence and invest in Income Generating Properties (as defined in the Purchase Agreement) that have been approved by our company’s Board of Directors, and proceeds from subsequent closings were to be used to invest in Income Generating Properties (as defined in the Purchase Agreement) that have been approved by our Board of Directors or as otherwise agreed to between us and OFI in writing prior to such subsequent closings. On March 16, 2018, we and OFI entered into a letter agreement, pursuant to which OFI agreed that we may use all proceeds for the purposes and uses described in a budget agreed to between us and OFI at the time the letter agreement was signed. In connection with such letter agreement, we agreed to provide OFI, on a quarterly basis, on or prior to 15 days after the end of each quarter, a report that describes, in reasonable detail, the actual expenses incurred, and payments made during such period compared to the expenses and payments specified in the budget for such period, certified by our Chief Financial Officer.
The terms of the Series B Preferred Stock are governed by a certificate of designation, or the Series B Certificate of Designation, filed by the Company with the Nevada Secretary of State on December 22, 2017. Pursuant to the Series B Certificate of Designation, we designated 15,000,000 shares of our preferred stock as Series B Preferred Stock. Following is a summary of the material terms of the Series B Preferred Stock:
| ● | Dividends. Holders of shares of Series B Preferred Stock shall receive cumulative dividends, pro rata among such holders, prior to and in preference to any dividend on our outstanding common stock at the per annum rate of 8% of the Series B Original Issue Price (as defined below). Dividends on each share of Series B Preferred Stock will accrue daily and be cumulative from December 22, 2017 (which we refer to as the Series B Original Issue Date) and shall be payable upon the occurrence of any voluntary or involuntary liquidation, dissolution or winding up of the Company (which we refer to as a Liquidation Event), a conversion or a redemption. The “Series B Original Issue Price” shall mean $1.00 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock. Holders shall also be entitled to receive dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-common-stock basis regardless of whether the Series B Preferred Stock is then convertible or otherwise subject to conversion limitations) to and in the same form as dividends actually paid on shares of our common stock when, as and if such dividends are paid on shares of the common stock. |
| ● | Liquidation. In the event of (i) a Liquidation Event or (ii) a merger or consolidation (other than one in which our stockholders own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of our assets (we refer to any such event as a Deemed Liquidation Event), the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of our assets available for distribution to stockholders before any payment shall be made to the holders of our common stock, Series A Convertible Preferred Stock or any other class of securities authorized that is specifically designated as junior to the Series B Preferred Stock (referred to herein as Junior Securities) by reason of their ownership thereof, butpari passu with the holders of shares of any class of securities authorized that is specifically designated aspari passu with the Series B Preferred Stock (referred to herein as the Parity Securities) on a pro rata basis, an amount per share equal to the Series B Original Issue Price, plus any accrued dividends thereon. If upon any such Liquidation Event or Deemed Liquidation Event, our assets available for distribution to stockholders shall be insufficient to pay the holders of shares of Series B Preferred Stock the full amount to which they shall be entitled and the holders of Parity Securities the full amount to which they shall be entitled, the holders of shares of Series B Preferred Stock and the holders of shares of Parity Securities shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. Upon a Liquidation Event or a Deemed Liquidation Event, in the event that following the payment of such liquidation preference we shall have additional cash and other assets available for distribution to stockholders, then the holders of shares of Series B Preferred Stock shall participatepari passu with the holders of shares of Parity Securities and Junior Securities based on the then current conversion rate (disregarding for such purposes any conversion limitations) with respect to all remaining distributions, dividends or other payments of cash, shares or other assets and property of our company, if any. |
| ● | Voting Rights. On any matter presented to our stockholders for their action or consideration, each holder of Series B Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series B Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter (subject to the conversion limitations described below). Except as provided by law or by the other provisions of the Series B Certificate of Designation, the holders shall vote together with the holders of shares of common stock as a single class. However, as long as any shares of Series B Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority of the outstanding shares of Series B Preferred Stock, or the Requisite Holders, (i) issue any class of equity securities that is senior in rights to the Series B Preferred Stock, (ii) issue any Parity Securities, (iii) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock or alter or amend the Series B Certificate of Designation, (iv) amend our articles of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (v) except pursuant to the redemption provisions of Parity Securities, redeem any shares of our preferred stock or common stock (other than pursuant to employee or consultant agreements giving us the right to repurchase shares at the original cost thereof upon the termination of services and provided that such repurchase is approved by our Board of Directors), or (vi) enter into any agreement with respect to any of the foregoing. |
| ● | Conversion. Each share of Series B Preferred Stock plus accrued, but unpaid, dividends thereon, or the Aggregate Preference Amount, shall be convertible, at any time and from time to time at the option of the holder thereof, into that number of shares of common stock determined by a formula (computed on the date of conversion), (i) the numerator of which is equal to the Aggregate Preference Amount and (ii) the denominator of which is equal to the quotient of the Conversion Price divided by $1.33. The “Conversion Price” for the Series B Preferred Stock shall initially be equal to $0.8684, subject to adjustment as described in the Series B Certificate of Designation. In addition, upon the earlier to occur of: (i) a Deemed Liquidation Event or (ii) if there has not been a breach or default by us under the Purchase Agreement that has occurred and is continuing, May 31, 2018, each share of Series B Preferred Stock plus accrued, but unpaid, dividends thereon shall be automatically converted into that number of shares of common stock determined by dividing $1.33 by the Conversion Price. Notwithstanding the forgoing, if we have not obtained approval from our stockholders with respect to the issuance of shares upon conversion in excess of 19.99% of the issued and outstanding common stock on the applicable conversion date (which we refer to as the Stockholder Approval), then we may not issue, upon conversion of the Series B Preferred Stock, a number of shares of common stock which, when aggregated with any shares of common stock issued on or after the Series B Original Issue Date and prior to such conversion date, would exceed 19.99% of the issued and outstanding shares of common stock (subject to adjustment for forward and reverse stock splits, recapitalizations and the like) (we refer to such number of shares as the Issuable Maximum). Each holder shall be entitled to a portion of the Issuable Maximum equal to the quotient obtained by dividing (i) the Series B Original Issue Price of such holder’s Series B Preferred Stock by (ii) the aggregate Series B Original Issue Price of all Series B Preferred Stock issued to all holders. |
| ● | Redemption. If (i) there is a breach by us of any of our representations and warranties contained in Sections 3.1(a) (Subsidiaries), 3.1(b) (Organization and Qualification), 3.1(c) (Authorization; Enforcement), 3.1(d) (No Conflicts), 3.1(f) (Issuance of the Shares), 3.1(g) (Capitalization), or 3.1(n) (Taxes) of the Purchase Agreement that has not been cured within 30 days after the date of such breach or (ii) Stockholder Approval has not been obtained by March 31, 2018 (each event being referred to herein as a Redemption Event), then each holder of Series B Preferred Stock may, at its option, require us to redeem any or all of the shares of Series B Preferred Stock held by such holder at a price per share equal to $1.33, plus accrued, but unpaid, dividends through and including the date of such redemption. We must provide a notice, or an Event Notice, to each holder of the occurrence of a Redemption Event of the kind described in (i) above (referred to herein as a Breach Event) as soon as practicable after becoming aware of such Breach Event, but in any event, not later than fifteen (15) days after such Breach Event and such notice shall provide a reasonable description of such Breach Event. A holder must send written notice of redemption, or a Redemption Notice, to us within ninety (90) days after (i) we provide such holder an Event Notice with respect to a Breach Event or (ii) the occurrence of a Redemption Event of the kind described in (ii) above. For the avoidance of doubt, if we do not timely provide an Event Notice, the holder shall nevertheless have the right to deliver a Redemption Notice in connection with any Redemption Event. If a holder fails to send a Redemption Notice on or prior to the 90th day after the occurrence of any Redemption Event, then such holder will lose such holder’s right to redemption with respect to the particular Redemption Event, but not any other Redemption Event. We did not obtain Stockholder Approval prior to March 31, 2018. |
The Purchase Agreement is subject to the usual pre- and post-closing representations, warranties and covenants. In addition, we agreed that, so long as the shares of Series B Preferred Stock purchased by OFI are outstanding, our debt (as defined by U.S. generally accepted accounting principles, or GAAP) shall not exceed 45% of our fixed assets without the prior written consent of the Requisite Holders. Subject to stockholder approval, we also agreed to amend the certificate of designation for our Series A Convertible Preferred Stock to change the conversion price from $2.5183 to $1.12024021352 such that each share of Series A Convertible Preferred Stock will be initially convertible into 56.20 shares of common stock instead of 25 shares of common stock. In addition, we agreed that at any time prior to the termination of the OFI Voting Agreement (as defined below), we shall cause any person who acquires any securities from us or any of our affiliates that, together with all securities held by such acquirer and its affiliates, will own, directly or indirectly, five percent (5%) or more of our outstanding common stock (after giving effect to the right of any such person to convert or exchange securities), to become a party to the OFI Voting Agreement by causing such person, as a condition to the delivery of such securities, to sign a counterpart signature page thereto that joins such person to the OFI Voting Agreement.
We also agreed to nominate two (2) directors to our Board of Directors upon request of OFI. In furtherance thereof, on December 22, 2017, Messrs. Suneet Singal and Darrel C. Menthe delivered resignation letters to our Board of Directors pursuant to which they resigned from the Board of Directors effective automatically on the third (3rd) day following written request to do so from OFI. Notwithstanding the fact that OFI has not yet requested Messrs. Singal and Menthe to resign from our Board of Directors, Messrs. Singal and Menthe did resign on March 3, 2018. Their resignations were not in connection with any known disagreement with the Company.
As promptly as possible following the first closing, we are also required to file a proxy statement and hold a special meeting of our stockholders to authorize and approve the issuance of shares of common stock upon conversion of the Series B Preferred Stock and the amendment to the certificate of designation for our Series A Convertible Preferred Stock described above. As of the date of this report, we have not yet filed such proxy statement.
In furtherance of obtaining such stockholder approval, on December 22, 2017, OFI entered into a shareholder voting support and confidentiality agreement, or the OFI Voting Agreement, with the Contributor and certain other significant stockholders of our company, including the Note Holders, pursuant to which the such stockholders agreed to vote their shares in favor of the transactions contemplated by the Purchase Agreement, including the issuance to OFI or its designees of common stock upon conversion of its Series B Preferred Stock equal to 20% or more of the common stock or 20% or more of the voting power outstanding before the issuance (which we refer to as the OFI 20% Proposal), and also agreed to certain transfer restrictions on the securities of our company owned by them. Under the OFI Voting Agreement, such stockholders may not transfer or otherwise dispose of any equity securities of our company until the earlier of: (i) the date of termination of the Purchase Agreement in accordance with its terms; (ii) the later of (a) the date that this registration statement becomes effective or (b) the first business day following approval of the OFI 20% Proposal by our stockholders, (iii) the mutual written consent of the parties to the OFI Voting Agreement, or (iv) December 31, 2018. Such transfer restrictions do not apply to the exercise of any option, warrant or other securities convertible or exchangeable for securities of our company, or following stockholder approval of the OFI 20% Proposal, to the following transfers: (i) if the stockholder is a corporation, partnership, limited liability company or other entity, any transfer to an affiliate if such transfer is not for value; or (ii) if the stockholder is an individual, transfers, (a) for nominal consideration or as a gift to any person acting on its behalf are expresslymember of such stockholder’s immediate family (defined as the spouse, parents, lineal descendants, the spouse of any lineal descendant, and brothers and sisters) or a trust for the benefit of such stockholder or any member of such stockholder’s immediate family, (b) in connection with estate or tax planning, (c) to non-profit organizations qualified in their entiretyas charitable organizations under Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, or (d) upon the death of such stockholder pursuant to a will or other instrument taking effect upon the death of such stockholder, or pursuant to the applicable laws of descent and distribution to such stockholder’s estate, heirs or distributes. The restrictions also do not apply to any transfer by the cautionary statements containedContributor or the Contributor Parent, in each case, to any holder of a security issued by it. The OFI Voting Agreement also includes a power of attorney pursuant to which each stockholder designated and appointed our company and its duly authorized officers and agents as its agents and attorney in fact to act on the stockholder’s behalf to execute any proxy relating to any meeting of our stockholders for the purposes set forth in the OFI Voting Agreement.
As a condition to the first closing, we entered into a registration rights agreement, or the OFI Registration Rights Agreement, with OFI, pursuant to which we agreed to register all shares of common stock that may be issued upon conversion of the Series B Preferred Stock, or the Registrable Securities, under the Securities Act. We agreed to file a registration statement covering the resale of such Registrable Securities within 30 days of the first closing and cause such registration statement to be declared effective under the Securities Act as soon as possible but, in any event, no later than 120 days following the filing date if such registration statement is filed on Form S-3 or 150 days if such registration statement is filed on Form S-1. If such registration statement is not filed or declared effective by the SEC on or prior to such dates, or if after such registration statement is declared effective, without regard for the reason thereunder or efforts therefor, such registration statement ceases for any reason to be effective for more than an aggregate of 30 trading days during any 12-month period, which need not be consecutive, then in addition to any other rights the holders of Series B Preferred Stock may have under the OFI Registration Rights Agreement or under applicable law, we shall pay to each holder an amount in cash, as partial liquidated damages and not as a penalty, equal to 1.0% of the product obtained by multiplying (x) the Series B Original Issue Price by (y) the number of shares of Registrable Securities held by the holder (such product referred to herein as the Investment Amount); provided that, in no event will we be liable for liquidated damages in excess of 1.0% of the Investment Amount in any single month and that the maximum aggregate liquidated damages payable to the holders under the OFI Registration Rights Agreement shall be ten percent (10%) of the Investment Amount. On January 23, 2018, we filed a registration statement on Form S-3 to register the shares issued to OFI in the first closing. OFI waived its right to liquidated damages in connection with the late filing of such registration statement.
Under the Purchase Agreement, we also agreed to indemnify and hold OFI and its successors and permitted assignees (collectively referred to herein as the Investor Indemnified Parties) harmless from, any and all Damages (as defined below) incurred or suffered by such Investor Indemnified Party arising out of any inaccuracy or other breach of any representation or warranty of our company in any of the Transaction Documents (as defined in the Purchase Agreement) or any breach of covenant or agreement made by us in any of the Transaction Documents. “Damages” means the amount of (i) the sum of the aggregate amount of all damages, losses, liabilities and expenses (including reasonable expenses of investigation and reasonable attorneys’ fees and expenses) in connection with any action, suit or proceeding whether involving a third party claim or a claim solely between the parties, but excluding any incidental, indirect or consequential damages, losses, liabilities or expenses; (ii) multiplied by the Indemnity Gross Up Factor. The “Indemnity Gross Up Factor” is equal to X divided by Y, where X is equal to 1 and Y is equal to 1 minus a fraction, the numerator of which is equal to the number of shares of common stock held by OFI, determined and on a fully diluted basis assuming the full conversion of shares of Series B Preferred Stock that OFI is then entitled to convert; and the denominator of which is the number of shares of common stock determined on a fully diluted basis. Notwithstanding the foregoing, no Investor Indemnified Party shall be entitled to indemnification unless and until the aggregate Damages incurred in respect of all claims collectively exceeds $50,000 whereupon Investor Indemnified Parties shall only be entitled to indemnification for all such Damages in excess of such $50,000 threshold.
The Purchase Agreement may be terminated by the written agreement of us and OFI, or by us or OFI if the final closing does not take place prior to December 31, 2018.
Our Prior Business Operations
Under its previous name, PhotoMedex, Inc., our company was, until the recent sale of the last significant business unit (its consumer products division which was sold to ICTV Brands, Inc., or ICTV, on January 23, 2017; see Note 2, Discontinued Operations, to our consolidated financial statements), as described below and in other sections of this section.
Before we commenced our current real estate business, we organized our business into three operating segments based upon our management structure, products and services offered, markets served and types of customers, as follows: The Consumer segment (sold to ICTV on January 23, 2017) derived its revenues from the design, development, manufacturing and selling of long-term hair reduction and acne consumer products. The Physician Recurring segment derived its revenues from the XTRAC (sold to MELA Sciences on June 22, 2015) procedures performed by dermatologists, the sales of skincare products (sold to Pharma Cosmetics on September 15, 2016), the sales of surgical disposables and accessories to hospitals and surgery centers (sold to Dalian JiKang Medical Systems September 1, 2015) and on the repair, maintenance and replacement parts on various products. The Professional segment generated revenues from the sale of equipment, such as lasers, medical and esthetic light and heat based products and LED products.
We still market and sell our LHE® brand products, which were included in the physician market provides the platform to expand our skin health solutions to spa markets, as well as traditional retail, online and infomercial outlets for home-use products.
The no!no!® line of products also includes a consumables-based revenue model, which helps provide us with a growing, high-margin recurring revenue stream as consumers make repeat purchases of refill Thermicon tips, buffers and topical products.
Sale of Prior Business
On March 31, 2016, we completed the sale to The Lotus Global Group, Inc. of all of the tangible and intangible assets of the Omnilux product line for $220 thousand ($110 thousand was received as a refundable deposit during December 2015 in advance and $110 thousand was received in April 2016), pursuant to the Agreement for Sale of Assets dated March 31, 2016. Management does not believe that the sale of the Omnilux product line represented a strategic shift for our company. As a result, the above transaction has not been reflected in the accompanying consolidated financial statements as discontinued operations (see Note 2, Discontinued Operations, to our consolidated financial statements). We recorded a loss on the disposal of those assets in the amount of $843 thousand for the year ended December 31, 2016.
On August 30, 2016, we entered into an Asset Purchase Agreement for the sale of our Neova product line. The sale was completed on September 15, 2016, resulting in immediate cash proceeds to us of $1.5 million and we recorded a loss of $1,731 thousand from the transaction during the third quarter ended September 30, 2016, and for the year ended December 31, 2016. The parties entered into several ancillary agreements as part of this transaction, including a Neova Escrow Agreement and a Neova Transition Services Agreement. Under the Neova Escrow Agreement, $250 thousand of the Purchase Price was placed into an escrow account held by U.S. Bank National Association as Escrow Agent. The funds were to remain in escrow until September 15, 2017, one year following the closing of the transaction. We received $158 thousand of these on December 13, 2017 and recognized an additional loss of $92 thousand on the sales of the Neova product line for the amount of funds withheld from the escrow account.
On October 4, 2016, we entered into an Asset Purchase Agreement with ICTV for the sale of our consumer division for $9.5 million, including $5 million in cash plus a $4.5 million royalty agreement. We also entered into a Transition Services Agreement, pursuant to which we agreed to provide ICTV with certain accounting, benefit, payroll, regulatory, IT support and other services for periods ranging from approximately three months to up to one year following the closing date, during which time ICTV would arrange to transition the services it receives to its own personnel.
This transaction was completed on January 23, 2017, (see Note 2 Discontinued Operations). We considered a number of factors before entering into the Asset Purchase Agreement, including, among other things, the price to be paid by ICTV, the strategic and financial benefits that the asset sale would provide to us, our extensive search process with respect to the sale of the business, the future business prospects of the business and the terms and conditions of the Asset Purchase Agreement. Ultimately, we concluded that the price offered by ICTV was a fair offer for the consumer products division.
On July 12, 2017, we entered into a Termination and Release Agreement under which the Asset Purchase Agreement described above was terminated and is of no further force and effect, except for certain surviving rights, obligations and covenants described in the Termination and Release Agreement. Pursuant to the Termination and Release Agreement, ICTV paid us $2 million in cash and we agreed that ICTV will have no further royalty or other payment obligations under the Asset Purchase Agreement. We derecognized the $4.5 million royalty receivable (which had been recognized on January 23, 2017) and recognized a total loss of $2 million in the nine-month period ended September 30, 2017, resulting in an adjustment of $2 million to the amount of the loss on the disposal of the asset. We had classified the assets of the consumer division as assets held for sale as of December 31, 2016.
As partial consideration for the releases provided by ICTV pursuant to the Termination and Release Agreement and in accordance with the terms therein, on July 12, 2017, we entered into a Bill of Sale and Assignment, which provides that we shall sell, assign, transfer, convey and deliver to ICTV, and ICTV purchase and accept from us, all of the right, title and interest, legal or equitable, in and to a deposit in the amount of $210 thousand held by a consumer division vendor, Sigmatron International, Inc., pursuant to an arrangement between us and Sigmatron International, Inc.
As part of the sale of the consumer product sold worldwide underline, which transaction was determined to represent a complete liquidation of a foreign subsidiary, the cumulative translation adjustment of $3,228 thousand related to that foreign entity was reclassified from accumulated other comprehensive income (loss) and reported as part of gain or loss from the sale.
Organizational Chart
The following chart depicts our no!no!® brand. The no!no! Skinorganizational structure following the sale of our prior business and the Contribution Transaction. All subsidiaries are wholly-owned unless otherwise indicated.
Our Real Estate Business
Our focus is to build our company into a 510(k)-cleared productleading real estate, asset management and development company, concentrating primarily on investments in high yield income producing assets and other opportunistic commercial properties via direct property ownership and asset management. Our objective is to generate long term net asset value growth while adhering to institutional best practices and a deep research process for all investments.
Income Producing Properties
For income producing properties, we intend to acquire assets that has been clinically demonstratedprovide recurring income with the potential for income growth over the long-term. We believe there can be an attractive risk/reward profile to resolve or improve acne lesions by 81% within 24 hours. It usessuch properties based on the same LHE® brand technology from our physician LHE® brand products but is optimized for home use.
Real Estate Development
We look to invest in land assets that can be developed into income generating commercial, residential and hospitality properties, for-sale residential properties, or mixed-use development opportunities. Such properties may require extensive planning, and for these investments, we may partner with local developers, architects, and engineers to maximize the area, allowing the muscles to relaxhighest and release pressure between the vertebrae allowing the spine to open up and decompress.
Competition
We believe that a significant barrier to entry into an applicable marketthe real estate business is the cost basis of the product, since our products are based upon a proprietary technology that allows us to build products inexpensively. From a marketing standpoint, if competitors are developing a product thatvery competitive. Our properties may compete with no!no!®, they then become tasked withlocal sites in attracting skilled labor during the challenge of building the marketing for that product.construction process and in attracting tenants and end-users upon completion. We invested roughly $62 million in 2014 in marketing and advertising. Furthermore, our comprehensive intellectual property position may serve as a deterrent to companies.
We believe that our present manufacturing capacity at these facilities is sufficientsize and scale provide an opportunity to meet foreseeable demand for our products.
Investment Strategy
Our diversified investment strategy provides us with flexibility to invest across real estate asset classes and utilize certain suppliers for the manufacture of selected standard components and subassemblies, which are manufactured to our specifications. Most major components and raw materials, including optics and electro-optic devices, are available from a variety of sources. We conduct all final testing and inspection of our products. We have established a quality control program, including a set of standard manufacturing and documentation procedures intended to ensure that, where required, our products are manufactured in accordance with applicable FDA regulations and the comparable requirements of the European Community and other countries, including for example Japan and Canada.
One of our Skin Care productscore strategies is that we intend to OEM contract manufacturers. In addition, we currently out-sourcefind investments in secondary and tertiary markets with assets that require minimal capital expenditures but generate initial unlevered cash flow yields that are higher than those in primary markets. We look to acquire assets in submarkets where the manufacturingpopulation and employment trends are positive and where the underlying asset serves a key purpose to the local community.
A second component of our LED products. The LED product equipmentinvestment strategy will revolve around sourcing asset management opportunities for which we would operate as an asset manager of real estate properties. We are not currently structured as a REIT, thus we have the ability to retain earnings and to operate in real estate asset management, development and peripheral real estate activities, items that may be limited by REIT requirements. We will look to utilize our existing infrastructure to provide efficiencies of scale to owners of real estate assets as we grow our portfolio over time.
Our criteria for evaluating investments includes, but is currently manufactured by an OEM manufacturer innot limited to, submarket location of the UK with tooling providedasset, economic and owned by us. We believe thatpopulation growth fundamentals of the manufacturing capacitylocation, credit quality of this supplier is sufficiently adequate for anticipated demand. Quality control is performedthe tenant, terms of the underlying leases, historical cash flow and capital expenditure needs at the OEM manufacturerproperty, ability to acquire financing secured by the property, tax and atregulatory risks associated with the investment, environmental and structural attributes of the property, long-term viability of the asset, and potential redevelopment opportunities of the real estate.
We do extensive research on these investment attributes when preparing our facilitiesinvestment memorandum. We compare the real estate acquisition we are making to other investments with similar risk profiles both inside and outside the direct real estate investment sector to best assess the merits of the opportunity.
Existing Portfolio
In 2017, we acquired (i) three vacant land sites intended for development as gas stations in the U.S. The hand-held devicesnorthern California, (ii) a majority membership interest in a limited liability company that owns a vacant land site located in Northern California, and the consumable products are manufactured by(iii) an OEM manufacturerinterest in Carlsbad, CA. We are currently reliant ona limited liability company which owns property located in Los Lunas, New Mexico being developed as a single supplier for LEDs.family residential development.
Our Intellectual Property
We do not have any material intellectual property rights relating to our real estate business. However, we do employ certain proprietary processes related to the real estate business which are protected as trade secrets of our company. We have not, hadat this time, registered any difficulties in product supply of LEDspatents, trademarks or copyrights associated with our real estate business and do not expect to date, but we are actively seeking an alternate supplier for the purpose of offsetting this single-supplier approach.
Our legacy global skin health business provided integrated disease management and Development
Historically, our policy iswas to file patent applications and to protect certain technology, inventions and improvements that are commercially important to the development of our business. As patents expire and expose our inventions to public use, we seeksought to mitigate the impact of such expirations by seeking protection of improvements. The patents in our Skin Care product line relate to use of our copper and manganese peptide-based technology for a variety of healthcare applications and to the composition of certain biologically active, synthesized compounds. Our strategy has been to apply for and maintain patent protection for certain compounds and their discovered uses that are believed to have potential commercial value in countries that offer significant market potential. As of December 31, 2014, we had
Our products and services arewere offered under trademarks and service marks, both registered and unregistered. We believe our trademarks encourageencouraged customer loyalty and aidaided in the differentiation of our products from competitors'competitors’ products. In connection with the sales of our Neova product line and our consumer products especially in our skincare products.division, we transferred the intellectual property associated with those product lines, including trademarks and trade names, to their respective purchasers. Accordingly, we had
Research and Development
Our research and development expenditures relating to our legacy business operations were approximately $143 thousand in 2017 and $1.2 million in 2016. As of January 23, 2017, the research and development personnel were transferred to ICTV in connection with the closing of the sale of the consumer product line assets.
Government Regulation
Regulations Relating to Legacy Business
Regulations Relating to Products and Manufacturing
Our products and research and development activities are regulated by numerous governmental authorities, principally the U.S. Food and Drug Administration or the FDA and corresponding state and foreign regulatory agencies. Any medical device or cosmetic we manufacture and/or distribute willwould be subject to pervasive and continuing regulation by the FDA. The U.S. Food, Drug and Cosmetics Act, or FD&C Act, and other federal and state laws and regulations govern the pre-clinical and clinical testing, design, manufacture, use, labeling and promotion of medical devices, including our XTRAC system, LED devices, surgical lasers and other products currently under development by us and govern the manufacture and labeling of the cosmetic products. Product development and approval for medical devices within this regulatory framework takes a number of years and involves the expenditure of substantial resources.
We have received approval from the European Union to affix the CE Mark to our XTRAC laser system, VTRAC™ lamp system, Omnilux LED system and our diode laser system.LHE products. This certification is a mandatory conformity mark for products placed on the market in the European Economic Area, which is evidence that they meet all European Community, or EC, quality assurance standards and compliance with applicable European medical device directives for the production of medical devices. This will enable us to market our approved products in all of the member countries that accept the CE Mark. We also will be required to comply with additional individual national requirements that are in addition to those required by these nations. Our products have also met the requirements for marketing in various other countries.
Failure to comply with applicable regulatory requirements can result in fines, injunctions, civil penalties, recalls or seizures of products, total or partial suspensions of production, refusals by the U.S and foreign governments to permit product sales and criminal prosecution.
Fraud and Abuse Laws
Because of the significant federal funding involved in Medicare and Medicaid, Congress and the states have enacted, and actively enforce, a number of laws whose purpose is to eliminate fraud and abuse in federal health care programs. Our business is subject to compliance with these laws.
Anti-Kickback Laws
In the U.S., there are federal and state anti-kickback laws that generally prohibit the payment or receipt of kickbacks, bribes or other remuneration in exchange for the referral of patients or other health-related business. The U.S. federal healthcare programs'programs’ Anti-Kickback Statute makes it unlawful for individuals or entities knowingly and willfully to solicit, offer, receive or pay any kickback, bribe or other remuneration, directly or indirectly, in exchange for or to induce the purchase, lease or order, or arranging for or recommending purchasing, leasing, or ordering, any good, facility, service, or item for which payment may be made in whole or in part under a federal healthcare program such as Medicare or Medicaid. The Anti-Kickback Statute covers "any“any remuneration,"” which has been broadly interpreted to include anything of value, including for example gifts, certain discounts, the furnishing of free supplies, equipment or services, credit arrangements, payments of cash and waivers of payments. Several courts have interpreted the statute'sstatute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the arrangement can be found to violate the statute. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. In addition, several courts have permitted kickback cases brought under the Federal False Claims Act to proceed, as discussed in more detail below.
Because the Anti-Kickback Statute is broadly written and encompasses many harmless or efficient arrangements, Congress authorized the Office of Inspector General of the U.S. Department of Health and Human Services, or OIG, to issue a series of regulations, known as "safe“safe harbors."” For example, there are regulatory safe harbors for payments to bona fide employees, properly reported discounts and rebates, and for certain investment interests. Although an arrangement that fits into one or more of these exceptions or safe harbors is immune from prosecution, arrangements that do not fit squarely within an exception or safe harbor do not necessarily violate the statute. The failure of a transaction or arrangement to fit precisely within one or more of the exceptions or safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct and business arrangements that arguably implicate the Anti-Kickback Statute but do not fully satisfy all the elements of an exception or safe harbor may be subject to increased scrutiny by government enforcement authorities such as the OIG.
Many states have laws that implicate anti-kickback restrictions similar to the Anti-Kickback Statute. Some of these state prohibitions apply, regardless of whether federal health care program business is involved, to arrangements such as for self-pay or private-pay patients.
Government officials have focused their enforcement efforts on marketing of healthcare services and products, among other activities, and recently have brought cases against companies, and certain sales, marketing and executive personnel, for allegedly offering unlawful inducements to potential or existing customers in an attempt to procure their business.
Federal Civil False Claims Act and State False Claims Laws
The federal civil False Claims Act imposes liability on any person or entity who, among other things, knowingly and willfully presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program, including Medicare and Medicaid. The "qui“qui tam,"” or "whistleblower"“whistleblower” provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In recent years, the number of suits brought against healthcare providers by private individuals has increased dramatically. Medical device companies, like us, can be held liable under false claims laws, even if they do not submit claims to the government, when they are deemed to have caused submission of false claims by, among other things, providing incorrect coding or billing advice about their products to customers that file claims, or by engaging in kickback arrangements with customers that file claims.
The False Claims Act also has been used to assert liability on the basis of misrepresentations with respect to the services rendered and in connection with alleged off-label promotion of products. Our future activities relating to the manner in which we sell our products and document our prices, such as the reporting of discount and rebate information and other information affecting federal, state and third-party reimbursement of our products, and the sale and marketing of our products, may be subject to scrutiny under these laws.
When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties of $5,500five to $11,000eleven thousand dollars for each separate false claim. There are many potential bases for liability under the False Claims Act. A number of states have enacted false claim laws analogous to the federal civil False Claims Act and many of these state laws apply where a claim is submitted to any state or private third-party payor. In this environment, our engagement of physician consultants in product development and product training and education could subject us to similar scrutiny. We are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the costs of defending such claims, as well as any sanctions imposed, could significantly affect our financial performance.
Regulations Relating Real Estate Business
Federal, State and/or Local Regulatory Compliance
We are, or will be, subject to a variety of Federal, state and/or local statutes, ordinances, rules, and Other Regulations
Environmental Regulatory Compliance
Under various Federal, state and/or local laws, ordinances and regulations, a current or previous owner or operator of a property may be required to investigate and/or clean-up hazardous or toxic substances released at that property. That owner or operator also may be held liable to third parties for bodily injury or property damage (investigation and/or clean-up costs) incurred by those parties in connection with the contamination at that site. These laws often impose liability without regard to whether the owner or operator knew of or otherwise caused the release of the hazardous or toxic substances. In addition, persons who arrange for the disposal or treatment of hazardous substances or other regulated materials also may be liable for the costs of removal or remediation of such substances at a disposal or treatment facility, whether or not such facility is owned or operated by such persons.
The costs of remediation or removal of hazardous or toxic substances can be substantial, and the presence of contamination, or the failure to remediate contamination discovered, at a property we own or operate may adversely affect our products are saferability to develop, construct on, sell, lease, or more effective thanborrow upon that property. Current and former tenants at a property we own may have, or may have involved, the alternatives. Additionally, theyuse of hazardous materials or generated hazardous wastes, and those situations could result in our incurring liabilities to remediate any resulting contamination if the responsible party is unable or unwilling to do so.
In addition, our properties may require changesbe exposed to a risk of contamination originating from other sources. While a property owner generally is not responsible for remediating contamination that has migrated on-site from an off-site source, the contaminant’s presence could have adverse effects on our pricing structure and revenue model before authorizing reimbursement.
Employees
As of March 31, 2018, we had 4 full-time employees devoted to the ongoing business of our company, which consisted of 2 executive officers and procedures. In most markets, there are private insurance systems,2 finance, legal and administration staff, as well as government-managed systems. Our XTRAC products remain substantially without approval for reimbursement in many international markets under either government or private reimbursement systems. Since our skincare products are primarily for cosmetic applications, reimbursement is not a critical factor in growing revenues for this product segment.
Our employees are not represented by a labor union nor covered by a collective bargaining agreement. We believe that we have good relations with our employees.
Available Information
Our website is www.photomedex.com.www.fcglobalrealty.com. Our annual reports on Form 10-K, quarterly reports on 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are available on our website at www.photomedex.comwww.fcglobalrealty.com as soon as reasonably practicable after we electronically file such reports with, or furnish them to, the SEC. The information on the Company'sour website is not a part of this Annual Report on Form 10-K.
| ITEM 1A. | RISK FACTORS. |
In addition to the other information contained in this Annual Reportreport and the exhibits hereto, the following risk factors should be considered carefully in evaluating our business. Our business, financial condition, cash flows or results of operations could be materially adversely affected by any of these risks. Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business, financial condition, cash flows or results of operations. The following discussion of risk factors contains forward-looking statements as discussed on page 1.above. Our business routinely encounters and addresses risks, some of which may cause our future results to be different – sometimes materially different – than we presently anticipate.
Risks Relating to Our Business Generally
Our financial condition as of December 31, 2017 raises substantial doubt about our ability to continue as a going-concern.
As of December 31, 2017, we had an accumulated deficit of approximately $134.45 million and shareholders’ deficit of approximately $2.90 million. To date, and subsequent to the Company's Business
Cash and cash equivalents as of December 31, 2017 were approximately $0.95 million. We have historically financed our activities with cash from operations, the private placement of equity and debt securities, borrowings under lines of credit and, in default under its senior credit facility,the most recent periods with the sale of certain assets and is currently operating under a forbearance arrangement.
On May 12, 2014, the CompanyMarch 31, 2017, we entered into an $85 million senior secured credit facilities ("the Facilities") with JP Morgan Chase ("Chase")Contribution Agreement under which included a $10 million revolving credit facility and a $75 million four-year term loan. The facilitiescertain real estate investment properties were utilizedcontributed to refinanceour company in exchange for the existing term debt with Chase, fund the acquisitionissuance of LCA and for workingour capital and other general corporate purposes. The facilities are secured by a first priority security interest in and lien on all assetsstock. Closing of the Company. All currentContribution Agreement occurred on May 17, 2017. However, the assets assumed in such contribution do not represent a business and future subsidiaries are guarantorsnot producing cash flows and/or revenues.
On December 22, 2017, we entered into the Purchase Agreement with OFI, under which OFI may invest up to $15 million in our company in a series of closings, in exchange for which OFI will receive shares of our newly designated Series B Preferred Stock at a purchase price of $1.00 per share. On December 22, 2017, we completed the first closing under the Purchase Agreement, pursuant to which OFI provided $1.5 million to us. On January 24, 2018, we completed a second closing under the Purchase Agreement, pursuant to which OFI provided approximately $2.2 million to us in. Under the Purchase Agreement, OFI may, but is not obligated to, make additional investments in one or more subsequent closings until an aggregate amount of $15 million has been invested or the Purchase Agreement has been terminated in accordance with its terms. OFI has no obligation to continue to invest in our company, and there are restrictions placed by OFI on the facilities.
We will be applied in direct order of maturity. The Company also agreed that, on or before the fifth calendar day of each month, the Company would pay against the Term Loan $125,000required to the extent that the cash-on-hand exceeds $5 million, and 100% of the cash-on-hand in excess of $7 million, also to be applied to the Term Loan in inverse order of maturity.
These conditions raise substantial doubt about our ability to the Lenders. In the event that the Company is unable to enter into such an acceptable arrangement, or if, by the end of the Forbearance Period, the Company and its Lenders have not entered into another forbearance agreement or otherwise reached an agreement regarding the Credit Agreement and the Facilities, the Lenders have the right to declare all of the obligations under the Credit Agreement and Facilities due and payable, including principal and interest, as authorized by the Credit Agreement, and to enforce additional obligations under the Second Amended Forbearance Agreement. Such a result would have a material adverse effect on the Company and its financial condition.
If adverse general economic conditions continue, the Company's future revenue, profitability and cash flow from operations could decrease and its liquidity and financial condition could be adversely impacted.
From time to time, the Companywe may seek additional equity or debt financing to make acquisitions or other investments, to provide for the capital expenditures, required to finance working capital requirements, continue itsour expansion, toor increase liquidity, develop new products and services or make acquisitions or other investments.liquidity. In addition, if itsour business plans change, general economic, financial or political conditions in itsour markets change, or other circumstances arise that have a material negative effect on itsour cash flow, the anticipated cash needs of itsour business as well as itsour conclusions as to the adequacy of itsour available sources of capital could change significantly.
Any of these events or circumstances could result in significant additional funding needs, requiring the Companyus to raise additional capital, and we cannot predict the timing or amount of any such capital requirements at this time. If financing is not available on satisfactory terms, or at all, the Companywe may be unable to expand its business or to develop newour business at the rate desired and itsour results of operations may suffer.
We are dependent upon dividends from our subsidiaries to meet our financial obligations.
We are a holding company and our principal assets are the Company does not continue to develop and commercialize new products and identify new markets for its products and technologies, the Company may not remain competitive, and its revenues and operating results could suffer.
If we fail to manage our growth effectively, our businesses could be receptive to its excimer laser technology or skincare products over competing products, services and therapies or that a cure will not be found for the underlying diseases the Company is focused on treating. Failure of the Company's products to achieve market acceptance could have a material adverse effect on the Company's business, financial condition and results of operations.
We expect to experience growth in potentially reduced prices or reduced demandour business, both organically and in relevant part, adversely affect the Company's revenuesthrough acquisitions. We expect to make significant investments to enable our future growth. Such growth may place a strain on our management and business operations.
We have outstanding litigation which we maintain a business relationship with such retailers and distributors, they may sell competing products or may not be able to sellsettle, or which we may not be able to settle on terms favorable to us.
We are involved in certain litigation relating to our products. Maintainingformer businesses, including a two product liability suits brought by a consumer regarding the no!no! product. We intend to vigorously defend claims brought against us, and to prosecute such suits to recoup sums owed to us. However, we may seek to settle such matters in order to avoid excessive legal fees and costs and the lengthy time such litigation may require in order to reach a resolution. However, there is no guarantee that we may be able to reach a settlement or resolution of such litigation, or that such a settlement or resolution will be reached in a manner that is advantageous to us, and in such cases we will need to proceed with litigation. Regardless of its outcome, litigation may result in substantial costs and expenses, and significantly divert the attention of management. There can be no assurance that we will be able to prevail in, or achieve a favorable settlement of, pending matters. In addition to the pending matters, future litigation, government proceedings, labor disputes, or environmental matters could lead to increased costs or interruption of our normal business relationships with these retailersoperations, which could involve a costly and distributorslengthy draw upon our resources and their continued successcould result in a resolution to the litigation which may be detrimental to us.
We are the subject of certain tax audits which may not be resolved without impacting our operations.
We have in the past, and are currently, the subject of certain audits by state agencies and international authorities for various tax matters including, but not limited to, sales and use and corporate income taxes, and unclaimed property reporting. While past audits have been resolved without significant impact upon us or our operations, there is importantno guarantee that future audits will be resolved in a manner that is satisfactory to maintainingus or that has no material impact upon our operations. Such results could include the Company's revenuespayment of assessments which could impact our remaining resources and profitability.
We depend on our executive officers and key personnel to implement our business strategy and could be harmed by the loss of its independent third-party distributors.their services and the inability to attract personnel for these positions.
We believe that our growth and future success will depend in large part upon the skills of our key management. Certain members of our management staff as well as other key employees may voluntarily terminate their employment with us at any time, with or without notice. There is substantial competition for personnel in the industries in which we operate, and we may face increased competition for such employees, resulting in the need to compensate these personnel at a higher-than-anticipated rate, a delay in replacing such personnel and integrating them into our operations, and the possibility that we may be unable to attract and retain these personnel. The Company's distributors could take one or moreloss of the following actions, anyservices of which could have a material adverse effect on its business, prospects and brand:
In particular, our success depends in part on search engines and other online sources for its website traffic. Our subsidiary's name, Radiancy, as well as the name of our flagship products, no!no!, and variations of those names, are included in search results as a result of both paid-search listings, where the Company purchases specific search terms that will result in the inclusion of its listing, and algorithmic searches that depend upon the searchable content on its sites. Search enginescontinued service and other online sources revise their algorithms from time to time in an attempt to optimize their search results.
Additionally, we do not currently maintain “key person” life insurance on the lives of Messrs. Bedi and Stolzar, our other executives or any of our employees. Our lack of insurance means that we may not have adequate compensation for the loss of the services of our key employees, which could affect our ability to maintain the level of services formerly provided by those persons.
In our industry, there is substantial competition for key personnel in the past, resultingregions in less sales leads, a lower-rate-of-return on our advertising spendwhich we operate and a lower level of saleswe may face increased competition for these products.
Our ability to use our net operating resultsloss carryforwards to offset future taxable income for U.S. federal income tax purposes may be limited as a result of “ownership changes” of our company caused by the Contribution Transaction. In addition, the amount of such carryforwards could be negatively impactedsubject to adjustment in the event of an examination by economic, political or other developments in foreign countries in which it or its subsidiaries do business.
If a corporation undergoes an “ownership change” under Section 382 of the U.S., Canada, Europe, Japan and Israel. Since September 11, 2001, there has been more intense scrutinyInternal Revenue Code of goods that are transported across international borders. As a result, some of our and our subsidiaries' products may face delays, and increase in costs due to such delays in delivering goods to its customers. Any events that interfere with,1986, as amended, or increase the costs of the transfer of goods across international borders, could have a material adverse effect on its business.
Our NOLs, which for federal income tax purposes expire over the next 20 years, may be subject to an annual limitation under Section 382 of the Code as a result of the completion of the Contribution Transaction. Consequently, our ability to utilize our pre-change NOLs may be subject to an additional layer of limitations imposed by Section 382 of the Code. The amount of the NOL carryforwards is subject to review and audit by the Internal Revenue Service and there can be no assurance that the benefit of such NOL carryforwards will be fully realized.
We are analyzing the tax implications of the ownership of our inactive subsidiaries in Israel and Europe, including the tax implications of dissolving or otherwise disposing of such subsidiaries. As a result of the application of Israeli and/or European tax laws, the dissolution or other factors thatdisposition of these subsidiaries may have an adverse impact on the Company's overall financial condition and results of operations. In addition, the Company hasresult in a relationship with GlobalMed, whereby it provides the Company with certain non-U.S. regulatory support. To the extent that the Company discontinues its relationship with GlobalMed, or if GlobalMed is otherwise unable to provide the Company with the resources and assistance that the Company needs, the Company may have a difficult time expanding into international marketssignificant tax in an effective manner.
Certain of our subsidiaries, both in the United States and in foreign jurisdictions, are participants in intercompany loans which originated at one of the foreign jurisdiction subsidiaries. The foreign subsidiaries could incur a tax liability as a result of holding those open loans. The subsidiary companies are not in a position to repay those loans in full. We and our subsidiaries’ boards are examining how best to proceed, but to either repay a loan, or to default and have the loan forgiven, could result in income being imputed to that subsidiary in the United States. While we and various subsidiaries hold large amounts of NOLs on a Federal level, the use of certain of those losses is restricted under Section 382 of the Code as a result of past changes of control of our company, and the transactions which occurred during 2017 may impose further restrictions on the use of these NOLs should those transactions have resulted in a change of control during 2017. Accordingly, we may be subject to significant and unexpected tax liability in Israel, may adversely affectEurope and/or the flow of vital components from our Israeli subcontractors to us. We cannot assure you that ongoing hostilities related to Israel will notUnited States and such liability would have a material and adverse effect on our businessfinancial condition and prospects.
The Contribution Transaction may not qualify for special tax treatment, for example, as a tax-free reorganization for U.S. federal income tax purposes, resulting in certain stockholders’ recognition of taxable gain or our share price.
There is currently no opinion as to catastrophic loss suchwhether the Contribution Transaction will qualify for special tax treatment, as, fire, flood, or earthquake. Any such loss at any of these facilities could disrupt operations, delay production, shipmentsfor example, a tax-free reorganization for U.S. federal income tax purposes. Moreover, there is no requirement we take all actions to ensure that the Contribution Transaction so qualifies and, revenue and result in significant expense to repair and replace those facilities.
If the Company fails to manage and protect its and its subsidiaries'subsidiaries’ network security and underlying data effectively, its businesses could be exposed to a cyber-attack or other disruption which could harm its operating results.
Like other large corporations, the Company relies upon a variety of information technology systems to transmit, process and store information in an electronic format for use in daily operations. In particular, the Company possesses and uses both personal health information and personal identification information in the conduct of its business, including credit card, insurance and banking information of our customers.customers and vendors. The size, inter-relationship and complexity of these systems, and the possession of such information, makes us vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, theft or loss of data privacy or other significant interference with the use and possession of such information, that could harm our business. Unauthorized disclosure or manipulation of such data, whether through breach of network security or other interception of this information, could expose the Company to costly litigation, damage its reputation and result in a lower revenue stream and the loss of some of its customers.
Our information systems require a constant and ongoing dedication of significant resources to maintain, protect, and enhance our existing systems as well as keep pace with changes in information processing technology and regulatory standards. In particular, maintaining the Company'sCompany’s network security is of critical importance because the online e-commerce systems used by our consumer product linesmay store proprietary and confidential customer and vendor data such as names, addresses, other personal information, bank account and credit card numbers. The Company uses commercially available encryption technology to transmit personal information when taking orders. However, third parties may be able to circumvent these security and business measures by developing and deploying viruses, worms and other malicious software programs that are designed to attack or attempt to infiltrate its systems and networks. Employee error, malfeasance or other mistakes in the storage, use or transmission of personal information could result in a breach of customer or employee privacy. The Company employs contractors and temporary and part-time employees who may have access to the personal information of customers, vendors and employees. It is possible such individuals could circumvent the Company'sCompany’s data security controls, which could result in a breach of customer privacy. In addition, third parties may attempt to hack into our systems to obtain data relating to our business plans, products or our proprietary technology. Any failure to maintain or protect these information technology systems and data integrity, including from cyber-attacks, intrusions or other breaches, could result in the unauthorized access to patient data, and personally identifiable information, theft of intellectual property or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations.
We are subject to the provisions of the U.S. Foreign Corrupt Practices Act and similar foreign anti-corruption laws.
The possessionForeign Corrupt Practices Act (the “FCPA”), as well as similar anti-corruption laws in foreign jurisdictions around the world, generally prohibit companies, their subsidiaries, affiliates, contractors and/or intermediaries, from offering and/or making improper payments, or providing anything of value, to non-U.S. government officials for the purpose of obtaining or retaining business or securing an unfair advantage in business matters. Certain parts of the world have experienced, or are continuing to experience, some measure of governmental corruption; while in other parts of the world, strict compliance with anti-bribery laws may conflict with local business customs and usepractices. Both the real estate business and the healthcare business are subject to particular scrutiny in such matters, due to the requirements of personal information in conducting its business subjectnumerous governmental approvals for real estate development and the predominance of government-sponsored healthcare systems around the world. The Company has established formal policies and procedures that prohibit, and monitor for, conduct which may violate these laws, but we cannot guarantee that employees, affiliates, representatives and/or agents of the Company will not engage in conduct that violates these laws and for which the Company may be held responsible.
Risks Relating to legislativeOur Real Estate Business
We have initiated an internal investigation into the validity of our subsidiary’s 17.9133% ownership interest in Avalon Jubilee LLC, the owner of property located in Los Lunas, New Mexico. If our investigation ultimately determines that issues exist relating to the validity of our ownership interest in Avalon Jubilee LLC, our financial condition will be materially adversely affected.
On January 12, 2018, we received a copy of a complaint, dated November 17, 2017, that was filed by Alpha Alpha, LLC in the Thirteenth Judicial District Court in the County of Valencia in the State of New Mexico against Avalon Jubilee, LLC, the holding company that owns the property in Los Lunas, New Mexico, HiTex, LLC, MCBB, LLC, Land Strategies, LLC, Ronald R. Cobb and regulatory burdensJohn Does 1 – 5. The suit asks the court to, among other things, determine whether there have been unauthorized transfers of interest in Avalon Jubilee LLC; and declare who are the holders of interests in Avalon Jubilee LLC. Although the complaint does not name our company or any of its subsidiaries or specifically question our interest in Avalon Jubilee LLC, it raises questions about whether the transfers of interest leading to our acquisition of our interest in Avalon Jubilee LLC were properly made in accordance with the Avalon Jubilee operating agreement. We have begun an internal investigation into the validity of our ownership interest in Avalon Jubilee LLC and will disclose the results of that investigation once it has been completed. Accordingly, we may be required to engage in costly litigation to validate our interest in Avalon Jubilee LLC. Alternatively, a court may ultimately determine that we do not own such interest in which our financial condition will be materially adversely affected as we will no longer be the owner of what we believe is a material asset of ours and be left only with potential claims against the transferors of such assets, which may not result in a full recovery of our losses. Either costly litigation or the loss of a material asset and the inability to fully recover such loss through lawsuits against the transferees of our interest in Avalon Jubilee LLC would have a material adverse effect on our financial condition and prospects.
Litigation against us or the Contributor Parties regarding the safeguardingacquisition from the Contributor could result in the payment of damages which could adversely affect our business, financial condition or results of operations.
If any plaintiffs in a litigation against us or the Contributor Parties, or any of their respective directors, secures relief adversely affecting our acquisition under the Contribution Agreement, such relief may result in our company becoming liable for damages related to one or more of the properties acquired from the Contributor. In addition, we could incur significant costs in connection with lawsuits, including costs associated with the indemnification of our directors and officers.
We are entering into a new business line and, therefore, there is only a limited history upon which investors can evaluate our performance and our future business prospects.
We have entered into the Contribution Agreement with the Contributor and the Contributor Parent, pursuant to which the Contributor has contributed real estate assets to our company. This Contribution Agreement represents a new business line for our company, which has no experience in the real estate sector. We will be relying on the experience of our management team for the operation and development of this informationbusiness line. As a result, our business will be subject to the substantial risks which are found in the early stages of a new business venture operating in the competitive real estate industry. Our future growth and development prospects must be evaluated in light of the risks, expenses and difficulties encountered by all companies in such situations, and in particular those companies which operate a business, such as real estate investment, in competitive environments that can be greatly affected by changes in economic conditions.
We may not be able to successfully integrate the acquired real estate business.
A successful integration of the operations of the real estate development business into our company will require that we devote significant management attention and resources to integrating our business practices, operations, and support functions into a public company structure. The challenges we may encounter include preserving customer, supplier, and other important relationships, addressing differences in business cultures, preserving employee morale, and retaining key employees while maintaining focus on meeting our operational and financial goals and the processesreal estate development business, and adequately addressing other business integration issues. The process of integrating a real estate development business, the diversion of management’s attention from other business efforts, and any subsequent delays in the integration process, could adversely affect our business and financial performance and the market price of our stock.
We are subject to demand fluctuations in the real estate industry. Any reduction in demand could adversely affect our business, results of operations, and financial condition.
Demand for properties similar to those owned by us and expected to be followedowned by us is subject to fluctuations that are often due to factors outside our control. We are not able to predict the course of the real estate markets or whether the current favorable trends in those markets can, or will, continue. In the event of an economic downturn, our results of operations may be adversely affected, and we may incur significant inventory impairments and other write-offs, a data breach.major decline in our gross margins from past levels, and substantial losses from operations of this business.
Adverse changes in economic conditions in markets where our real estate investments are or may be made and where prospective purchasers and utilizers of these properties live could reduce the demand for and utilization of these properties and, therefore, adversely affect our operations and financial condition.
The real estate investment business in which we have become involved as a result of our signing of the Contribution Agreement will be conducted in the United States and may also be conducted in various global locales. Adverse changes in economic conditions in these markets, and in the markets where prospective purchasers and utilizers of our to-be-acquired properties live, could negatively impact those properties and their profitability. Unfavorable changes in job growth, employment levels, consumer income and spending patterns, a decline in consumer confidence, increases in interest rates, and an oversupply of similar properties, could reduce the demand, and depress the prices we may ask, for these properties, resulting in lower sales and income from these properties and a negative impact on our results of operations and financial condition.
Adverse weather conditions, natural disasters, and other unforeseen and/or unplanned conditions could disrupt our real estate developments.
Adverse weather conditions and natural disasters, such as hurricanes, tornadoes, earthquakes, floods, droughts, and fires, could have serious impacts on our ability to develop and market individual real estate offerings. Properties that we look to acquire may also be affected by unforeseen planning, engineering, environmental, or geological conditions or problems, including conditions or problems which arise on third party properties adjacent to or in the vicinity of properties which we expect to own and which may result in unfavorable impacts on our prospective properties. As our proposed real estate investments may be located in multiple countries, with differing climates and geological characteristics, each property will face different known and unknown risks. Any interferenceadverse event or circumstance could cause a delay in, prevent the completion of, or increase the cost of, one or more of these properties expected to be developed and brought to market by us, thereby resulting in a negative impact on our operations and financial results.
If the market value of our real estate investments decreases, our results of operations will also likely decrease.
The market value of each real estate investment will depend on market conditions both locally and globally. We expect to acquire land for each expansion into a new market at a cost based upon then-current economic conditions. If local and/or global economic conditions deteriorate, or if the demand for such properties decreases below the levels anticipated at the time of acquisition of a property, we may not be able to make a profit on such property comparable to those profits made by the Contributor and the Contributor Parent in the past. As a result of declining economic conditions, we may experience lower than anticipated or forecast results or profits, and/or may not be able to recover our costs of a project when a property is brought to market.
We rely on subcontractors to construct each property, and on building supply companies to provide components for each property’s construction. The failure of one or more of these subcontractors to properly construct these facilities, or any defects in the components obtained from building supply companies, could adversely affect these properties, and thus our operations.
We engage and rely on subcontractors to perform the actual construction of the buildings upon each property we purchase. Also, we purchase the components used in our construction projects from third party independent building supply companies. We utilize industry standard quality control programs, but despite these programs, we may find that subcontractors are utilizing improper construction practices or the components purchased from building supply companies do not perform as specified in the project’s plans. We may also find that our subcontractors are inadequately capitalized or have insufficient staffing to undertake the required work. In such events, we may incur substantial additional costs to repair substandard construction at our properties, to comply with the plans and local legal requirements. The cost of satisfying local legal building code obligations may be significant, and we may not be able to recover these costs from our subcontractors, suppliers and/or unauthorizedtheir respective insurers.
Legal challenges or governmental regulations may delay the start or completion of construction on our projected real estate ventures, increase our expenses, or limit our construction activities, which could have a negative impact on operations.
Each of our current and future real estate developments may experience a delay and/or increased expenses in construction, marketing and/or operation due to legal challenges to the development. These challenges may be brought by private parties or by governmental authorities, resulting in delays in the start or completion of each project’s construction or requiring changes to the design or construction of each development. Any delay or change in a development’s construction would result in increased expenses to us in the development of the property, which could in turn negatively impact our financial results with respect to that development and with respect to our overall operations.
Numerous governmental authorities are typically involved in each new development project, and such authorities have broad discretion in exercising their approval authority. Various local, state, and federal statutes, ordinances, rules, and regulations concerning building, zoning, sales, and similar matters apply to and/or affect the real estate development industry and govern matters including construction, marketing, sales, operation, lending, and other activities concerning each development. In the United States, there have been numerous changes in regulations that limit the availability or use of land, including regulations which limit growth in certain communities, the use of utilities including water and sewer outlets, road construction and utilization, and other related matters. Each jurisdiction in which we expect to invest in real estate development will have different and varying levels of regulation which must be taken into account when planning and implementing such developments. For example, we may be required to change or modify our plans due to alterations in local planning or laws. As a result, we could incur substantial costs related to compliance with legal and regulatory requirements with regard to each real estate development, negatively impacting our business by causing delays, increasing costs, or limiting our ability to operate in those locations.
If a development project experiences increased costs or shortages of labor or components, or other circumstances beyond our control, there could be delays or increased costs in developing such project, which could negatively impact our finances and operating results.
We may invest in real estate development projects in a number of countries and regions, including the United States Each project may be negatively impacted by local circumstances beyond our control, including labor shortages, disputes and work stoppages, union organizing activities, price changes and delays in availability of building materials and components, and a lack of adequate utility and road infrastructure and services. Any change in these circumstances could delay the start or completion of, or increase the cost of, one or more developments. We may not be able to recover any additional such costs through an increase in the prices for our properties, and therefore our operating results may be negatively affected.
Changes in tax laws, taxes or fees may increase the cost of each development, and such changes could adversely impact our finances and operational results.
Each development project will be subject to different tax laws, tax levies and governmental fees, depending upon its geographic location. Any increase or change in such laws, taxes, or fees, including real estate property taxes, and fees to fund schools, open space, utility and road improvements, could increase the cost of a development and thus have an adverse effect on our operations. Such changes could also negatively impact potential and/or actual users and purchasers of a development because potential buyers may factor such changes into their decisions to utilize or purchase a property.
We will incur significant advance costs in each real estate development before that development begins to generate revenue from sales and/or public usage, and as a result, we may not recover our costs in whole or in part, may recover those costs slower than originally anticipated, or may incur higher costs as a result of any delays in completion of a project, resulting in an adverse impact to our operating results.
We expect to make a number of significant cash outlays for each real estate development before the construction on that development begins, and considerably before any development begins to generate revenue. Such cash outlays will include expenditures to buy, rent, lease or otherwise acquire land, to plan, design and develop a property, to conduct site studies as necessary for development, to provide basic utility and infrastructure access to this informationa property, to obtain permits, licenses, and other required regulatory approvals, to post surety bonds and such other construction guarantees as required by law, and to actually construct the project building(s) and to fully develop a property. These processes can take up to several years before a development is completed and ready to generate any revenue for us. The time to complete each development will vary, based on local geographic conditions, legal requirements, regulatory and community concerns, the ability to obtain required construction materials and labor, and other factors that may be unique to each project. We will face the risk that, during construction, demand for a project may change, alter or decline, and we may be forced to take steps to adjust to these changes in demand, including altering a project and its scope, and selling the property at lower than anticipated or planned prices or at prices that generate lower profit margins or losses. Inflation, economic changes or downturns, asset carrying costs (including interest on funds that are used to acquire land and/or construct a building) may also be generated and may be significant. As a result of these factors, we may experience adverse impacts on our operating results, and if a development experiences a significant decline in value, we may also be required to recognize material write-downs of the book value of a project building in accordance with GAAP.
The real estate industry is highly competitive and if other property developers are more successful or offer better value to customers, our business could suffer.
The real estate industry is highly competitive, regardless of locale, and we will face competitors in each location where we develop, construct, market, sell and/or operate real estate ventures. Competitors will range from small local companies to large international conglomerates with financial resources much greater than those of our company. We have to compete in each market for land, raw materials, construction components, financing, environmental resources, utilities, infrastructure, labor, skilled management, governmental permits and licensing and other factors critical to the successful development of each project. We compete against both new and existing developments and developers. Any increase in or change to any competitive factor could result in our inability to begin or complete development of a project in a timely manner, increased costs for the design, development and completion of a project, and/or higher costs and/or lower revenues from the marketing, sales and/or operation of a development. As a result, we may experience lower revenue and decreased profits due to these factors, impacting our operations and our overall financial results.
Future terrorist activity and/or international instability could adverse impact our real estate developments and financial operations.
We expect to operate real estate developments in a variety of locales, including the United States. A terrorist attack against the United States or other foreign country, an increase in terroristic threats or suspected activity, and/or an increase in domestic or international instability, whether or not located in a country in which we have real estate assets, could significantly affect our business by slowing, delaying or halting construction of real estate developments, increasing the cost of such developments, and/or reducing the sales and/or usages of such properties, thereby adversely affect our business.
We may incur environmental liabilities with respect to our development projects.
The properties we will target for investment will be subject to a variety of local, state and federal statutes, ordinances, rules and regulations concerning the protection of health and the environment. The particular environmental laws that apply to any given community vary greatly according to the community site, the site’s environmental conditions and the present and former use of the site. Environmental laws may result in delays, may cause us to lose existing customers; have difficulty preventing, detecting, and controlling fraud; cause disputes with customers, physicians,incur substantial compliance and other health care professionals; render uscosts and may prohibit or severely restrict development in certain environmentally sensitive regions or areas. Furthermore, under various federal, state and local laws, ordinances and regulations, an owner of real property may be liable for the costs or removal or remediation of certain hazardous or toxic substances on or in such property. Such laws often impose such liability without regard to whether we knew of, or were responsible for, the presence of such hazardous or toxic substances. The cost of any required remediation and our liability therefor as to any property are generally not limited under such laws and could exceed the value of the property and/or the aggregate assets of our company. The presence of such substances, or the failure to properly remediate contamination from such substances, may adversely affect our ability to sell the real estate or to borrow using such property as collateral.
If we fail to diversify our real estate investment portfolio, downturns relating to certain geographic regions, types of assets, industries or business sectors may have a more significant adverse impact on our income and assets than if we had a diversified development property portfolio.
We are not required to observe specific diversification criteria. Therefore, our target portfolio may at times be concentrated in certain asset types that are subject to legal claimshigher risk of foreclosure or secured by assets concentrated in a limited number of geographic locations. To the extent that our real estate portfolio will be concentrated in limited geographic regions, types of assets, industries or business sectors, downturns relating generally to such region, type of asset, industry or business sector may result, for example, in tenants defaulting on their lease obligations at a number of properties within a short time period, which may reduce future projected net income and liability;the value of our publicly traded securities and, accordingly, adversely affect our business and prospects.
Our co-venture partners, co-tenants or other partners in co-ownership arrangements could take actions that decrease the value of an investment to us and lower our valuation.
Certain of the development properties could involve joint ventures, tenant-in-common investments or other co-ownership arrangements with third parties having investment objectives that are may or may not be similar to those of our company for the acquisition, development or improvement of properties, as well as the acquisition of real estate-related investments. We also may purchase and develop properties in joint ventures or in partnerships, co-tenancies or other co-ownership arrangements with the sellers of the properties, affiliates of the sellers, developers or other persons. Such investments may involve risks not otherwise present with other forms of real estate investment, including, for example:
| ● | the possibility that a co-venturer, co-tenant or partner in an investment might become bankrupt; |
| ● | the possibility that the investment may require additional capital that we or our partner do not have, which lack of capital could affect the performance of the investment or dilute our interest if the partner were to contribute our share of the capital; |
| ● | the possibility that a co-venturer, co-tenant or partner in an investment might breach a loan agreement or other agreement or otherwise, by action or inaction, act in a way detrimental to us or the investment; |
| ● | that such co-venturer, co-tenant or partner may at any time have economic or business interests or goals that are or that become inconsistent with the business interests or goals of our company; |
| ● | the possibility that we may incur liabilities as the result of the action taken by our partner or co-investor; |
| ● | that such co-venturer, co-tenant or partner may be in a position to take action contrary to our instructions or requests or contrary to our policies or objectives; or |
| ● | that such partner may exercise buy/sell rights that force us to either acquire the entire investment, or dispose of our share, at a time and price that may not be consistent with our investment objectives. |
Any of the above might subject a property to liabilities in excess of those contemplated and thus reduce our returns on that investment.
Uninsured losses relating to real property or excessively expensive premiums for insurance coverage may adversely affect the value of your stock.
The nature of the activities at certain properties could expose us and our operators to potential liability for personal injuries and, in certain instances, property damage claims. For instance, there are types of losses, generally catastrophic in nature, such as losses due to wars, acts of terrorism, earthquakes, pollution, environmental matters or extreme weather conditions such as hurricanes, floods and snow storms that are uninsurable or not economically insurable, or may be insured subject to limitations, such as large deductibles or co-payments. We may not carry all the usual and customary insurance policies which would be carried by a similarly-positioned company, and we may not be carrying those insurance policies in amounts and types sufficient to cover every risk which may be encountered by our company. Insurance risks associated with potential terrorist acts could sharply increase the premiums we will pay for coverage against property and casualty claims. Mortgage lenders generally insist that specific coverage against terrorism be purchased by commercial property owners as a condition for providing mortgage, bridge or mezzanine loans. It is uncertain whether such insurance policies will be available, or available at reasonable cost, which could inhibit our ability to finance or refinance our planned to-be-acquired properties. In such instances, we may be required to provide other financial support, either through financial assurances or self-insurance, to cover potential losses. We cannot assure you that it will have adequate coverage for such losses. If any of our properties incur a casualty loss that is not fully covered by insurance, the value of our assets will be reduced by the amount of any such uninsured loss. In addition, other than the capital reserve or other reserves we may establish, we do not expect to have any contingent sources of funding in place to repair or reconstruct any uninsured damaged property, and we cannot assure you that any such sources of funding will be available to us for such purposes in the future. Also, to the extent we must pay unexpectedly large amounts for insurance, we could suffer reduced earnings that would result in regulatory sanctionsa decreased value attributed to our publicly traded stock.
We could face losses with respect to abandoned predevelopment costs.
The development process inherently requires that a large number of opportunities be pursued with only a few being developed and constructed. We may incur significant costs for predevelopment activity for projects that are abandoned that directly affect our results of operations. We expect to institute procedures and controls that are intended to minimize this risk, but it is likely that there will be predevelopment costs charged to expense on an ongoing basis.
We may not have adequate financing to fund our future property acquisitions and project developments, and such capital resources may not be available to us on commercially reasonable terms, or penalties;at all.
The implementation of our new business plan including the prospective acquisition of development properties and the completion of construction projects on such properties will involve considerable sums of capital. We currently do not have any such capital and will be required to raise acquisition, construction and related funds in the future on a project by project basis. We may not be successful in our efforts to raise such funds, or capital that we can acquire may not be reasonably priced. In such a case, we may not be able to successfully effect our new business plan. Such a failure would have a material adverse effect on our financial results, our future business prospects and our public market stock valuation.
Risk Factors Relating to Legacy LHE Business
We are exposed to credit risk of some of our customers.
We accept payment for certain of our products through credit cards and customer financing and our exposure to these credit risks may increase during an economic slowdown. Although we have programs in place that are designed to monitor and mitigate the associated risk, there can be no assurance that such programs will be effective in reducing our credit risks. Future losses, if incurred, could harm our business and have an effect on our operating results and financial condition.
We may be adversely affected by product liability claims, unfavorable court decisions or legal settlements.
Sales of the LHE products may lead to potential product liability claims arising from the design, manufacture and marketing of these products. Such claims may be subject to many uncertainties and outcomes which are not predictable, and we may incur significant legal expenses and causein defending these claims regardless of whether we are found to be liable for the claims. While we carry certain product liability insurance coverages, the actual cost to us to incur additional significant expenses or lose revenues; render us unable to accept and process credit card transactions in our consumer businesses; or suffer other adverse consequences,of any product liability claim could be materially different than the amount of the current coverages we carry, which could have a material adverse effect on our business, financial condition or results of operations.
Risks Relating to the Company's brand and reputation.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
On February 20, 2018, we received written notification from The Nasdaq Stock Market that the Company grows, it will need more capacity from those existing call centers, orclosing bid price of our common stock had been below the Company will need to identify and contract with new call centers. The Company may not be able to continue to locate and contract for call center capacity on favorable terms, or at all. Additionally, the rates those call centers charge the Company may increase, or those call centers may not continue to provide service at the current levels.
If we do not generate sufficient cash flowachieve compliance by August 19, 2018, we expect that Nasdaq would provide notice that our securities are subject to meet our debt service and working capital requirements, we may need to seek additional financing or sell assets. This may make it more difficult for us to obtain financing on terms that are acceptable to us, or at all. Without any such financing, we could be forced to sell assets to make up for any shortfall in our payment obligations under unfavorable circumstances. If necessary, we may not be able to sell assets quickly enough or for sufficient amounts to enable us to meet our obligations.
Our stock price has been and continues to be volatile.
The market price for the Company'sour common stock could fluctuate due to various factors. In addition to other factors described in this section, these factors may include, among others:
| ● | conversion of outstanding stock options or warrants; |
| ● | announcements by |
| ● | developments in existing or new litigation; |
| ● | changes in government regulations; |
| ● | fluctuations in |
| ● | general market and economic conditions. |
In addition, the stock markets have, in recent years, experienced significant volume and price fluctuations. These fluctuations often have been unrelated to the operating performance of the specific companies whose stock is traded. Market prices and the trading volume of our stock may continue to experience significant fluctuations due to the matters described in this Item 1A,above, as well as economic and political conditions in the United States and worldwide, investors'investors’ attitudes towards our business prospects, and products, and changes in the interests of the investing community. As a result, the market price of the Company'sour common stock has been and may continue to be adversely affected and our shareholdersstockholders may not be able to sell their shares or to sell them at desired prices.
We may be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.
The Company's programSEC has adopted regulations which generally define so-called “penny stocks” to repurchase itsbe an equity security that has a market price less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions. Our common stock is a “penny stock” and is subject to Rule 15g-9 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. This rule imposes additional sales practice requirements on broker-dealers that sell such securities partiallyto persons other than established customers and “accredited investors” (generally, individuals with a net worth in relationexcess of $1 million or annual incomes exceeding $200,000 or $300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser’s written consent to short-sellingthe transaction prior to sale. As a result, this rule may affect the ability of itsbroker-dealers to sell our securities and may not have been successful into stemming such short-selling.
For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in penny stock, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and 2013. Short-selling of its securities was believedthe registered representative and current quotations for the securities. Finally, monthly statements are required to have caused investors with a long-term interestbe sent disclosing recent price information for the penny stock held in the Company to demand thataccount and information on the company share their long-term view. The Company believed that the effects of its repurchase program would demonstrate the long-term view of its long-term investors. However, therelimited market in penny stock.
There can be no guaranteeassurance that the program was orour common stock will be regarded as successful.
Our management will have broad discretion over the use of the proceeds from the future sale of the securities.
Our Board of directorsDirectors may determine from time to time that there is a need to obtain additional capital through the issuance of additional shares of the Company'sour common stock or other securities. These issuances would likely dilute the ownership interests of the Company'sour current investors and may dilute the net tangible book value per share of the Company'sour common stock. Investors in subsequent offerings may also have rights, preferences and privileges senior to the Company'sour current stockholders which may adversely impact the Company'sour current stockholders.
We have not paid dividends in the past and principal stockholdersdo not expect to pay dividends in the foreseeable future.
We have never declared or paid cash dividends on our capital stock. We currently have substantial control over usintend to retain all future earnings for the operation and could delayexpansion of our business and, therefore, do not anticipate declaring or preventpaying cash dividends in the foreseeable future.
The payment of dividends will be at the discretion of our Board of Directors and will depend on our results of operations, capital requirements, financial condition, prospects, contractual arrangements, any limitations on payments of dividends present in any of our future debt agreements and other factors our Board of Directors may deem relevant. If we do not pay dividends, a change in corporate control.
Securities analysts may not initiate coverage for our common stock together with their affiliates, beneficially own, in the aggregate, approximately 46.3% of our outstanding common stock. Asor may issue negative reports and this may have a result, these stockholders, if they were to act together, could have significant influence over the outcome of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets. In addition, these stockholders, if they were to act together, could have significant influence over the management and affairs of our company. Accordingly, this concentration of ownership might harmnegative impact on the market price of our common stock.
The trading market for our common stock by:
Nevada law and the Company'sour charter documents contain provisions that could delay or prevent actual and potential changes in control, even if they would benefit stockholders.
Our articles of incorporation authorize the issuance of preferred shares which may be issued with dividend, liquidation, voting and redemption rights senior to our common stock without prior approval by the stockholders. The preferred stock may be issued for such consideration as may be fixed from time to time by theour Board of Directors. TheOur Board of Directors may issue such shares of preferred stock in one or more series, with such designations, preferences and rights or qualifications, limitations or restrictions thereof as shall be stated in the resolution of resolutions.
The issuance of preferred stock could adversely affect the voting power and other rights of the holders of common stock. Preferred stock may be issued quickly with terms calculated to discourage, make more difficult, delay or prevent a change in control of the Companyour company or make removal of management more difficult. As a result, theour Board of Directors'Directors’ ability to issue preferred stock may discourage the potential hostile acquirer, possibly resulting in beneficial negotiations. Negotiating with an unfriendly acquirer may result in, among other things, terms more favorable to the Companyus and itsour stockholders. Conversely, the issuance of preferred stock may adversely affect any market price of, and the voting and other rights of the holders of the common stock. The Company presently has no plans to issue any preferred stock.
These and other provisions in the Nevada corporate statutes and our charter documents could delay or prevent actual and potential changes in control, even if they would benefit the Company's stockholders.
| ITEM 1B. |
Not Applicable.
| ITEM 2. |
We lease a 10,6725,581 sq. ft. facility in Horsham, Pennsylvania that houses our executive offices and marketing. The term of the lease runs through November 30, 2015. In addition, we lease a 7,140 sq. ft. facility in Orangeburg, New York that houses parts of sales and operations.finance. The term of the lease runs until September 30, 2016.
We lease office space at a 17,222 sq. ft. buildingfacility in Hod-Hasharon, Israel,Willow Grove, Pennsylvania that is used for marketing, operations and research and development.currently houses part of our legal department. The term of the lease runs untilexpired on April 30, 2017.
Some of our executives occupy office manufacturing and warehousing space in Carlsbad, California. The lease expires on September 30, 2015. Our Carlsbad facility houses the manufacturing and development operations for our excimer laser business. We will begin negotiations to renew this lease within the next two months; we expect that this lease will be renewed without incident.
In 2017, we acquired (i) three vacant land sites intended for development as gas stations in northern California, (ii) a 75% membership interest in a limited liability company that owns a vacant land site located in Northern California, in which profits and trade dress infringement,losses are allocated 75% to our company and false25% to the noncontrolling member subject to a preferred equity split in which the noncontrolling member earns the first 10% of net profits and misleading advertising. A second suit against Viatek was filedthe balance of the 90% is to be paid along the terms of the 75% split to our company and 25% to the noncontrolling member (iii) an interest in Canada, wherea limited liability company which owns property located in Los Lunas, New Mexico being developed as a single family residential development.
The proposed gas station sites are located in Atwater and Merced, California. We intend to explore our options for the Pearl is offered on that country's The Shopping Channel, alleging trademark and trade dress infringement, and false and misleading advertising. Viatek's response containsdevelopment of these properties. We may (i) lease a varietyproperty to a developer who will handle all further development of counterclaims and affirmative defenses against both Radiancy and its parentthe property, with our company PhotoMedex, including, among other counts, claims regarding the invalidity of Radiancy's patents and antitrust allegations regarding Radiancy's conduct.
Below description of existing land and prosecuting that motion. As of December 31, 2014, discovery and related court hearings continuedevelopment assets upon contribution:
| Location | State | Status | Percentage Interest Contributed |
| Atwater | CA | Existing building on site, needs new plan submittal | 100.0% |
| Atwater | CA | Existing building on site, needs new plan submittal | 100.0% |
| Merced County | CA | Original map approved, plan needs to be modified | 100.0% |
| Los Lunas(1) | NM | Active construction and sale property | 17.9% |
| Merced(2) | CA | Under evaluation | 75.0% |
(1) Based on percentage interest in both the US and the Canadian cases. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the caseasset transferred by contributed entity. Refer to Item 1A. “Risk Factors.”
(2) Based on membership interest in contributed entity assigned to our company.
| ITEM 3. | LEGAL PROCEEDINGS. |
JFURTI Litigation
Our company is still in the early stages of discoverya party to determine the validity of any claim or claims made by Viatek. Therefore, the Company has not recorded any reserve or contingent liability related to this particular legal matter. However, in the future, as the case progresses, the Company may be required to record a contingent liability or reserve for this matter.
The suit is the ninth filed by Jacob Frydman and/or JFURTI, LLC in a dispute between the plaintiffs and the First Capital group of companies, which entered into a series of agreements with Mr. Frydman beginning in September 2015. Mr. Frydman had founded, sponsored, and taken public United Realty Trust Incorporated, a Real Estate Investment Trust, or the REIT. Mr. Frydman was the CEO and Chairman of the REIT as well as the owner of various other United Realty branded companies affiliated with the REIT business. In September 2015, Mr. Frydman and Mr. Singal negotiated and agreed to a transaction between various First Capital branded companies, on the one hand, and the United Realty branded companies affiliated with the REIT business, on the other hand, as a result of which the REIT was rebranded as the Contributor Parent.
After the September 2015 transaction was concluded, several disputes arose between the parties. This suit is the ninth action brought by Mr. Frydman in state and federal courts relating to these disputes, and the second attempt by Mr. Frydman and JFURTI to bring federal claims derivatively in this Court against First Capital entities and other parties. The first action, titled JFURTI, LLC and Jacob Frydman v. Forum Partners Investment Management LLC et al., No. 16 Civ. 8633 or the Prior Action, commenced on November 7, 2016 and asserted, inter alia, derivative RICO and securities fraud claims. The Court dismissed the action in a decision and order dated April 27, 2017.
Following dismissal of the Prior Action, Mr. Frydman sent letters to each member of the Contributor Parent’s Board of Directors, or the Demand Letter, demanding that the Board investigate and remediate the dissipation of assets as alleged by plaintiffs. In particular, the Demand Letter questioned (i) a letter of intent with Presidential Realty Corporation, or Presidential, announced in an 8-K filed by the Contributor Parent on or about July 18, 2016; (ii) the Contributor Parent’s use of funds raised between September 15, 2015 and February 28, 2016; (iii) an interest contribution agreement with Presidential entered into on or about December 16, 2016; (iv) the Contributor Parent’s failure to file quarterly and annual reports; (iv) an interest contribution agreement entered into on March 31, 2017 with our company; and (v) other purportedly fraudulent acts such as publishing an artificially inflated net asset value, defaulting on certain mortgage loans, misrepresentations by Mr. Singal with respect to certain properties contributed to the Contributor Parent through the Master Agreement executed on September 15, 2015, and various loan agreements with Forum Partners Investment Management LLC, or Forum. The Demand Letter also demanded inspection of certain corporate documents pursuant to Md. Code § 2-512.
The Contributor Parent commenced such an investigation, and offered such an inspection, but Mr. Frydman and JFURTI failed to wait for the results of the investigation or make any inspection, and instead brought suit in the same court as the Prior Action. The suit alleges, among other claims, violations of the Federal securities laws between November 7, 2012 and November 14, 2013. A mediation on possible settlement of this action was held on November 10, 2014; the parties including the Company's insurance carrier have agreed on a possible settlement. The Company has paid its own legal fees up to the deductible cap on its insurance policy, and all amounts to be paid to plaintiffs and plaintiff's counsel will be paid by the carrier§ 10(b) of the insurance policy. This settlement is subject to reviewExchange Act and approval by the District Court, which has not yet rendered its opinion.
The parties have reachedsubmitted a possible settlementmotion for an order (i) staying all proceedings in these suits,this action for 60 days, or until the end of 2017, and (ii) extending the defendants time to respond to the complaint, or to make a motion with respect to the complaint, until 45 days after the Contributor Parent’s response to the Demand Letter. The Court granted that motion on October 31, 2017. Upon completion of their investigation, the Contributor Parent provided a response to the Demand Letter, denying all claims made in the letter. A Motion to Dismiss this action has now been filed with the Company contributing less than $100,000Court on behalf of all plaintiffs.
Our company intends to the settlement, plus the payment of its legal fees, and the remainder of the settlement being covered by the insurance carriers. This settlement is subject to review and approval by the state court, which has not yet rendered its opinion.
Linda Andrews Litigation
During 2016, Linda Andrews, an alleged user of the Company'sno!no! Hair device, filed a product liability claim against our company, its subsidiary Radiancy, Inc., was served with a class action lawsuit filedand Dr. Dolev Rafaeli, in the SuperiorUnited States District Court for the Middle District of Florida, Orlando Division, alleging that use of the device had caused a relapse of and complication to a pre-existing medical condition resulting from her treatment for cancer. The complaint alleged, among other claims, that Radiancy failed to provide adequate warnings regarding the operation of the device. We and Dr. Rafaeli filed a motion to dismiss the claims against them and Radiancy filed an answer to the Complaint. Ms. Andrews then sought leave to amend her complaint to clarify the claims. Our company, Radiancy and Dr. Rafaeli filed appropriate responses and renewed the motion to dismiss the claims against our company and Dr. Rafaeli.
On June 22, 2017, the United States District Court for the Middle District of Florida, Orlando Division, dismissed the claims against our company and Dr. Dolev Rafaeli without prejudice. Radiancy remained a defendant in the State of California, County of Kern.suit.
Radiancy entered into a settlement with Ms. Andrews in 2017. The suit was filed by April Cantley, who purchased Radiancy's no!no! Hair products. It alleges various violations of state business and consumer protection codes including false and misleading advertising, breach of express and implied warranties and breachterms of the California Legal Remedies Act. The complaint seeks certification of the class,settlement are confidential.
Other Litigation
Our company and certain subsidiaries are involved in other miscellaneous litigation and legal actions, including product liability, consumer, commercial, tax and governmental matters, which consists of customers in the State of California who purchased the no!no! Hair devices. The complaint also seeks an unspecified amount of monetary damages, pre-and post-judgment interest and attorneys' fees, expert witness fees and other costs. Radiancy has filed an Answer to this Complaint; the case is now in the discovery phase. Radiancy and its officers intend to vigorously defend themselves against this lawsuit. Discovery has now commenced in this action. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case has only been initiated and no discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters.
Market Information
Our common stock is listed on the Nasdaq Global SelectCapital Market ("Nasdaq") under the symbol "PHMD."“FCRE” (formerly “PHMD”). The following table sets forth, for the periods indicated, the high and low closing sale prices per share of our common stock:
| High | Low | ||
| Year Ended December 31, 2014: | |||
| Fourth Quarter | $5.97 | $1.05 | |
| Third Quarter | 12.61 | 6.20 | |
| Second Quarter | 15.73 | 11.81 | |
| First Quarter | 16.80 | 13.00 | |
| Year Ended December 31, 2013: | |||
| Fourth Quarter | $15.86 | $11.53 | |
| Third Quarter | 16.59 | 14.62 | |
| Second Quarter | 16.95 | 14.71 | |
| First Quarter | 16.47 | 13.95 |
| High | Low | |||||||
| Year Ended December 31, 2017: | ||||||||
| Fourth Quarter | $ | 1.46 | $ | 0.82 | ||||
| Third Quarter | 1.27 | 0.71 | ||||||
| Second Quarter | 1.77 | 1.12 | ||||||
| First Quarter | 2.64 | 1.73 | ||||||
| Year Ended December 31, 2016: | ||||||||
| Fourth Quarter | $ | 4.78 | $ | 1.03 | ||||
| Third Quarter | 6.50 | 1.10 | ||||||
| Second Quarter | 2.65 | 1.05 | ||||||
| First Quarter | 3.05 | 1.85 | ||||||
$1.70Approximate Number of Holders of Our Common Stockper share.
As of March 13, 2015,30, 2018, we had approximately 642 1,095 stockholders of record, without giving effect to determining the number of stockholders who held shares in "street name"“street name” or other nominee accounts.
Dividend Policy
We have not declared or paid any dividend on our common stock, since our inception. We do not anticipate that any dividends on our common stock will be declared or paid in the foreseeable future. Under the terms of the Second Amended and Restated Forbearance Agreement dated February 28, 2015, we may not declare or pay dividends on our common stock.
Securities Authorized for Issuance under Equity Compensation Plans
See Item 12 “Security Ownership of allCertain Beneficial Owners and Management and Related Stockholder Matters.”
Recent Sales of ourUnregistered Securities
We have not sold any equity compensation plans, including planssecurities during the 2017 fiscal year that were assumed through acquisitions and individual arrangementsnot previously disclosed in a quarterly report on Form 10-Q or a current report on Form 8-K that provide forwas filed during the issuance of equity securities as compensation, as of December 31, 2014. See Notes 1 and 12 to the consolidated financial statements for additional discussion.
| EQUITY COMPENSATION PLAN INFORMATION | |||||
Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights | Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (A)) | |||
| (A) | (B) | (C) | |||
| Equity compensation plans | |||||
| approved by security holders | 2,540,733 | $15.99 | 3,465,202 | ||
| Equity compensation plans not approved by security holders | - | - | - | ||
| Total | 2,540,733 | $15.99 | 3,465,202 | ||
Purchases of Equity Securities
No repurchases of our common stock were made during the fourth quarter of 2017.
| Year Ended December 31, | ||||||||||||||||||||
| (In thousands, except per-share data) | ||||||||||||||||||||
| 2014 | 2013 | 2012 | 2011 | 2010 | ||||||||||||||||
| Statement of Operations Data: | ||||||||||||||||||||
| Revenues | $ | 163,541 | $ | 224,664 | $ | 220,651 | $ | 132,082 | $ | 70,071 | ||||||||||
| Costs of revenues | 38,619 | 45,035 | 46,642 | 26,296 | 16,465 | |||||||||||||||
| Gross profit | 124,922 | 179,629 | 174,009 | 105,786 | 53,606 | |||||||||||||||
| Selling, general and administrative | 142,880 | 154,278 | 143,817 | 107,377 | 34,596 | |||||||||||||||
| Engineering and product development | 3,086 | 3,306 | 2,914 | 1,057 | 839 | |||||||||||||||
| Income (loss) from continuing operations before financing income (expense) and interest | (21,044 | ) | 22,045 | 27,278 | (2,648 | ) | 18,171 | |||||||||||||
| Interest and other financing income (expenses), net | (4,387 | ) | 702 | (351 | ) | (68 | ) | (283 | ) | |||||||||||
| Income (loss) from continuing operations before tax expense (benefit) | (25,431 | ) | 22,747 | 26,927 | (2,716 | ) | 17,888 | |||||||||||||
| Income tax (expense) benefit | (36,312 | ) | (4,370 | ) | (4,438 | ) | 2,022 | (6,287 | ) | |||||||||||
| Income (loss) from continuing operations | $ | (61,743 | ) | $ | 18,377 | $ | 22,489 | $ | (694 | ) | $ | 11,601 | ||||||||
| Discontinued operations: | ||||||||||||||||||||
| Loss from discontinued operations | (15,155 | ) | - | - | - | - | ||||||||||||||
| Estimated loss on sale of discontinued operations | (44,598 | ) | - | - | - | - | ||||||||||||||
| Net income (loss) | $ | (121,496 | ) | $ | 18,377 | $ | 22,489 | $ | (694 | ) | $ | 11,601 | ||||||||
| Basic net income (loss) per share: | ||||||||||||||||||||
| Continuing operations | $ | (3.25 | ) | $ | 0.90 | $ | 1.10 | $ | (0.06 | ) | $ | 1.13 | ||||||||
| Discontinued operations | $ | (3.16 | ) | $ | 0.00 | $ | 0.00 | $ | 0.00 | $ | 0.00 | |||||||||
| Basic net income (loss) per share | $ | (6.41 | ) | $ | 0.90 | $ | 1.10 | $ | (0.06 | ) | $ | 1.13 | ||||||||
| Diluted net income (loss) per share: | ||||||||||||||||||||
| Continuing operations | $ | (3.25 | ) | $ | 0.89 | $ | 1.08 | $ | (0.06 | ) | $ | 0.99 | ||||||||
| Discontinued operations | $ | (3.16 | ) | $ | 0.00 | $ | 0.00 | $ | 0.00 | $ | 0.00 | |||||||||
| Diluted net income (loss) per share | $ | (6.41 | ) | $ | 0.89 | $ | 1.08 | $ | (0.06 | ) | $ | 0.99 | ||||||||
| Shares used in computing net income (loss) per share | ||||||||||||||||||||
| Basic | 18,940 | 20,455 | 20,356 | 11,602 | 10,256 | |||||||||||||||
| Diluted | 18,940 | 20,657 | 20,764 | 11,602 | 11,725 | |||||||||||||||
| Balance Sheet Data (At Period End): | ||||||||||||||||||||
| Cash and cash equivalents and short-term deposits | $ | 10,692 | $ | 59,501 | $ | 62,348 | $ | 16,549 | $ | 22,081 | ||||||||||
| Working capital | 25,537 | 83,058 | 95,677 | 30,768 | 27,511 | |||||||||||||||
| Total assets | 187,763 | 220,108 | 211,890 | 144,331 | 46,387 | |||||||||||||||
| Long-term debt (net of current portion) | 37,793 | 82 | - | 8 | - | |||||||||||||||
| Other long-term liabilities | 1,229 | 3,640 | 4,067 | 2,405 | 837 | |||||||||||||||
| Stockholders' equity | $ | 42,265 | $ | 160,361 | $ | 167,327 | $ | 110,725 | $ | 28,900 | ||||||||||
Not applicable.
The following financial data, in this narrative, are expressed in thousands, except for the earnings per share. The following management’s discussion and analysis should be read in conjunction with our financial statements and the Consolidated Financial Statementsnotes thereto and related notes includedthe other financial information appearing elsewhere in this Report.
Overview
Our company, founded in 1980, is transitioning from its former business as a skin health company to a real estate development and Overviewasset management company, concentrating primarily on investments in high quality income producing assets, hotel and resort developments, residential developments and other opportunistic commercial properties.
Until the recent sale of Businessour consumer products division, we were a global skin health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. Starting in 2014, we began to sell off certain business units and product lines and on January 23, 2017, we sold the last remaining major product line, our consumer products division, (see Note 2 Discontinued Operations, to our consolidated financial statements). Following this transaction, we had only minimal operations and assets remaining of immaterial value to our company. We are in the process of selling those assets, remaining inventory and assets of this business line, after which time we will no longer operate within the skin health business.
As a result of the Contribution Transaction described below, we became a real estate development and asset management company. Our current strategic focus is built upon three key components:
For income producing properties, we intend to acquire assets that provide recurring income with the potential for income growth over the long-term. We believe there can be an attractive risk/reward profile to such properties based on the location and the underlying creditworthiness of the tenants. We intend to use such income generation to fund additional acquisitions and development opportunities and general corporate purposes. In addition, we intend to invest in land assets that can be developed into income generating properties. We believe that our size and scale provide an opportunity to take advantage of smaller-tier assets that most traditional investors do not focus on due to size limitations, thus creating unique investment opportunities. In particular, we intend to target assets in secondary and tertiary markets with assets that require minimal capital expenditures but generate initial unlevered cash flow yields that are one of only a few aesthetic companies to have developed professional technologies geared toward physicians and med spas and adapting them for the home-use market and have successfully sold millions of these products to consumers. Our professional- and consumer-use products are listed below, noting that this is not an exhaustive listinghigher than those in primary markets.
A second component of our product portfolio but represents our current key areasinvestment strategy will revolve around sourcing asset management opportunities for which we would operate as an asset manager of focus.
Recent Developments
Contribution Agreement
On March 31, 2017, we entered into the Contribution Agreement with the Acquiror and the Contributor Parties, which was amended on August 3, 2017, October 11, 2017 and December 22, 2017. Pursuant to the Interest Contribution Agreement, as amended, the Contributor transferred $10 million of assets to the Acquiror, consisting of the following: (i) three vacant land sites intended for development as gas stations located in northern California, a 75% interest in a limited liability company that owns a vacant land site intended for development as a gas station, located in northern California; and (iii) a 100% interest in a limited liability company, which we refer to as the Avalon Interest, which owns a 17.9133% interest in a limited liability company called Avalon Jubilee LLC that owns property located in Los Lunas, New Mexico being developed as a single family residential development.
In exchange for these assets, we issued to the Contributor 879,234 shares of our common stock, which represented approximately 19.9% of our issued and outstanding common stock immediately prior to the Closing Date, at a per share value of $2.5183, or approximately $2.2 million in the aggregate. We issued the remaining $7.8 million of the approximately $10 million consideration to the Contributor in the form of 123,668 shares of our newly designated non-voting Series A Convertible Preferred Stock. Each share of the Series A Convertible Preferred Stock is convertible into 25 shares of our common stock, subject to the satisfaction of certain conditions, including stockholder approval of such conversion.
We elected to early adopt ASU 2017-01,Business Combinations (Topic 805) Clarifying the Definition of a Business.Accordingly, the determination of whether the transaction represents a business combination was evaluated by applying ASU 2017-01 guidance. We have determined that the group of assets assumed do not include (and also, none of them on a stand-alone basis) include, an input and a substantive process that together significantly contribute to the ability to create output and thus it was determined that the contribution represents an acquisition of assets rather than a business combination. Accordingly, the total sum of the fair value of consideration given (i.e. the fair value of the equity interests issued) together with the transaction costs, was allocated to the individual assets acquired and liabilities assumed based on their relative fair values at the date of acquisition. Such allocation did not give rise to goodwill.
See Item 1 “Business—Recent Developments—Contribution Transaction” for more information.
Payout Notes and Stock Grant Agreement
Under the Contribution Agreement, amounts due to Dr. Dolev Rafaeli and Dennis M. McGrath under their employment agreements, as well as amounts due to Dr. Yoav Ben-Dror for his services as a board member and officer of our foreign subsidiaries, were converted to convertible secured notes in the principal amounts of approximately $3.1 million, $0.98 million and $1.5 million, respectively, following approval from our stockholders on October 12, 2017 (which we refer to as the Payout Notes). The Payout Notes were due on October 12, 2018, carried a ten percent (10%) interest rate, payable monthly in arrears commencing on December 1, 2017, and were secured by a security interest in all of our assets pursuant to a security agreement that we entered into with the holders of the Payout Notes on October 12, 2017.
On December 22, 2017, we entered into the Stock Grant Agreement, with Dr. Dolev Rafaeli, Dennis M. McGrath and Dr. Yoav Ben-Dror (collectively referred to herein as the Note Holders) to (i) cause the early conversion of the Payout Notes into an aggregate of 5,628,291 shares of our common stock (which we refer to as the Payout Shares), (ii) effectuate the release of all security interests associated with the Payout Notes, (iii) provide for the issuance of an aggregate of 1,857,336 additional shares of common stock to the Note Holders as consideration for the various agreements of the Note Holders contained in the Stock Grant Agreement (which we refer to as the Additional Shares), (iv) provide for certain cash payments to the Note Holders in amounts equal to the interest payments that would have been made to the Note Holders absent the conversion of the Payout Notes, (v) obtain the agreement of the Note Holders to provide certain support services to our company, and (vi) obtain the conditional resignation of certain of the Note Holders from our Board of Directors. Accordingly, the Payout Notes were paid in full.
Pursuant to the Stock Grant Agreement, we agreed to make twelve (12) monthly payments on the first of each month commencing on January 1, 2018 of approximately $21, $7 and $10 thousand respectively, to Messrs. Rafaeli, McGrath, and Ben-Dror, respectively (which we refer to as the Cash Payments). The Cash Payments are consideration for certain consulting services provided by the Note Holders specified in the Stock Grant Agreement.
See Item 1 “Business—Recent Developments—Payout Notes and Stock Grant Agreement” for more information.
Private Placement
On December 22, 2017, we entered into the Purchase Agreement with OFI, under which OFI may invest up to $15 million in our company in a series of closings, in exchange for which OFI will receive shares of our newly designated Series B Preferred Stock at a purchase price of $1.00 per share.
On December 22, 2017, we completed the first closing under the Purchase Agreement, pursuant to which OFI provided $1.5 million to us in exchange for 1,500,000 shares of Series B Preferred Stock. On January 24, 2018, we completed a second closing under the Purchase Agreement, pursuant to which OFI provided approximately $2.2 million to us in exchange for 2,225,000 shares of Series B Preferred Stock. Under the Purchase Agreement, OFI may, but is not obligated to, make additional investments in one or more subsequent closings until an aggregate amount of $15 million has been invested or the Purchase Agreement has been terminated in accordance with its terms.
Under the Purchase Agreement, the proceeds from the first closing were to be used for working capital and general corporate purposes, the proceeds from the second closing were to be used to perform due diligence and invest in Income Generating Properties (as defined in the Purchase Agreement) that have been approved by our company’s Board of Directors, and proceeds from subsequent closings were be used to invest in Income Generating Properties (as defined in the Purchase Agreement) that have been approved by our Board of Directors or as otherwise agreed to between us and OFI in writing prior to such subsequent closings. On March 16, 2018, we and OFI entered into a letter agreement, pursuant to which OFI agreed that we may use all proceeds for the purposes and uses described in a budget agreed to between us and OFI at the time the letter agreement was signed. In connection with such letter agreement, we agreed to provide OFI, on a quarterly basis, on or prior to 15 days after the end of each quarter, a report that describes, in reasonable detail, the actual expenses incurred, and payments made during such period compared to the expenses and payments specified in the budget for such period, certified by our Chief Financial Officer.
The Purchase Agreement may be terminated by the written agreement of us and OFI, or by us or OFI if the final closing does not take place prior to December 31, 2018.
See Item 1 “Business—Recent Developments—Private Placement” for more information.
Going Concern
The accompanying financial statements have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
As of December 31, 2017, we had an accumulated deficit of approximately $134.45 million and shareholders’ deficit of approximately $2.9 million. To date, and subsequent to the recent sale of our last significant business unit, we have dedicated most of our financial resources to general and administrative expenses. At present, we are only generating de minimis income from our legacy operating activities.
Cash and cash equivalents as of December 31, 2017 were approximately $0.95 million. We have historically financed our activities with cash from operations, the private placement of equity and debt securities, borrowings under lines of credit and, in the most recent periods with the sale of certain assets and business units.
On March 31, 2017, we entered into the Contribution Agreement, under which certain real estate investment properties were contributed to our company in exchange for the issuance of our capital stock. Closing of the Contribution Agreement occurred on May 17, 2017. However, the assets assumed in such contribution do not represent a business and are not producing cash flows and/or revenues.
On December 22, 2017, we entered into the Purchase Agreement with OFI, under which OFI may invest up to $15 million in our company in a series of closings, in exchange for which OFI will receive shares of our newly designated Series B Preferred Stock at a purchase price of $1.00 per share. On December 22, 2017, we completed the first closing under the Purchase Agreement, pursuant to which OFI provided $1.5 million to us. On January 24, 2018, we completed a second closing under the Purchase Agreement, pursuant to which OFI provided approximately $2.2 million to us in. Under the Purchase Agreement, OFI may, but is not obligated to, make additional investments in one or more subsequent closings until an aggregate amount of $15 million has been invested or the Purchase Agreement has been terminated in accordance with its terms. OFI has no obligation to continue to invest in our company, and there are restrictions placed by OFI on the use of these funds.
We will be required to obtain additional liquidity resources in order to support our operations. We are addressing our liquidity needs by seeking additional funding from lenders and investors. There are no assurances, however, that we will be able to obtain an adequate level of financial resources required for the short and long-term support of our operations.
These conditions raise substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of liabilities that may result from the outcome of this uncertainty.
Reportable Segments
Before we commenced our current real estate business, we organized our business into three operating segments based upon our management structure, products through their existing retail and home shopping networks.
Results of Operations
The following table sets forth key components of our results of operations during the years ended December 31, 2014, 20132017 and 2012, respectively. We use2016, both in dollars and as a mixpercentage of direct-to-consumer advertising that includes infomercials, commercials, catalogour revenues.
(All dollar amounts in thousands)
| Year Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Amount | Amount | |||||||
| Revenues | $ | — | $ | — | ||||
| Cost of revenues | — | — | ||||||
| Gross profit | — | — | ||||||
| Operating expenses: | ||||||||
| General and administrative expenses | 10,817 | — | ||||||
| Impairment of investment in other company | 862 | |||||||
| Loss from continuing operations before interest and other financing expense, net | (11,679 | ) | — | |||||
| Revaluation of asset contribution related financial instruments, net | (1,392 | ) | — | |||||
| Revaluation of Option to purchase redeemable convertible B preferred stock | (3,018 | ) | — | |||||
| Interest and other financing expense, net | (267 | ) | — | |||||
| Loss from continuing operations | (16,356 | ) | — | |||||
| Discontinued operations: | ||||||||
| Loss from discontinued operations, net of taxes | (2,459 | ) | (13,264 | ) | ||||
Net loss | $ | (18,815 | ) | $ | (13,264 | ) | ||
General and internet-based marketing campaigns, coupled with select retail resellers, such as Neiman Marcus, Henri Bendel, Planet Beauty, Bed, Bath & Beyond and others; home shopping channels such as HSN; and online retailers such as Dermadoctor.com and Drugstore.com. We believe these channels complement each other, as consumers that have seen our direct-to-consumer advertising may purchase at our retailers, and those who have seen our solutions demonstrated at our retailers may purchase solutions through our websites or call centers.
Impairment of Investment in Other Company.The Company evaluates investments in other company for impairment whenever events or changes in circumstances indicate that the carrying amount of an investment may not be recoverable in accordance with ASC 320 “Investments - Debt and home shopping channels. Our main international targeted markets include Asia Pacific, Europe and South America.
Revaluation of Asset Contribution. For the year ended December 31, 2017, the revaluation of asset contribution increased to approximately $1.39 million due to the re-measurement of the asset contribution that resulted in a loss due to the reduced fair value of the asset.
Revaluation of Option to Purchase Redeemable Convertible B Preferred Stock.For the year ended December 31, 2017, the revaluation of the option to purchase redeemable convertible B preferred stock increased to approximately $3.0 million due to excess of the initial value of the option liability over the proceeds received, net with the device. We have historically employed a direct sales force marketing primarily to dermatologists to create awarenesschanges in the fair value of the XTRAC therapy. Beginning in 2012 we initiated direct to patient XTRAC advertising inOption at December 31, 2017.
Interest and Other Financing Expense, Net. Net interest and other financing expense for the United States targeted at psoriasis and vitiligo patients through testing a varietyyear ended December 31, 2017 was approximately $0.27 million. The functional currency of media including television and radio. We continue to increase our advertising expenditures in this area to reach the more than 10 million patients in the United States afflicted with these diseases.
Loss. The factors discussed above resulted in support of the NEOVA line. We have historically marketed to physicians in the dermatology and plastic surgery field, but plan to supplement these efforts with a direct-to-consumer approach to lead patients into those practices. NEOVA addresses a sizeable global market for anti-aging skin care products. In addition, we have increased marketing exposure to NEOVA by offering an introduction to the product line as an added-value purchase to consumers responding to our no!no! brand advertising.
Liquidity and other aesthetic practitioners. We view this fully trained sales staff as a resource in expanding the Professional segment of our revenues.
As of December 31, 2014,2017, we had a deficit approximately $2.71 million of working capital compared to a deficit of approximately $2.35 million as of December 31, 2016. Cash and cash equivalents were approximately $0.95 million as of December 31, 2017, as compared to approximately $2.68 million as of December 31, 2016.
The following table provides detailed information about our salesnet cash flow for all financial statement periods presented in this report:
Cash Flow
(In thousands)
| Year Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Net cash provided by (used in) operating activities | $ | (9,298 | ) | $ | 358 | |||
| Net cash provided by investing activities | 6,797 | 2,148 | ||||||
| Net cash provided by (used in) financing activities | 906 | (684 | ) | |||||
| Effect of exchange rate changes on cash | 208 | (2,789 | ) | |||||
| Net decrease in cash and cash equivalents | (1,387 | ) | (967 | ) | ||||
| Cash and cash equivalents at beginning of year | 2,335 | 3,302 | ||||||
| Cash and cash equivalent at end of year | $ | 948 | $ | 2,335 | ||||
Net cash and marketing personnel consistedused in operating activities was approximately $9.3 million for the year ended December 31, 2017 compared to approximately $0.36 million net cash provided by operating activities for the year ended December 31, 2016. The primary reason for the change was loss on asset sale to ICTV and the significant reductions in accounts payable and accrued liabilities settled during the year ended December 31, 2017.
Net cash provided by investing activities was approximately $6.8 million for the year ended December 31, 2017 compared to approximately $2.15 million for the year ended December 31, 2015. The primary reason for the change was the cash received from the sale of 92 full-time positions.the consumer division to ICTV for the year ended December 31, 2017.
Net cash provided by (used in) financing activities was approximately $0.9 million for the year ended December 31, 2017 compared to approximately $0.68 million net cash used in financing activities for the year ended December 31, 2016. The increase was due to the funding received from OFI in December 2017.
We have historically financed our activities with cash from operations, the private placement of equity and debt securities, borrowings under lines of credit and, in the most recent periods with sale of certain assets and business units.
On January 23, 2017, we sold our consumer products division to ICTV for a total selling price of $9.5 million, (see Note 2 Discontinued Operations, to our consolidated financial statements). We collected $5 million of that purchase price and the remaining amount of up to $4.5 million was to be payable through a contingent royalty on the sale of consumer products by ICTV. That royalty was settled in July 2017 for a payment of $2 million to our company. Furthermore, while the Company is a party to a Securities Purchase Agreement with Opportunity Fund I-SS, LLC, and has raised certain funds under that Agreement, Opportunity Fund has no obligation to continue to invest in the Company, and there are restrictions placed by Opportunity Fund on the use of these funds.
On December 22, 2017, we entered into the Purchase Agreement with OFI, under which OFI may invest up to $15 million in our company in a series of closings, in exchange for which OFI will receive shares of our newly designated Series B Preferred Stock at a purchase price of $1.00 per share. On December 22, 2017, we completed the first closing under the Purchase Agreement, pursuant to which OFI provided $1.5 million to us. On January 24, 2018, we completed a second closing under the Purchase Agreement, pursuant to which OFI provided approximately $2.2 million to us in. Under the Purchase Agreement, OFI may, but is not obligated to, make additional investments in one or more subsequent closings until an aggregate amount of $15 million has been invested or the Purchase Agreement has been terminated in accordance with its terms. OFI has no obligation to continue to invest in our company, and there are restrictions placed by OFI on the use of these funds.
We will be required to obtain additional liquidity resources in order to support our operations. At this time, there is no guarantee that we will be able to obtain an adequate level of financial resources required for the short and long-term support of our operations or that we will be able to obtain additional financing as needed, or meet the conditions of such financing, or that the costs of such financing may not be prohibitive.
Off-Balance Sheet Arrangements
At December 31, 2017, we had no off-balance sheet arrangements.
Impact of Inflation
We have not operated in a highly inflationary period, and we do not believe that inflation has had a material effect on our revenues or expenses.
Critical Accounting Policies
The discussion and analysis of our financial condition and results of operations in this Report are based upon our Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States.GAAP. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses and disclosures at the date of the financial statements. On an on-going basis, we evaluate our estimates, including, but not limited to, those related to revenue recognition, accounts receivable, inventories, impairment of property and equipment and of intangibles and accruals for warranty claims. We use authoritative pronouncements, historical experience and other assumptions as the basis for making estimates. Actual results could differ from those estimates.
Acquisition of Investment Properties.The Company allocates the purchase price of real estate to identifiable tangible assets such as land, building, land improvements and tenant improvements acquired based on their fair value. In estimating the fair value of each component management considers appraisals, replacement cost, its own analysis of recently acquired and existing comparable properties, market rental data and other related information. The Company’s investment properties as of December 31, 2017 were acquired on May 17, 2017, and included four vacant land sites set for development into gas stations. The Company determined that the fair value of these investment properties on the acquisition date was $2,600.
Impairment of Investment Properties. Our long-lived assets include mainly these investment properties. The Company periodically evaluates its long-lived assets, including investment properties, for indicators of impairment in accordance with ASC 360, “Property, Plant, and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The judgments regarding the existence of indicators of impairment are based on the operating performance, market conditions, as well as the Company’s ability to hold and its intent with regard to each property. The judgments regarding whether the carrying amounts of these assets may not be recoverable are based on estimates of future undiscounted cash flows from properties which include estimates of future operating performance and market conditions. During the year ended December 31, 2017, based on managements’ most recent analyses, impairment losses related to the Company’s investment properties have not been identified.
Impairment of Investment in Other Company.The Company evaluates investments in other company for impairment whenever events or changes in circumstances indicate that the carrying amount of an investment may not be recoverable in accordance with ASC 320 “Investments - Debt and Equity Securities”. The judgments regarding declines in value are based on operating performance, market conditions and the Company’s ability and intent to hold as well as its ability to influence significant decisions of the venture. During the year ended December 31, 2017, based on managements’ most recent analyses, impairment losses have been identified related to the Company’s investment in other company amounting to $862.
Option to Purchase Redeemable Convertible B Preferred Stock.The fair value of the option to purchase redeemable convertible B preferred stock that was issued to an investor in connection with a securities purchase agreement in December 2017 (the Initial Date) was estimated using the Black-Scholes-Merton option-pricing model. We accounted for the aforesaid option according to the provisions of ASC 480, “Distinguishing Liabilities from Equity” since the option is considered freestanding, as the Company believes it is legally detachable and separately exercisable. In addition, the option is exercisable for Convertible B Preferred Stock which are subject to possible redemption at the option of the holder. We classified the option as non-current liability, remeasured at fair value each reporting period until the option will be exercised or expired, with changes in the fair values being recognized in our statement of comprehensive loss as financial income or expense. The fair value of the Option was estimated at the Initial Date and December 31, 2017 by using hybrid method that includes scenario of conversion and scenario liquidation and the Black-Scholes option pricing model. In the first scenario, the Series B Preferred Stock price applied in the model was assumed based on the as-converted price on the date of estimation. Expected volatility was estimated by using a group of peers in the real estate development, homebuilding and income-producing properties sectors, and applying a 75% percentile ranking based on the total capitalization of the Company. In the second scenario, the option was estimated based on the value of the option in a proposed liquidation scenario. A probability weighting was applied to determine the expected value of the option. During the year ended December 31, 2017, the Company recorded a loss amounting to $4,084 as an excess of the initial value of the option liability over the proceeds received and income from revaluation of the option to purchase redeemable convertible B preferred stock in total amount of $1,194.
Revenue Recognition. We recognizerecognized revenues from the product sales when the following four criteria have beenwere met: (i) the product hashad been shipped and we havehad no significant remaining obligations; (ii) persuasive evidence of an arrangement exists;existed; (iii) the price to the buyer iswas fixed or determinable; and (iv) collection iswas probable. Revenues from product sales arewere recorded net of provisions for estimated chargebacks, rebates, expected returns and cash discounts.
We shipshipped most of our products FOB shipping point, although from time to time certain customers, for example governmental customers, will insist upon FOB destination. Among the factors we taketook into account when determining the proper time at which to recognize revenue arewas when title to the goods transferstransferred and when the risk of loss transfers.transferred. Shipments to distributors or physicians that dodid not fully satisfy the collection criterion arewere recognized when invoiced amounts arewere fully paid or fully assured.
With respect to sales arrangements under which the buyer hashad a right to return the related product, revenue iswas recognized only if all the following arewere met: the price iswas fixed or determinable at the date of sale; the buyer hashad paid, or iswas obligated to pay and the obligation iswas not contingent on resale of the product; the buyer'sbuyer’s obligation would not be changed in the event of theft or physical destruction or damage of the product; the buyer hashad economic substance; we dodid not have significant obligations for future performance to directly bring about resale of the product by the buyer; and the amount of future returns cancould be reasonably estimated.
We provideprovided a provision for product returns based on the experience with historical sales returns, in accordance with ASC Topic 605-15 with respect to sales of product when right of return exists. As of December 31, 2014, accrued sales returns provision was $7,651 or 4.7% of total recognized revenues of $163,541. As of December 31, 2013, accrued sales returns provision was $16,046 or 7.1% of total recognized revenues of $224,664. The return provisions are influenced by product mix and in 2014 there was lower rate toward the direct channel.
Inventories. We have two distribution channels for our phototherapy treatment equipment. We either (i) sell our lasers through a distributor or directly to a physician or (ii) place our lasers in a physician's office (at no charge to the physician) and generally charge the physician a fee for an agreed upon number of treatments. In some cases, the customer and we stipulate to a quarterly or other periodic target of procedures to be performed, and accordingly revenue is recognized ratably over the period.
Allowance for Doubtful Accounts. Accounts receivable arewere reduced by an allowance for amounts that may become uncollectible in the future. From time to time, our customers disputedisputed the amounts due to us, and, in other cases, our customers experienceexperienced financial difficulties and cannotcould not pay on a timely basis. In certain instances, these factors ultimately result in uncollectible accounts. The determination of the appropriate reserve needed for uncollectible accounts involves significant judgment. Such factors include changes in the financial condition of our customers as a result of industry, economic or customer-specific factors. A change in the factors used to evaluate collectability could result in a significant change in the allowance needed. As of December 31, 20142017 and 2013,2016, the allowance for doubtful accounts was $13,559$0 and $10,734approximately $1.19 million, or 8.3%0% and 4.8%3.1%, respectively of the total recognized revenues of each year.
The allowance for doubtful accounts provisions are influenced by product mix and in 2013 there was higher rate toward the direct channel.
| Balance at January 1, 2016 | $ | 3,581 | ||
| Disposal on sale of assets | (1,039 | ) | ||
| Impairment of goodwill | (2,257 | ) | ||
| Translation differences | (285 | ) | ||
| Balance at December 31, 2016 | $ | — |
During the third quarter of 2016, we recorded goodwill and other intangible asset impairment charges of approximately $3.52 million, as we determined that a portion of the value of our goodwill and other intangible assets which affect the amount of future period amortization expense and possible impairment expense that we will incur. Management's judgments regarding the existence of impairment indicators, on an interim or annual basis, are based on various factors, including market conditions and operational performance of our business. As of December 31, 2014 and 2013, we had $41,196 and $45,463 of goodwill and other intangibles, accounting for 22% and 21% of our total assets, respectively. The goodwill is not amortizable; the other intangibles are. The determination of the value of such intangible assets requires management to make estimates and assumptions that affect our consolidated financial statements. We test our goodwill for impairment, which was acquired as part of the reverse acquisition on December 13, 2011, at least annually. This test is conducted in December of each yearimpaired in connection with the annual budgetingthen pending transaction with ICTV. We recorded an impairment of the entire remaining balance of Consumer segment goodwill in the amount of approximately $2.26 million and forecast process. Also, on a quarterly basis, we evaluate whether events or changesrecorded the impairment of the Consumer segment of the intangibles for its licensed technology in circumstances have occurred that would negatively impact the realizable valueamount of approximately $1.26 million (see Note 2 Discontinued Operations, to our intangibles or goodwill.
Stock-based compensation. We account for stock based compensation to employees in accordance with the “Share-Based Payment” accounting standard. The standard requires estimating the fair value as of equity-based payment awards on the date of acquisition.grant using an option-pricing model. The balancesvalue of these acquired intangibles,the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in our consolidated statement of operations. The fair value of employee stock options is estimated using a Black-Scholes valuation model. The fair value of restricted shares is based on the quoted market price of our common stock on the date of issuance. Compensation costs for share-based payment awards are recorded using the graded vesting attribution method over the vesting period, net of amortization, were:
Income taxes.As part of the process of preparing our consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process requires us to estimate our actual current tax exposure and make an assessment of temporary differences resulting from differing treatment of items, for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from future taxable income and, to the extent we believe that recovery is more likely than not, we establish a valuation allowance. After evaluating the effectsAt year end December 31, 2016, material amounts of valuation allowances were recorded representing: 100% of the reverse merger and integration of Radiancy's business on its net operating lossesdeferred tax assets in the U.K., management determinedUS and in the UK. Our assessment for the year ended December 31, 2017, is that the NOLs remain usable against future income of the U.K. subsidiary.a 100% valuation allowance is still required. To the extent we establish a valuation allowance or increase this allowance in a period, we must include an expense within the tax provision in the consolidated statement of operations. Significant management judgment is required in determining our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. In the event that we generate taxable income in the jurisdictions in which we operate and in which we hashave net operating loss carry-forwards that we can utilize to offset all or part of this taxable income, we may be required to adjust our valuation allowance.
On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act or the Tax Act. The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, reducing the U.S. federal corporate tax rate from 35 percent to 21 percent; eliminating the corporate alternative minimum tax or AMT and changing how existing AMT credits can be realized; creating a new limitation on deductible interest expense; changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; limitations on the deductibility of certain executive compensation.
In December 2017, the SEC issued Staff Accounting Bulletin No. 118, or SAB 118, which addresses situations where the accounting is incomplete for the income tax effects of the Act. SAB 118 directs taxpayers to consider the impact of the Act as “provisional” when a company does not have the necessary information available, prepared or analyzed (including computations) to finalize the accounting for the change in tax law. Companies are provided a measurement period of up to one year to obtain, prepare, and analyze information necessary to finalize the accounting for provisional amounts or amounts that cannot be estimated as of December 31, 2017.
With regards to the Tax Act impact on the tax provision as it relates to the company for period year-ending December 31, 2017, we have recognized the provisional impact of tax reform related to the revaluation of deferred tax assets and liabilities from 35% to 21% of $17.2 million tax expense, which is offset by a reduction in the valuation allowance.
In the years ended December 31, 2017 and 2016, we reported financial results for both operations and discontinued operations. ASC 740-20-45 sets down the general rule for allocating income tax expense or benefit between operations and discontinued operations. The general rule requires the computation of tax expense or benefit by entity taking into consideration all items of income, expense, and tax credits. Next, a computation is made taking into consideration only those items related to continuing operations. Any difference is allocated to items other than continuing operations e.g. discontinued operations. Under these general rules, no tax expense or benefit would be allocated to discontinued operations.
An exception to these rules apply under ASC 740-20-45-7 where an entity has 1) a loss from continuing operations and income related to other items such as discontinued operations and 2) the entity would not otherwise recognize a benefit for the loss from continuing operations under the approach described in ASC 740-20-45. This fact pattern applies for the years ended December 31, 2016 for entities in the US and the UK. Application of this rule exception results in the allocation of tax expense to discontinued operations with an offsetting amount of tax benefit reported by the US and UK companies.
We implementedfollow ASC Topic 740-10, "Income Taxes"“Income Taxes” which clarifyclarifies the accounting for uncertainty in tax positions. ASC Topic 740-10 requires that we recognize in our financial statements the impact of a tax position, if that position will more likely than not be sustained upon examination, based on the technical merits of the position, without regard the likelihood that the tax position may be challenged. If an uncertain tax position meets the "more-likely-than-not"“more-likely-than-not” threshold, the largest amount of tax benefit that is greater than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded.
The total share-based compensation expense was $4,938approximately $1.47 million and $4,985approximately $1.97 million for the years ended December 31, 20142017 and 2013,2016, respectively.
Recent Accounting Pronouncements
Recent Accounting Pronouncements Adopted
On March 30, 2016, the FASB issued ASU 2016-09, “Compensation-Stock Compensation”, which effects all entities that issue share-based payment awards to their employees. The amendments in this update cover such areas as the recognition of Operations
| For the Year Ended December 31, 2014 | ||||||||||||
| Product Sales | Services | Total | ||||||||||
| Consumer | $ | 120,931 | $ | - | $ | 120,931 | ||||||
| Physician Recurring | 11,369 | 22,871 | 34,240 | |||||||||
| Professional | 8,370 | - | 8,370 | |||||||||
| Total Revenues | $ | 140,670 | $ | 22,871 | $ | 163,541 | ||||||
| For the Year Ended December 31, 2013 | ||||||||||||
| Product Sales | Services | Total | ||||||||||
| Consumer | $ | 188,259 | $ | - | $ | 188,259 | ||||||
| Physician Recurring | 13,059 | 15,489 | 28,548 | |||||||||
| Professional | 7,857 | - | 7,857 | |||||||||
| Total Revenues | $ | 209,175 | $ | 15,489 | $ | 224,664 | ||||||
| For the Year Ended December 31, 2012 | ||||||||||||
| Product Sales | Services | Total | ||||||||||
| Consumer | $ | 188,425 | $ | - | $ | 188,425 | ||||||
| Physician Recurring | 12,843 | 8,441 | 21,284 | |||||||||
| Professional | 10,942 | - | 10,942 | |||||||||
| Total Revenues | $ | 212,210 | $ | 8,441 | $ | 220,651 | ||||||
| For the Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Direct-to-consumer | $ | 86,709 | $ | 130,785 | $ | 125,208 | ||||||
| Distributors | 1,865 | 15,553 | 24,851 | |||||||||
| Retailers and home shopping channels | 32,357 | 41,921 | 38,366 | |||||||||
| Total Consumer Revenues | $ | 120,931 | $ | 188,259 | $ | 188,425 | ||||||
| For the Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| North America | $ | 90,643 | $ | 147,682 | $ | 141,478 | ||||||
| International | 30,288 | 40,577 | 46,947 | |||||||||
| Total Consumer Revenues | $ | 120,931 | $ | 188,259 | $ | 188,425 | ||||||
| For the Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| XTRAC Treatments | $ | 22,871 | $ | 15,489 | $ | 8,441 | ||||||
| Neova skincare | 6,795 | 8,243 | 8,156 | |||||||||
| Other | 4,574 | 4,816 | 4,687 | |||||||||
| Total Physician Recurring Revenues | $ | 34,240 | $ | 28,548 | $ | 21,284 | ||||||
| For the Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| North America | $ | 30,714 | $ | 25,260 | $ | 18,607 | ||||||
| International | 3,526 | 3,288 | 2,677 | |||||||||
| Total Physicians Recurring Revenues | $ | 34,240 | $ | 28,548 | $ | 21,284 | ||||||
| For the Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Dermatology equipment | $ | 5,025 | $ | 3,962 | $ | 4,174 | ||||||
| LHE equipment | 1,849 | 2,240 | 4,241 | |||||||||
| Other equipment | 1,496 | 1,655 | 2,527 | |||||||||
| Total Professional Revenues | $ | 8,370 | $ | 7,857 | $ | 10,942 | ||||||
| For the Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| North America | $ | 1,804 | $ | 2,012 | $ | 3,026 | ||||||
| International | 6,566 | 5,845 | 7,916 | |||||||||
| Total Professional Revenues | $ | 8,370 | $ | 7,857 | $ | 10,942 | ||||||
| For the Year Ended December 31, 2014 | ||||||||||||
| Product Sales | Services | Total | ||||||||||
| Consumer | $ | 20,307 | $ | - | $ | 20,307 | ||||||
| Physician Recurring | 5,499 | 7,219 | 12,718 | |||||||||
| Professional | 5,594 | - | 5,594 | |||||||||
| Total Cost of Sales | $ | 31,400 | $ | 7,219 | $ | 38,619 | ||||||
| For the Year Ended December 31, 2013 | ||||||||||||
| Product Sales | Services | Total | ||||||||||
| Consumer | $ | 26,794 | $ | - | $ | 26,794 | ||||||
| Physician Recurring | 6,216 | 6,806 | 13,022 | |||||||||
| Professional | 5,219 | - | 5,219 | |||||||||
| Total Cost of Sales | $ | 38,229 | $ | 6,806 | $ | 45,035 | ||||||
| For the Year Ended December 31, 2012 | ||||||||||||
| Product Sales | Services | Total | ||||||||||
| Consumer | $ | 28,965 | $ | - | $ | 28,965 | ||||||
| Physician Recurring | 6,428 | 5,084 | 11,512 | |||||||||
| Professional | 6,165 | - | 6,165 | |||||||||
| Total Cost of Sales | $ | 41,558 | $ | 5,084 | $ | 46,642 | ||||||
| Company Profit Analysis | For the Year Ended December 31, | |||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Revenues | $ | 163,541 | $ | 224,664 | $ | 220,651 | ||||||
| Percent (decrease) increase | (27.2 | %) | 1.8 | % | ||||||||
| Cost of revenues | 38,619 | 45,035 | 46,642 | |||||||||
| Percent decrease | (14.2 | %) | (3.4 | %) | ||||||||
| Gross profit | $ | 124,922 | $ | 179,629 | $ | 174,009 | ||||||
| Gross margin percentage | 76.4 | % | 80.0 | % | 78.9 | % | ||||||
| Consumer Segment | For the Year Ended December 31, | |||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Revenues | $ | 120,931 | $ | 188,259 | $ | 188,425 | ||||||
| Percent decrease | (35.8 | %) | (0.1 | %) | ||||||||
| Cost of revenues | 20,307 | 26,794 | 28,965 | |||||||||
| Percent decrease | (24.2 | %) | (7.5 | %) | ||||||||
| Gross profit | $ | 100,624 | $ | 161,465 | $ | 159,460 | ||||||
| Gross margin percentage | 83.2 | % | 85.8 | % | 84.6 | % | ||||||
| Physician Recurring Segment | For the Year Ended December 31, | |||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Revenues | $ | 34,240 | $ | 28,548 | $ | 21,284 | ||||||
| Percent increase | 19.9 | % | 34.1 | % | ||||||||
| Cost of revenues | 12,718 | 13,022 | 11,512 | |||||||||
| Percent (decrease) increase | (2.3 | %) | 13.1 | % | ||||||||
| Gross profit | $ | 21,522 | $ | 15,526 | $ | 9,772 | ||||||
| Gross margin percentage | 62.9 | % | 54.4 | % | 45.9 | % | ||||||
| Professional Segment | For the Year Ended December 31, | |||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Revenues | $ | 8,370 | $ | 7,857 | $ | 10,942 | ||||||
| Percent increase (decrease) | 6.5 | % | (28.2 | %) | ||||||||
| Cost of revenues | 5,594 | 5,219 | 6,165 | |||||||||
| Percent increase (decrease) | 7.2 | % | (15.3 | %) | ||||||||
| Gross profit | $ | 2,776 | $ | 2,638 | $ | 4,777 | ||||||
| Gross margin percentage | 33.2 | % | 33.6 | % | 43.7 | % | ||||||
Recent Accounting Pronouncements Not Adopted Yet
In February 2016, the FASB issued ASU No. 2016-02, Leases. This guidance will require that lease arrangements longer than 12 months result in accordance with GAAP, management provides certain non-GAAP measuresan entity recognizing an asset and liability equal to the present value of the lease payments in the statement of financial performance. These non-GAAP measures include non-GAAP adjusted income.
| For the Year ended December 31, | ||||||||||||
| 2014 | 2013 | Change | ||||||||||
| Net (loss) income | $ | (121,496 | ) | $ | 18,377 | $ | (139,873 | ) | ||||
| Adjustments: | ||||||||||||
| Depreciation and amortization | 6,912 | 6,119 | 793 | |||||||||
| Interest expense, net | 2,979 | 10 | 2,969 | |||||||||
| Income tax expense | 36,312 | 4,370 | 31,942 | |||||||||
| EBITDA | (75,293 | ) | 28,876 | (104,169 | ) | |||||||
| Stock-based compensation expense | 4,938 | 4,985 | (47 | ) | ||||||||
| Acquisition costs | 2,879 | - | 2,879 | |||||||||
| Major litigation | 2,974 | - | 2,974 | |||||||||
| Extraordinary items, according to credit facility definition | 2,812 | - | 2,812 | |||||||||
| Loss from discontinued operations | 15,155 | - | 15,155 | |||||||||
| Loss from sale of discontinued operations | 44,598 | - | 44,598 | |||||||||
| Non-GAAP adjusted (loss) income | $ | (1,937 | ) | $ | 33,861 | $ | (35,798 | ) | ||||
| For the Year ended December 31, | ||||||||||||
| 2013 | 2012 | Change | ||||||||||
| Net income | $ | 18,377 | $ | 22,489 | $ | (4,112 | ) | |||||
| Adjustments: | ||||||||||||
| Depreciation and amortization | 6,119 | 5,611 | 508 | |||||||||
| Interest expense, net | 10 | 398 | (388 | ) | ||||||||
| Income tax expense | 4,370 | 4,438 | (68 | ) | ||||||||
| EBITDA | 28,876 | 32,936 | (4,060 | ) | ||||||||
| Stock-based compensation expense | 4,985 | 6,197 | (1,212 | ) | ||||||||
| Non-GAAP adjusted income | $ | 33,861 | $ | 39,133 | $ | (5,272 | ) | |||||
In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash” (ASU 2016-18), which requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents will be sufficient to satisfy our working capital needs, capital asset purchases, outstanding commitmentswhen reconciling beginning-of-period and other liquidity requirements associated with our existing operations throughend-of-period total amounts shown on the statement of cash flows. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and beyond the first quarter of 2016.
In May 2017, the CompanyFASB issued ASU 2017-09 guidance on changes to terms and its financial condition.
| Payments due by period | ||||||||||||||||
Contractual Obligations | Total | Less than 1 year | 1 – 3 years | 4 – 5 years | ||||||||||||
| Credit facility obligations* | $ | 76,500 | $ | 38,732 | $ | 37,768 | $ | - | ||||||||
| Rental and Operating lease obligations | 19,744 | 6,532 | 13,211 | - | ||||||||||||
| Notes payable | 729 | 704 | 25 | - | ||||||||||||
| Total | $ | 96,973 | $ | 45,968 | $ | 51,004 | $ | - | ||||||||
| ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. |
Item 7A. Not applicable.Quantitative and Qualitative Disclosure about Market Risk
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA. |
The financial statements required by this Item 8 are included in this Report and begin on page F-1.
We maintain disclosure controls and procedures that are(as defined in Rule 13a-15(e) under the Exchange Act). Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SECthe rules and forms of the SEC and that such information is accumulated and communicated to our management, including our Chief Executive Officerchief executive officer and Chief Financial Officer,chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.
As required by Rule 13a-15(e) of the Exchange Act, our newly-appointed management has carried out an evaluation, with the participation and evaluatingunder the supervision of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of December 31, 2017. Based upon, and as of the date of this evaluation, management recognizedhas determined that, despite the significant deficiency described below, our disclosure controls and procedures no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Management’s Annual Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) underfor the Exchange Act. Our management conducted an assessment of the effectiveness of the Company's internalCompany. Internal control over financial reporting based onrefers to the framework established inprocess designed by, or under the 2013 Internal Control-Integrated Framework issuedsupervision of, our principal executive officer and principal financial and accounting officer, and effected by the Committeeour board of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, ourdirectors, management has determined that the Company's internal control over financial reporting was effective as of December 31, 2014.
| (1) | pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; |
| (2) | provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with the authorization of our management and directors; and |
| (3) | provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. |
As described above, our newly-appointed Chief Executive Officer and Chief Financial Officer have evaluated the maintenanceeffectiveness of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.
During its evaluation, management discovered that certain controls were not performing as expected. We also have audited,classified that under-performance as a significant deficiency in accordance with theour internal controls. Under standards ofestablished by the Public Company Accounting Oversight Board, (United States),a significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of our financial reporting. The review discovered that the consolidatedprocessing and approval for payment of certain payables was being handled by the same person, rather than one individual entering the payables and another approving them for payment. This deficiency arose in part because of a reduction in the size of our accounting staff that required staff members to assume additional duties. The new controls implemented by our new management now require an additional layer of approval prior to processing payments, along with two individuals to execute and approve payments made by us. Further, we have inserted more frequent reviews of payables entries and bank statements. Management believes the additional controls will provide another layer of review for these accounting processes and ensure the effectiveness of our disclosure controls and procedures.
Changes in Internal Controls over Financial Reporting
We regularly review our system of internal control over financial statementsreporting and make changes to our processes and systems to improve controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include such activities as implementing new, more efficient systems, consolidating activities, and migrating processes.
There have been no changes in our internal control over financial reporting during the fourth quarter of fiscal year 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Our independent registered public accounting firm is not required to attest to the Company aseffectiveness of and for the year ended December 31, 2014 and our report dated March 16, 2015, expressed an unqualified opinion on thoseinternal control over financial statements.
| ITEM 9B. | OTHER INFORMATION. |
We have no information to disclose that was required to be disclosed in a report on Form 8-K during fourth quarter of our two executives, Dr. Dolev Rafaeli and Mr. Dennis McGrath, entered into Amended and Restated Employment Agreements (the "Amended Agreements") with the Company which supersede their respective Amended and Restated Employment Agreements previously entered into on August 5, 2014
The Amended Agreements also clarify the executives' rights to resign due to "Good Reason" in the event of a breach of the Amended Agreements by the Company or for any reason during the 30-day period immediately following a Change of Control of the Company and to payment of deferred bonuses in connection with the termination of their employment.
| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE. |
Directors and Executive Officers and Corporate Governance
Following is information about our directors and executive officers. Members of our Board of Directors are encouraged to attend meetings of the Board of Directors and the Annual Meeting of Stockholders. The Board of Directors held twelve meetings and executed six unanimous written consents in lieu of a meeting in 2014.
| NAME | AGE | POSITION | ||||
| Chief Financial Officer and Chief Investment Officer | ||||||
| Dr. Bob Froehlich | 64 | Chairman of the Board of Directors | ||||
| Dennis M. McGrath | ||||||
| Director | ||||||
| Dr. Dolev Rafaeli | ||||||
| Director | ||||||
| 60 | Director |
Vineet P. Bedi has served as our Chief Executive Officer since January 2, 2018. Mr. Bedi has over 15 years of experience in real estate investing, private equity, capital markets and Executive Officers
Matthew Stolzar has served as our Chief Financial Officer and Chief Investment Officer since January 2, 2018. Mr. Stolzar has 11 years of experience in finance, including capital markets, real estate private equity and public securities investing. Mr. Stolzar was most recently Head of Research and a Managing Director at KRV Capital, LP, a dedicated real estate securities and hard assets opportunity fund investment adviser, where he focused on deep value investments. Mr. Stolzar worked at KRV from March 2016 to September 2017. Prior to that, he was Head of Research and a Senior Analyst at Pyrrho Capital Management, a global cross-capital structure event driven investment manager, where he focused on hard asset sectors including real estate, financials, energy and mining. Mr. Stolzar worked at Pyrrho from July 2012 to March 2016. Prior to Pyrrho, Mr. Stolzar was an Investment Professional at Och-Ziff Real Estate from August 2007 to December 2011, where he analyzed and executed real estate private equity and credit transactions across the residential, commercial and hospitality sectors. Mr. Stolzar began his career as an Investment Banking Analyst at Credit Suisse in the Real Estate Group. Mr. Stolzar received his B.A. with Honors in Economics and a Minor in Mathematics from Stanford University and is a CFA Charterholder.
Dr. Bob Froehlich has served as the Chairman of our Board of Directors since May 2017. Dr. Froehlich has amassed over 40 years of experience in and around Wall Street. He began his career in the public sector from 1975 until 1985, working as a Budget Analyst for the City of Dayton, Ohio, the Chief Financial Officer for Montgomery County, Ohio’s Water & Sewer District and the first City Manager for the City of Beavercreek, Ohio. In 1985, he transitioned to the private sector where he was unanimously electeda senior executive with Ernst & Whinney from 1985 to serve1989. From 1989 to 1997, Dr. Froehlich held several senior executive roles at Van Kampen Merritt which after its merger with American Capital became Van Kampen American Capital. In 2001, he was appointed Vice Chairman of Scudder Investments when Scudder Funds merged with Kemper Funds. In 2002, when Deutsche Bank acquired Scudder Investments, Dr. Froehlich was named Vice Chairman of Deutsche Asset Management, a role he held until he retired in 2009. He came out of retirement in 2009 to help rebrand Hartford Financial after its near financial collapse serving as Non-Executivea Senior Executive with The Hartford Mutual Funds. In 2012, he retired for the second time. Since his second retirement from Wall Street, Dr. Froehlich has begun a new chapter in his professional career by building a portfolio of boards spanning private, public, not-for-profit and mutual fund companies. From a private company perspective, on June 4, 2014, Dr. Froehlich became the Chairman of the Board, on December 12, 2011. Mr. Pell wasCEO, President & Owner of the Kane County Cougars Baseball Club, the Class “A” minor league affiliate of the Arizona Diamondbacks and a member of Radiancy's Boardthe Midwest League. He was a Co-Owner and Director since 1998. Mr. Pell has founded overJanuary 7, 2013. On August 2, 2016, Dr. Froehlich was appointed an Independent Director for Galen Robotics, Inc., a dozen successful medical technology companies duringspin-off from John Hopkins University, focusing on the past three decades. In 1979, he founded Pentax Precision Instruments, which was sold to Asahi Optical Co. in 1990. In 1983, he founded American Endoscopy Inc., which was sold to C.R. Bard, Inc. (BCR-NYSE) in 1986. In 1984, he founded Versaflex Inc., which was sold to Medtronic in 1988. In 1989, he founded Heart Technology Corp., which went public in the U.S. in 1992 and was sold to Boston Scientific Corp. (BSX-NYSE) in 1995. In 1991, he founded InStent Inc., which becamesurgical robotic microsurgery market. From a public company in 1995perspective, on October 3, 2014, Dr. Froehlich was appointed an Independent Director for AXAR Acquisition Corp. (formerly AR Capital Acquisition Corp.) (NASDAQ: AXAR), a special purpose acquisition corporation formed for the purpose of effecting a merger, capital stock exchange or similar business combinations. He serves as Chairman of the Compensation Committee and a member of the Audit Committee. In July 2014, Dr. Froehlich was sold to Medtronic in 1996. In 1994, he founded Influenceappointed an Independent Director and Audit Committee, Conflicts Committee and Nominating & Governance Committee member for NexPoint Capital, Inc., whicha publicly registered non-traded business development company. From a not-for-profit company perspective, Dr. Froehlich serves on the Board of Directors of The Midwest League of Professional Baseball Clubs, Inc., on the Board of Directors and as Chairman of the Board for Kane County Cougars Foundation, Inc., and as an Independent Trustee and Distribution Committee Chairman and Audit Committee, and Litigation Committee member for Highland Capital Mutual Funds, a major mutual fund company. Previously, from 2017 to 2018, Dr. Froehlich was soldappointed an Independent Director, Nominating & Corporate Governance Committee member and Audit Committee Chairman for First Capital Investment Corporation, a publicly registered non-traded business development company with an objective of investing primarily in small and middle market companies in the United States. From 2013 to American Medical Systems2016, Dr. Froehlich was an Independent Director and Audit Committee Chairman for ARC Healthcare Trust, Inc. in 1999. Working with Dr. Shlomo Ben-Haim, Mr. Pell founded Biosense Inc. in 1994,
Richard J. Leider has served as a member of Vision-Sciences, Inc. (VSCI-NASDAQ).our Board of Directors since May 2017. Mr. PellLeider has a B.S. in political science from Brooklyn College and over 20more than 25 years of experience in the medical technology industry.commercial real estate industry with active involvement in its sub-specialties of office, hospitality, investment, development, construction and strategic management. A hospitality veteran, Mr. PellLeider directed the repositioning, renovation and execution of the successful conversion of the Resort at Squaw Creek into a condominium hotel facility. Since March 2003, he has served as president of Paramount Hotels Inc. a California hotel management company. A principal and cofounder of Anvil Builders Inc., Mr. Leider has directed business development for that company since July 2010. From June 2005 to December 2008, he led the global real estate platform at Tano Capital, LLC and formerly directed the investment platform in Northern California on behalf of Buchanan Street. He was a managing director of global operations at Citadon, Inc., of San Francisco, a provider of Internet solutions for the real estate and construction industries, from June 2000 to December 2001. From 1996 to 2000, he was an executive director at DTZ Staubach Tie Leung in Hong Kong. While in Asia, Mr. Leider’s responsibilities included all aspects of the real estate life cycle, from advisory services to opportunistic institutional direct investment. Prior to his tenure with DTZ Staubach Tie Leung, Mr. Leider was a senior vice president at CBRE in San Francisco. Mr. Leider graduated from the University of California at Berkeley in 1981, earning a B.A. in Political Economies of Industrial Societies, and later studied at Worchester College at Oxford University. Mr. Leider serves on the Boards of Mercy Housing, American Cancer Society, Union Square Business Improvement District and its Public Policy Committee. He is a member of the Urban Land Institute, and CCIM Institute (Certified Commercial Investment Manager). Mr. Leider also serves as an independent board member of First Capital Real Estate Trust Incorporated. Mr. Leider was selected to serve on the Company's boardour Board because of his over thirty-years' experience in leadership rolestwenty-five years’ background in the medical devicecommercial real estate industry.
Yoav Ben-Dror was appointed toDennis M. McGrath has served as a member of our Board of Directors since July 2009. He currently serves as the Executive Vice President and was electedChief Financial Officer of PAVmed, Inc. (Nasdaq: PAVM, PAVMW) since March 2017. Previously, from 2000 to serve2017, Mr. McGrath served in several senior level positions of our company, including from 2011 to 2017 as Non-Executivedirector, President, and Chief Financial Officer. Prior to our reverse merger with Radiancy, Inc. in December 2011, he also served as Chief Executive Officer from 2009 to 2011 and served as Vice Chairman on December 12, 2011. Dr. Ben-Dror wasPresident of Finance and Chief Financial Officer from 2000 to 2009. He received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the chairman2011 Investment Deal of Radiancy's Board since 2006.the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the Ernst & Young 2013 Entrepreneur of the Year. He is an entrepreneur with more than 30 years ofhas extensive experience in mergers and acquisitions, both domestically and internationally, and particularly involving public company acquisitions, including Surgical Laser Technologies, Inc., (formerly, Nasdaq: SLTI), ProCyte Corporation (formerly, Nasdaq: PRCY), LCA Vision, Inc. (formerly, Nasdaq: LCAV) and Think New Ideas, Inc. (formerly, Nasdaq: THNK). Prior to joining our company, he served in several senior level positions of AnswerThink Consulting Group, Inc. (then, Nasdaq: ANSR, now, The Hackett Group, Nasdaq: HCKT), a business consulting and technology integration company, including from 1999 to 2000 as Chief Operating Officer of the Internet Practice, the largest division of AnswerThink Consulting Group, Inc., while concurrently during the merger of the companies, serving as the acting Chief Financial Officer of Think New Ideas, Inc. (then, Nasdaq: THNK, now, Nasdaq: HCKT), an interactive marketing services and business solutions company. Mr. McGrath also served from 1996 until 1999 as Chief Financial Officer, Executive Vice President and director of TriSpan, Inc., an internet commerce solutions and technology consulting company, which was acquired by AnswerThink Consulting Group, Inc. in 1999. During his tenure at Arthur Andersen & Co., where he began his career, he became a Certified Public Accountant in 1981, holds inactive licenses in Pennsylvania and New Jersey, and has a B.S., maxima cum laude, in accounting from LaSalle University. In addition to continuing as a director of PhotoMedex, he serves as the audit chair and a director of several medical devicesdevice companies, including DarioHealth Corp. (Nasdaq: DRIO), Noninvasive Medical Technologies, Inc. and financial innovations.Cagent Vascular, LLC, and as an advisor to the board of an orphan drug company, Palvella Therapeutics, LLC. Formerly from 2007 to 2009, Mr. McGrath served as a director of Embrella Cardiovascular, Inc. (sold to Edwards Lifesciences Corporation, NYSE: EW). He currentlyalso serves on the Board of Dagon Batey-Mamguroth Le-Israel Ltd (silo houses), Final Inc. (high-frequency financial algorithm technology), Fitango Inc. (social network), Neurotech Solutions Ltd. (human cognitionTrustees for Manor College and behavior with an emphasis on attention deficit/hyperactivity disorder (ADHD)), and Impact First Investments Ltd. (investment management firm that specializes in social investing). He is a director at Keren Shemesh Foundation for the Encouragement of Young Entrepreneurs (in association with YBI (Youth Business International), a foundation assisting young entrepreneurs in transforming an idea into a successful sustainable small business), a director at Hatnuah Hezrachit Hachadasha Ltd. (social activity), and a trustee at the Hecht-Zilzer Trust (charity). Dr. Ben Dror previously served on the Board of Cellcom Israel Ltd. (CEL-NYSE), Dubek Ltd. (tobacco), Magic Box Ltd. (financial algorithm technology) and Holon Institute of Technology (H.I.T.), and was a member of the Board of Trustees of the Holon Institute of Technology (H.I.T.). He was also involved with InStent Inc., Influence Medical Technologies Ltd. and Disc-O-Tech Medical Technologies Ltd. Dr. Ben Dror is a member of the Israel Bar and holds a Doctor of the Science of Jurisprudence (J.S.D.) from the School of Law (Boalt Hall), University of California, Berkeley. Dr. Ben-DrorVisitors for Taylor University. Mr. McGrath was selected to serve on the Company's boardour Board because of his extensive background30 years’ experience in the development and implementation of innovative business and financial entrepreneurship.marketing practices.
Dr. Dolev Rafaeliwas appointed has served as a member of our Board of Directors since December 2011. He previously served as our Chief Executive Officer and director infrom December 2011.2011 until May 2017. Dr. Rafaeli joined our subsidiary Radiancy in February 2006 as president and CEO. He has over 2329 years of experience managing international operations. Prior to joining Radiancy, Dr. Rafaeli served from 2004 to 2006 as president and CEO of the USR Group, a consumer electronics products manufacturer, managing operations in Israel, China, Hong Kong and the U.S. Between 2000 and 2004, Dr. Rafaeli founded and served as general manager of Orbotech Ltd. (ORBK-NASDAQ), an automated optical inspection capital equipment manufacturer for the electronics industry in China and Hong Kong, where he was instrumental in building these operations into a $100 million a year business. Between 1997 and 2000, Dr. Rafaeli served as CEO of USR Ltd., a global electronics contract manufacturing company providing design, supply chain and manufacturing services to dozens of clients in the communications, consumer and medical device fields. USR Ltd. employed approximately 1,000 individuals. Dr. Rafaeli previously served as director of operations and manager of the Arad manufacturing facility for Motorola in its Land Mobile Product Solutions division, manufacturing and distributing communications, consumer and other infrastructure electronics products in excess of $400 million annually. Dr. Rafaeli graduated with a B.Sc. in industrial engineering and management cum laude and a M.Sc. in operations management from the Technion-Israel Institute of Technology, and holds a Ph.D. in business management from Century University and an MBA (with distinction) from Cornell University. Dr. Rafaeli was selected to serve on the Company's boardour Board because of his over twenty-years'twenty five years of senior executive and board of directors’ experience with private and public multi-national companies and his vast mergers and acquisitions successful track record.
Michael R. Stewart has served as a member of our Board of Directors since May 17, 2017. Mr. Stewart is a seasoned executive with over 25 years of experience in consumerC-level positions and 36 total years’ experience in executive management, operations and finance. He brings a wealth of expertise with particular strength in operations, financial management, strategy, M&A, capital raise, FDA matters, medical reimbursement as well as sales, marketing, product development and international salesproduct launch. He has extensive U.S. and operations.
Pursuant to the present as a consultant to LSB Industries (NYSE: LXU);Stock Grant Agreement, dated December 22, 2017, Dr. Dolev Rafaeli and from 1995 to 2006, was a large shareholder in Westmoreland Coal (AMEX: WLB), and was active on its board of directors in directing the reorganization of the company and its emergence from Chapter 11. Mr. Sight was selected to serve on the Company's board because of his twenty-years' experience in business operations and management.
Our directors currently have terms which will end at our next annual meeting of the stockholders or until their successors are elected and qualify, subject to February 2003, and served as chairman from October 1993 to October 2005. He served astheir prior death, resignation or removal. Officers serve at the vice-chairmandiscretion of the Board of DirectorsDirectors.
Family Relationships
There are no family relationships among any of Vision-Sciences from May 1992 to October 1993, as honorary chairmanour officers or directors.
Involvement in Certain Legal Proceedings
To the best of our knowledge, none of our directors or executive officers has, during the past ten years:
| ● | been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offences); |
| ● | had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time; |
| ● | been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity; |
| ● | been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated; |
| ● | been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or |
| ● | been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member. |
Corporate Governance
Overview
Our Board of Directors from October 1991 to October 1993, and as the chairman of the Board of Directors from September 1990 to October 1991. He has been on the Board of Directors of Vision-Sciences since
Governance Structure
Our Board of Directors has chosen to appoint a separate Chairman who is currently set at a maximum of eight.
The Board of Directors also has provided for the post of Vice Chairman, who will fulfill the duties of the Chairman when circumstances preclude the Chairman from fulfilling the duties of the chairmanship.
Our Board of Directors administers its risk oversight function as a whole by making risk oversight a matter of collective consideration. While management is responsible for identifying risks, our Board of Directors has charged the Audit Committee of the Board of Directors with evaluating financial and accounting risk, the Compensation Committee of the Board of Directors with evaluating risks associated with employees and compensation. Investor-related risks are usually addressed by the Board as a whole. We believe an independent Chairman of the Board adds an additional layer of insight to our Board of Directors'Directors’ risk oversight process.
Independent Directors
In considering and Corporate Governancemaking decisions as to the independence of each of the directors of the Company, the Board considered transactions and Audit Committees
Audit Committee
Our Board of Directors has established an Audit Committee to assist it in fulfilling its responsibilities for select committees. In addition,general oversight of the integrity of our consolidated financial statements, compliance with legal and regulatory requirements, the independent auditors’ qualifications and independence, the performance of our independent auditors and an internal audit function and risk assessment and risk management. The duties of our Audit Committee include:
| ● | appointing, evaluating and determining the compensation of our independent auditors; |
| ● | reviewing and approving the scope of the annual audit, the audit fee and the financial statements; |
| ● | reviewing disclosure controls and procedures, internal control over financial reporting, any internal audit function and corporate policies with respect to financial information; |
| ● | reviewing other risks that may have a significant impact on our financial statements; |
| ● | preparing the Audit Committee report for inclusion in the annual proxy statement; |
| ● | establishing procedures for the receipt, retention and treatment of complaints regarding accounting and auditing matters; |
| ● | approving all related party transactions, as defined by applicable Nasdaq Rules, to which the Company is a party; and |
| ● | evaluating annually the Audit Committee charter. |
The Audit Committee works closely with management as well as our independent auditors. The Audit Committee has the authority to obtain advice and assistance from, and receive appropriate funding from us for, outside legal, accounting or other advisors as the Audit Committee deems necessary to carry out its duties.
Our Board of Directors has adopted a written set of corporate governance guidelines and a code of business conduct and ethics and a code of conductcharter for our chief executive and senior financial officers that generally formalize practices that we already had in place. We have adopted a Code of Ethics on Interactions with Health Care Professionals, an Anti-Fraud Program and a policy for compliance with the Foreign Corrupt Practices Act. To view the charters of our Audit Compensation and Nominations and Corporate Governance Committees, Code of Ethics, corporate governance guidelines, codes of conduct and whistle blower policy, please visit our website at www.photomedex.com,under the Corporate Governance sectionCommittee. The members of the Investor Relations page (this website address is not intended to functionAudit Committee are Dr. Bob Froehlich, Richard J. Leider and Michael R. Stewart. Mr. Stewart serves as a hyperlink and the information contained on our website is not intended to be a partChair of this Report). In compliance with Nasdaq rules, the majority of our Board of Directors is comprised of independent directors. Audit Committee.
The Board of Directors determined in 2014 that except for Messrs. Rafaeli and McGrath, who are our Chief Executive Officer and Chief Financial Officer, respectively, all current memberseach member of the Audit Committee satisfies the independence and other composition requirements of the SEC and The Nasdaq Stock Market. Our Board has determined that Dr. Bob Froehlich and Michael R. Stewart both qualify as an “audit committee financial expert” under Item 407(d)(5) of Directors are independent underRegulation S-K and have the revised listing standards ofrequisite accounting or related financial expertise required by applicable Nasdaq rules.
Nasdaq.
Our Compensation Committee discharges the Board of Directors'Directors’ responsibilities relating to compensation of our Chief Executive Officer and other executive officers, produces an annual report on executive compensation for inclusion in our annual proxy statement and this Report and provides general oversight of compensation structure. Other specific duties and responsibilities of the Compensation Committee include:
| reviewing and approving objectives relevant to executive officer compensation; |
| evaluating performance and recommending to the Board of Directors the compensation, including any incentive compensation, of our Chief Executive Officer and other executive officers in accordance with such objectives; |
| reviewing employment agreements for executive officers; |
| recommending to the Board of Directors the compensation for our directors; |
| administering our equity compensation plans (except the Non-Employee Director Stock Option Plan) and other employee benefit plans; |
| evaluating human resources and compensation strategies, as needed; and |
| evaluating periodically the Compensation Committee charter. |
Our Board of Directors has adopted a written charter for the Compensation Committee. The members of the Compensation Committee is currently composed of Messrs. Ben-Dror, Connellyare Richard J. Leider and Pell. Dr. Ben-DrorMichael R. Stewart. Mr. Leider serves as the ChairmanChair of the Compensation Committee. Our Board of Directors determined that each member of the Compensation Committee in 2014 satisfies the independence requirements of Nasdaq. The Compensation Committee held four formal meetings during 2014.Nasdaq Stock Market.
The Compensation Committee reviews executive compensation from time to time and reports to the Board of Directors, which makes all final decisions with respect to executive compensation. The Compensation Committee adheres to several guidelines in carrying out its responsibilities, including performance by the employees, our performance, enhancement of stockholder value, growth of new businesses and new markets and competitive levels of fixed and variable compensation. The report of the Compensation Committee for 2014 is presented below.
Nominations and Corporate Governance Committee.
Our Board of Directors has established a Nominations and Corporate Governance Committee for the purpose of reviewing all Board of Director-recommended and stockholder-recommended nominees, determining each nominee'snominee’s qualifications and making a recommendation to the full Board of Directors as to which persons should be our Board of Directors'Directors’ nominees. Our Board of Directors has adopted a written charter for the Nominations and Corporate Governance Committee. The Nominations and Corporate Governance Committee is composed of Messrs. Sight and Oneda; Mr. Oneda resigned from the Board and its Committees effective July 31, 2014. Mr. Sight serves as the Chairman of the Nominations and Corporate Governance Committee. The Nominations and Corporate Governance Committee held two meeting during 2014 in conjunction with a meeting of the full Board of Directors.
| identifying and recommending to our Board of Directors individuals qualified to become members of our Board of Directors; |
| recommending to our Board of Directors the director nominees for the next annual meeting of stockholders; |
| recommending to our Board of Directors director committee assignments; |
| reviewing and evaluating succession planning for our Chief Executive Officer and other executive officers; |
| monitoring the independence of our directors; |
| developing and overseeing the corporate governance principles applicable to members of our Board of Directors, officers and employees; |
| monitoring the continuing education for our directors; and |
| evaluating annually the Nominations and Corporate Governance Committee charter. |
Our Board of Directors has adopted a written charter for the Nominations and Corporate Governance Committee. The members of the Nominations and Corporate Governance Committee considers these requirements when recommending nominees to our Boardare Dr. Bob Froehlich and Richard J. Leider. Dr. Froehlich serves as the Chair of Directors. the Nominations and Corporate Governance Committee.
Our Nominations and Corporate Governance Committee utilizes a variety of methods for identifying and evaluating nominees for our directors. Our Nominations and Corporate Governance Committee will regularly assess the appropriate size of our Board of Directors and whether any vacancies on the Board of Directors are expected due to retirement or other circumstances. When considering potential director nominees, the Nominations and Corporate Governance Committee also considers the candidate'scandidate’s character, judgment, diversity, age, skills, including financial literacy and experience in the context of the needs of PhotoMedexthe Company and of our existing directors.
Our Nominations and Corporate Governance Committee does not have a specific policy with regard to the Company.
Stockholder Communications with the Board of Directors
Our Board of Directors has established a process for stockholders to communicate with the Board of Directors or with individual directors. Stockholders who wish to communicate with our Board of Directors or with individual directors should direct written correspondence to Michele Pupach, Corporate Counsel at mpupach@photomedex.com or to the following address (our principal executive offices):address: Board of Directors, c/o Corporate Secretary, 100 Lakeside2300 Computer Drive, Horsham,Building G, Willow Grove, Pennsylvania 19044.19090. Any such communication must contain:
| a representation that the stockholder is a holder of record of our capital stock; |
| the name and address, as they appear on our books, of the stockholder sending such communication; and |
| the class and number of shares of our capital stock that are beneficially owned by such stockholder. |
Ms. Pupach or the Corporate Secretary, as the case may be, will forward such communications to our Board of Directors or the specified individual director to whom the communication is directed unless such communication is unduly hostile, threatening, illegal or similarly inappropriate, in which case Ms. Pupach or the Corporate Secretary, as the case may be, has the authority to discard the communication or to take appropriate legal action regarding such communication.
Code of Ethics
We have adopted a Code of Ethics that applies to all of our employees, officers and directors. The Code of Ethics is available on our web site atwww.fcglobalrealty.com under the Corporate Governance section of the Investor Relations page. We intend to provide disclosure of any amendments or waivers of our Code of Ethics on our website within four business days following the date of the amendment or waiver.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our directors and executive officers and beneficial holders of more than 10% of our common stock to file with the CommissionSEC initial reports of ownership and reports of changes in ownership of our equity securities. As of March 16, 2015, weWe believe, based solely on a review of the copies of such reports furnished to us, and representations of these persons that no other reports were filed and that all reports needed to be filed have been filed for the year ended December 31, 2014.
The Compensation Committee of our Board of Directors is responsible for reviewing and approving the annual compensation of our Named Executive Officers. The Compensation Committee is composed solely of directors who are not our current or former employees, and each is independent under the revised listing standards of Nasdaq. Our Board of Directors has delegated to the Compensation Committee the responsibility to review and approve our compensation and benefits plans, programs and policies, including the compensation of our Chief Executive Officer and our President and Chief Financial Officer as well as middle-level management and other key employees. The Compensation Committee administersfollowing table sets forth information concerning all of our executive compensation programs, incentive compensation plans and equity-based plans and provides oversight for all of our other compensation and benefit programs.
| Name and Principal Position | Year | Salary ($) | Non-Equity Incentive Plan Compensation ($) (1) | Stock Awards ($) (2) | Option Awards ($) (2) | All Other Compensation ($) (3) | Total ($) |
| Dolev Rafaeli, Chief Executive Officer | 2014 | 468,000 | 2,106,970 | 702,000 | 0 | 19,152 | 3,296,122 |
| 2013 | 450,000 | 2,246,640 | 0 | 451,345 | 35,673 | 3,183,658 | |
| 2012 | 450,000 | 2,206,982 | 0 | 1,106,000 | 40,549 | 3,803,531 | |
| Dennis M. McGrath, President and Chief Financial Officer | 2014 | 353,000 | 316,000 | 514,800 | 0 | 22,735 | 1,206,535 |
| 2013 | 337,500 | 234,000 | 0 | 332,570 | 17,642 | 921,712 | |
| 2012 | 325,000 | 234,000 | 0 | 711,000 | 18,487 | 1,288,487 |
| Name and Principal Position | Year | Salary ($) | Stock Awards ($) (1) | Non-Equity Incentive Plan Compensation ($) (2) | All Other Compensation ($) (3) | Total ($) | ||||||||||||||||||
Suneet Singal, | 2017 | 67,500 | 0 | 910,000 | 0 | 977,500 | ||||||||||||||||||
| Former Chief Executive Officer(4) | 2016 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
Stephen Johnson, | 2017 | 182,308 | 0 | 0 | 0 | 182,308 | ||||||||||||||||||
| Former Chief Financial Officer(5) | 2016 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
Dr. Dolev Rafaeli, | 2017 | 3,260,307 | 0 | 0 | 111,758 | 3,372,065 | ||||||||||||||||||
| Former Chief Executive Officer(6) | 2016 | 495,000 | 71,719 | 1,200,000 | 46,347 | 1,813,066 | ||||||||||||||||||
Dennis M. McGrath, | 2017 | 970,284 | 0 | 0 | 58,698 | 1,028,983 | ||||||||||||||||||
| Former Chief Financial Officer(6) | 2016 | 395,000 | 52,594 | 316,000 | 45,156 | 808,750 | ||||||||||||||||||
| The amounts shown for |
| (2) | The amounts shown for Dr. Rafaeli and Dennis M. McGrath relate to the |
| (3) |
| (4) | Mr. Singal served as our Chief Executive Officer from May 17, 2017 until January 2, 2018. Under Mr. Singal’s employment agreement, he was entitled to an annual base salary of $250,000, as well as bonuses and other equity compensation as determined by our Compensation Committee. On October 11, 2017, we entered into an amended a restated employment agreement with Mr. Singal. Under this agreement, Mr. Singal was entitled to a base salary of $250,000 per annum, payable in accordance with our normal payroll practices, provided however, that the base salary would accrue, and not be paid, until (i) the 20% Unsecured Convertible Promissory Note issued to the Contributor by our company on July 25, 2017 had been repaid in full and (ii) Mr. Singal began working for our company on a full-time basis. In connection with Mr. Singal’s resignation, on December 22, 2017, we entered into a separation agreement with Mr. Singal, pursuant to which Mr. Singal agreed to resign and we agreed to issue to Mr. Singal 1,000,000 shares of our common stock, 333,333 shares of which vested immediately, 333,333 shares of which will vest upon the first anniversary of the separation agreement, and 333,334 shares of which will vest upon the second anniversary of the separation agreement. The parties agreed that the issuance of such shares is in lieu of any other payment that Mr. Singal may already be entitled to receive under his employment agreement. |
| (5) | Mr. Johnson served as our Chief Financial Officer from May 17, 2017 until January 2, 2018. Under Mr. Johnson’s employment agreement, he was entitled to an annual base salary of $300,000, as well as bonuses and other equity compensation as determined by our Compensation Committee. In connection with Mr. Johnson resignation, on December 22, 2017, we entered into a separation agreement with Mr. Johnson, pursuant to which Mr. Johnson agreed to resign and we agreed to pay to Mr. Johnson $405,432.70 in twelve (12) installments. We also agreed to pay for the health (medical, dental and/or vision) insurance policies for Mr. | |
| payout note, (v) | ||
Mr. McGrath resigned as our Chief Financial Officer on May 17, 2017. Under Mr. McGrath’s employment agreement, he was entitled to an annual base salary of $395,000, an annual bonus in an amount not less than $316,000, as well other equity compensation as determined by our Compensation Committee. In connection with Mr. McGrath’s resignation, we and Mr. McGrath agreed to convert all compensation due under any applicable benefit plans and programs of the Company; and
Name | Benefit | Before Change in Control Termination w/o Cause or for Good Reason ($) | After Change in Control Termination w/o Cause or for Good Reason ($) | Voluntary Termination | Death (1) | Disability (1) | Change in Control |
| Dolev Rafaeli | Salary & bonus (1)(2) | $ 6,780,000 | $6,780,000 | 0 | 0 | 0 | N/A |
| Health continuation | 22,628 | 22,628 | 0 | 0 | 0 | N/A | |
| AD&D insurance | 7,052 | 7,052 | 0 | 0 | 0 | N/A | |
| Executive life ins. | 26,608 | 26,608 | 0 | 0 | 0 | N/A | |
Accelerated vesting (3) | 344,250 | 344,250 | 0 | 0 | 0 | N/A | |
TOTAL(4) | $ 7,180,538 | $ 7,180,538 | 0 | 0 | 0 | N/A | |
| Dennis McGrath | Salary & bonus (1)(2) | $ 2,844,000 | $ 2,844,000 | 0 | 0 | 0 | N/A |
| Health continuation | 22,628 | 22,628 | 0 | 0 | 0 | N/A | |
| AD&D insurance | 7,052 | 7,052 | 0 | 0 | 0 | N/A | |
| Executive life ins. | 32,352 | 32,352 | 0 | 0 | 0 | N/A | |
Accelerated vesting (3) | 252,450 | 252,450 | 0 | 0 | 0 | N/A | |
TOTAL(4) | $ 3,158,482 | $ 3,158,482 | 0 | 0 | 0 | N/A |
| Estimated Possible Payouts Under Non-Equity Incentive Plan Awards | All Other Stock Awards: Number of Shares of Stock (#) | Closing Price on Grant Date ($/Sh) | Grant Date Fair Value of Stock and Option Awards ($) (1) | ||||
| Name | Grant Date | Threshold ($) | Target ($) | Maximum ($) | |||
| Dolev Rafaeli | 11/7/14 | - | $2,106,970 | - | 225,000 | 3.12 | 702,000 |
| Dennis McGrath | 11/7/14 | - | $316,000 | - | 165,000 | 3.12 | 514,800 |
Outstanding Equity Awards Value at Fiscal Year-EndYear End Table
The following table includes certain information with respect to the value of all unexercised options and unvested shares of restricted stock previously awarded to the executive officers named above at the fiscal year end,ended December 31, 2014.
| Option Awards(1) | Stock Awards(2) | |||||||||||||||||
| Name | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Un-exercisable | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | Option Exercise Price ($) | Option Expiration Date | Number of shares or units of stock that have not vested (#) | Market value of shares of units of stock that have not vested ($) | Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested (#) | Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested ($) | |||||||||
| Suneet Singal | 0 | 0 | 0 | N/A | N/A | 666,667 | 576,667 | 0 | N/A | |||||||||
| Stephen Johnson | 0 | 0 | 0 | N/A | N/A | 0 | N/A | 0 | N/A | |||||||||
| Dr. Dolev Rafaeli | 28,000 | 0 | 0 | 100.00 | 3/18/2022 | 0 | N/A | 0 | N/A | |||||||||
| 9,500 | 0 | 0 | 100.00 | 2/28/2023 | 0 | N/A | 0 | N/A | ||||||||||
| Dennis | 1,750 | 0 | 0 | 31.20 | 6/15/19 | 0 | N/A | 0 | N/A | |||||||||
| McGrath | 2,120 | 0 | 0 | 100.00 | 12/13/21 | 0 | N/A | 0 | N/A | |||||||||
| 10,020 | 0 | 0 | 78.00 | 12/13/21 | 0 | N/A | 0 | N/A | ||||||||||
| 18,000 | 0 | 0 | 100.00 | 3/18/22 | 0 | N/A | 0 | N/A | ||||||||||
| 7,0000 | 0 | 0 | 100.00 | 2/28/23 | 0 | N/A | 0 | N/A | ||||||||||
| Dolev Rafaeli | 56,0000 | 84,000 | 0 | 20.00 | 3/18/2022 | 0 | 0 | N/A | N/A |
| 9,500 | 38,000 | 0 | 20.00 | 2/28/2023 | 0 | 0 | N/A | N/A | |
| 0 | N/A | 0 | N/A | N/A | 0 | 0 | 225,000 | 344,250 | |
| Dennis McGrath | 8,750 | 0 | 0 | 6.24 | 6/15/19 | 0 | 0 | N/A | N/A |
| 10,600 | 0 | 0 | 20.00 | 12/13/21 | 0 | 0 | N/A | N/A | |
| 50,100 | 0 | 0 | 15.60 | 12/13/21 | 0 | 0 | N/A | N/A | |
| 36,000 | 54,000 | 0 | 20.00 | 3/18/22 | 0 | 0 | N/A | N/A | |
| 7,000 | 28,000 | 0 | 20.00 | 2/28/23 | 0 | 0 | N/A | N/A | |
| 0 | N/A | 0 | N/A | N/A | 0 | 0 | 165,000 | 252,450 |
| All options grants were under the Amended and Restated 2005 Equity Compensation Plan. |
| Option Awards | Stock Awards | |||||||
| Number of Shares Acquired on Exercise (#) | Value Realized on Exercise ($) | Number of Shares Acquired on Vesting (#) | Value Realized on Vesting ($) (1) | |||||
| Dennis M. McGrath | - | - | 100,000 | 137,000 | ||||
| (2) | The amount shown represents the grant of restricted stock. This amount is equal to the aggregate grant-date fair value with respect to the award made, computed in accordance with FASB ASC Topic 718 (formerly SFAS 123R). |
Director Compensation
Directors who are also our employeesexecutive officers receive no separate compensation for serving as directors or as members of committees of our Board of Directors. Directors who are not our employees are compensated under the Non-Employee Director Plan. Effective December 12, 2011, each outsideEach other director receives an annual cash retainer of $40,000, payable quarterly and the chairman of each committee receives an additional annual fee of $10,000 for audit, $5,000 for each of compensation and nominations. The table below sets forth our non-employee directors'non-executive officer directors’ compensation through December 31, 2014.
Name | Fees Earned ($) | Stock Awards ($) (1) | All Other Compensation ($) (2) | Total ($) | ||||
| Lewis Pell | 40,000 | 0 | 0 | 40,000 | ||||
| Yoav Ben-Dror | 45,000 | 0 | 360,000 | 405,000 | ||||
| Katsumi Oneda | 30,000 | 0 | 0 | 30,000 | ||||
| James W. Sight | 45,000 | 0 | 0 | 45,000 | ||||
| Stephen P. Connelly | 40,000 | 0 | 0 | 40,000 | ||||
| Trevor S. Harris | 37,500 | 74,700 | 0 | 112,200 |
Name | Fees earned or paid in cash ($) | All other compensation ($) |
Total ($) | |||||||||
| Dr. Robert Froehlich(1) | 28,125 | 0 | 28,125 | |||||||||
| Richard J. Leider(1) | 28,125 | 0 | 28,125 | |||||||||
| Darrell C. Menthe(1) | 25,000 | 0 | 25,000 | |||||||||
| Michael R. Stewart(1) | 31,250 | 0 | 31,250 | |||||||||
Lewis Pell(2) | 17,100 | 0 | 17,100 | |||||||||
| Dr. Yoav Ben-Dror(2)(3) | 15,200 | 960,134 | 975,334 | |||||||||
Stephen P. Connelly(2) | 17,100 | 0 | 17,100 | |||||||||
Dennis McGrath(4) | 25,000 | 1,003,983 | 1,028,983 | |||||||||
Dr. Dolev Rafaeli(4) | 25,000 | 3,347,065 | 3,372,065 | |||||||||
| (1) | New Directors compensated for the period of May 17, 2017 through December 31, 2017. |
| (2) | Lewis C. Pell, Dr, Ben-Dror, and Stephen P. Connelly, resigned from the Board effective May 17, 2017. |
| (3) | We and Dr. Ben-Dror agreed to convert all compensation due under his previous agreements into a secured convertible payout note to be issued following stockholder approval. On October 12, 2017, we issued the payout note in the principal amount of $1,515,000 to Dr. Ben-Dror. The | |
| (4) | See Summary Compensation Table – Fiscal Years Ended December 31, 2017 and 2016. |
| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The following table reflects,sets forth information regarding beneficial ownership of our voting stock as of March 13, 2015, the beneficial common stock ownership of: (a)30, 2018 (i) by each of our directors, (b) each executive officer, (c) each person who is known by us to be a beneficial holder of five percent (5%) orbeneficially own more than 5% of our common stock,voting stock; (ii) by each of our officers and (d)directors; and (iii) by all of our executive officers and directors as a group. Unless otherwise providedspecified, the address of each of the persons set forth below is in care of the accompanying footnotes, the information used in the table below was obtained from the referenced beneficial owner.
Name and Address Of Beneficial Owner (1) | Number of Shares Beneficially Owned | Percentage of Shares Beneficially Owned (1) |
Lewis C. Pell (2) | 2,120,319 | 9.54% |
Yoav Ben-Dror (3) | 1,553,421 | 7.01% |
Dolev Rafaeli (4) | 1,583,347 | 7.13% |
Dennis M. McGrath (5) | 429,274 | 1.93% |
James W. Sight (6) | 479,496 | 2.16% |
Stephen P. Connelly (7) | 20,194 | * |
Trevor Harris (8) | 5,000 | * |
Katsumi Oneda (9) | 1,325,164 | 6.00% |
Shlomo Ben-Haim (10) | 1,806,263 | 8.17% |
Paradigm Capital Mgt. (11) | 1,230,700 | 5.57% |
Stonepine Capital L.P. (12) | 1,206,789 | 5.46 |
All directors and officers as a group (seven persons) (13) | 6,191,051 | 27.88% |
| Name and Address of Beneficial Owner | Amount of Beneficial Ownership(1) | Percent of Common Stock(2) | Percent of Series B Preferred Stock(3) | Percent of Total Voting Stock(4) | ||||||||||||||||
| Common Stock | Series B Preferred Stock | |||||||||||||||||||
| Vineet P. Bedi, Chief Executive Officer | 0 | 0 | * | 0 | * | |||||||||||||||
| Matthew Stolzar, Chief Financial Officer | 0 | 0 | * | 0 | * | |||||||||||||||
| Bob Froehlich, Chairman of the Board | 58,159 | 0 | 0.52 | % | 0 | 0.34 | % | |||||||||||||
| Richard J. Leider, Director | 0 | 0 | * | 0 | * | |||||||||||||||
| Dennis M. McGrath, Director(5) | 1,068,128 | 0 | 9.45 | % | 0 | 6.24 | % | |||||||||||||
| Dr. Dolev Rafaeli, Director(6) | 3,355,900 | 0 | 29.71 | % | 0 | 19.60 | % | |||||||||||||
| Michael R. Stewart, Director | 0 | 0 | * | 0 | * | |||||||||||||||
| All directors and officers as a group (7 persons named above) | 4,482,187 | 0 | 39.54 | % | 0 | 26.12 | % | |||||||||||||
Dr. Yoav Ben-Dror 66 Pinkas st Tel Aviv 6215719 Israel | 1,814,639 | 0 | 16.12 | % | 0 | 10.62 | % | |||||||||||||
Suneet Singal(7) 410 Park Ave, 14th Floor New York, NY 10022 | 1,212,567 | 0 | 10.77 | % | 0 | 7.10 | % | |||||||||||||
Opportunity Fund I-SS, LLC(8) c/o OP Fund I Manager, LLC | 0 | 3,725,000 | * | 100 | % | 34.10 | % | |||||||||||||
*Less than 1%.
| (1) | Beneficial |
| (2) | Based on 11,868,619 shares of |
| (4) | Percentage of Total Voting Stock represents total ownership with respect to all shares of our common stock |
| (5) | Includes |
| (6) | Includes |
| (7) | Includes 879,234 shares of common stock held by First Capital Real Estate Operating Partnership, LP. Mr. Singal is the Chief Executive Officer of First Capital Real Estate Trust Incorporated, which |
| (8) | Kristen Pigman is the Director of OP Fund I Manager, LLC, which is the member and manager ofOpportunity Fund I-SS, LLC, and has voting and dispositive power over the securities held by it. Mr. Pigman disclaims beneficial ownership of such securities. |
Changes in Control
On December 22, 2017, we entered into a Securities Purchase Agreement with OFI under which OFI may invest up to $15 million in the Company in a series of closings, in exchange for which OFI will receive shares of our Series B Preferred Stock, at a purchase price of $1.00 per share. A change of control of the Company may occur if OFI invests such maximum amount. We do not currently have any other arrangements which if consummated may result in a change of control of the Company
Securities Authorized for Issuance under Equity Compensation Plans
The following is a summary of all of our equity compensation plans, including plans that were assumed through acquisitions and individual arrangements that provide for the issuance of equity securities as compensation, as of December 31, 2017. See Notes 1 and 12 to the consolidated financial statements for additional discussion.
(In thousands, except share and per share amounts)
EQUITY COMPENSATION PLAN INFORMATION
Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights | Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (A)) | ||||||||||
| (A) | (B) | (C) | ||||||||||
| Equity compensation plans approved by security holders | 1,000 | $ | 75.00 | 147,088 | ||||||||
| Equity compensation plans not approved by security holders | — | — | — | |||||||||
| Total | 1,000 | $ | 75,00 | 147,088 | ||||||||
Options have been granted to employees and/or consultants out of our 2005 Equity Compensation Plan. Restricted stock awards of 6,500 thousand were issued but not vested as of December 31, 2017. Options to our outside directors will be made from our 2000 Non-Employee Director Stock Option Plan. Additionally, all outstanding options were granted as compensation for benefits inuring to us other than for benefits from capital-raising activities. With limited exceptions under Nasdaq membership requirements, we intend in the future to issue options pursuant to equity compensation plans which have already been approved by our stockholders.
| ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE. |
Item 13. Transactions with Related PersonsCertain Relationships
The following includes a summary of transactions since the beginning of our 2016 fiscal year, or any currently proposed transaction, in which we were or are to be a participant and Related Transactions, the amount involved exceeded or exceeds the lesser of $120 or one percent of the average of our total assets at year-end for the last two completed fiscal years, and in which any related person had or will have a direct or indirect material interest (other than compensation described under “Executive Compensation”). We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm’s-length transactions. (All amounts in thousands, except share and per share amounts.)
| ● | On August 3, 2017, October 11, 2017 and December 22, 2017, we entered into amendments to the Contribution Agreement. Suneet Singal, our Chief Executive Officer and Director at the time that we entered into such amendments, is also the Chief Executive Officer of the Contributor Parent, which is the general partner of the Contributor. |
| ● | On December 22, 2017, we entered into a Letter Agreement with Suneet Singal and certain entities related to or affiliated with him, including the Contributor Parties, pursuant to which Mr. Singal and such entities agreed that they would not, without the prior written consent of OFI, transfer or otherwise dispose of any or all of our equity securities held them, including any additional equity securities which they may subsequently acquire, until 180 days following the dissolution of OFI, but no later than December 31, 2018, subject to certain exceptions. |
| ● | On October 22, 2017, all amounts due to Dr. Dolev Rafaeli and Dennis M. McGrath under their employment agreements, as well as amounts due to Dr. Yoav Ben-Dror for his services as a board member and officer of our foreign subsidiaries, were converted to secured convertible payout notes in the principal amounts of $3,134, $978 and $1,515, respectively. These payout notes were due on October 12, 2018, carried a ten percent (10%) interest rate, payable monthly in arrears commencing on December 1, 2017, and were secured by a security interest in all of our assets. |
| ● | On December 22, 2017, we entered into the Stock Grant Agreement with Dr. Dolev Rafaeli, Dennis M. McGrath and Dr. Yoav Ben-Dror to (i) cause the early conversion of the payout notes into an aggregate of 5,628,291 shares of our common stock, (ii) effectuate the release of all security interests associated with the payout notes, (iii) provide for the issuance of an aggregate of 1,857,336 additional shares of common stock as consideration for the various agreements of such note holders contained in the Stock Grant Agreement, (iv) provide for twelve (12) monthly payments of approximately $21, $7 and $10 to Messrs. Rafaeli, McGrath, and Ben-Dror, respectively, on the first of each month commencing on January 1, 2018, which amounts are equal to the interest payments that would have been made absent the conversion of the payout notes, (v) obtain the agreement of such note holders to provide certain support services to us, and (vi) obtain the conditional resignation of Messrs. Rafaeli and McGrath from our Board of Directors. Accordingly, the payout notes were paid in full. |
| ● | On December 22, 2017, we entered into a Registration Rights Agreement with Dr. Dolev Rafaeli, Dennis M. McGrath and Dr. Yoav Ben-Dror, pursuant to which we agreed to register the 1,857,336 additional shares to be issued under the Stock Grant Agreement under the Securities Act. |
| ● | OFI has made certain loans to the Contributor or one of its affiliates under a separate transaction, which are secured by the Series A Preferred Stock and the Common Stock issued to the Contributor pursuant to the Contribution Agreement on May 17, 2017. At the time of the OFI transaction with our company, Suneet Singal was Chief Executive Officer and a member of our Board of Directors and was also the Chief Executive Officer of the Contributor Parent. Accordingly, the Purchase Agreement between the Company and OFI was considered an interested party transaction and was approved by a majority of our non-interested directors. |
Director Independence
Our Board of our directors pursuant to which we have agreed to indemnify each director against claims brought against them in their capacities as our directors. These indemnification agreements also require us to maintain directors' and officers' liability insurance for our directors.
| ITEM 14. | PRINCIPAL ACCOUNTING FEES AND SERVICES. |
We engaged Fahn Kanne & Co. Grant Thornton Israel ("Grant Thornton Israel") as our independent auditors for 20142017 and 2013.
| 2014 | 2013 | |||
Audit Fees (1) | $474,500 | $327,000 | ||
Audit-Related Fees (2) | 18,000 | 18,000 | ||
Tax Fees (3) | 368,000 | 126,000 | ||
All Other Fees (4) | - | 116,000 | ||
| Total | $860,500 | $587,000 |
(In thousands)
| 2017 | 2016 | |||||||
| Audit Fees(1) | $ | 200 | $ | 200 | ||||
| Audit-Related Fees(2) | — | — | ||||||
| Tax Fees(3) | 105 | 433 | ||||||
| Total | $ | 305 | $ | 633 | ||||
| (1) | Consists of fees billed for the audit of our annual financial statements, review of financial statements included in our Quarterly Reports on Form 10-Q and services that are normally provided by the auditors in connection with statutory and regulatory filings or engagements. |
| (2) | Consists of assurance and related services that are reasonably related to the performance of the audit and reviews of our financial statements and are not included in |
| (3) | Consists of all tax related services. |
EngagementPre-Approval Policies and Procedures
Under the Sarbanes-Oxley Act of the Independent Auditor. The Audit Committee is responsible for approving every engagement of Grant Thornton Israel to perform audit or non-audit services for us before Grant Thornton Israel is engaged to provide those services. Under applicable Commission rules, the Audit Committee is required to pre-approve the2002, all audit and non-audit services performed by the independentour auditors must be approved in orderadvance by our board of directors to ensureassure that theysuch services do not impair the auditors' independence. The Commission's rules specifyauditors’ independence from us. In accordance with its policies and procedures, our board of directors pre-approved the types of non-audit services that an independent auditor may not provide to its audit client and establish the Audit Committee's responsibility for administration of the engagement of the independent auditors.
| ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES. |
a)List of Documents Filed as a Part of This Report:
(1)Index to Financial Statements:
| Report of Independent Registered Public Accounting Firm | F-2 |
| Consolidated Balance Sheets, December 31, 2017 and 2016 | F-3 |
| Consolidated Statements of Comprehensive Loss, Years ended December 31, 2017 and 2016 | F-4 |
Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Deficit, Years ended December 31, 2017 and 2016 | F-5 |
| Consolidated Statements of Cash Flows, Years ended December 31, 2017 and 2016 | F-6 |
| Notes to Consolidated Financial Statements | F-8-F-47 |
(2)Index to Financial Statement SchedulesSchedules:
All schedules have been omitted because they are notthe required not applicable, or the information is otherwise set forthincluded in the consolidated financial statements or the notes thereto.
(a)(3)Index to Exhibits:Exhibits
See exhibits listed under subsectionsPart (b) of this Item 15 are hereby incorporated by reference.
(b)Exhibits:Exhibits
| 10.26 | Asset Purchase Agreement, dated | |
| 10.28 | Supplemental Agreement, dated September | |
| 10.30 | Escrow Agreement, dated June 22, 2015, among MELA Sciences, Inc., the Company and U.S. Bank National Association (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 26, 2015) |
| XBRL Taxonomy Extension Calculation Linkbase Document | ||
| XBRL Taxonomy Extension Definition Linkbase Document | ||
| XBRL Taxonomy Extension Label Linkbase Document | ||
| XBRL Taxonomy Extension Presentation Linkbase Document | |
* Filed herewith
† Executive Compensation Plan or Agreement.
++XBRL (Extensible Business Reporting Language) information is furnished and shall not be deemed "filed" by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
| ITEM 16. | FORM 10-K SUMMARY. |
None.
| FC GLOBAL REALTY INCORPORATED (FORMERLY: PHOTOMEDEX, INC.) AND SUBSIDIARIES | |||||
FC GLOBAL REALTY INCORPORATED (FORMERLY: PHOTOMEDEX, INC.) AND SUBSIDIARIES
Index to Consolidated Financial Statements
| Page | ||||
Opinion on the financial statements
We have audited the accompanying consolidated balance sheets of FC Global Realty Incorporated (Formerly: PhotoMedex Inc.) (a Nevada corporation) and Subsidiariessubsidiaries (the "Company"“Company”) as of December 31, 20142017 and 2013, and2016, the related consolidated statements of comprehensive (loss) income,loss, changes in equityredeemable convertible preferred stock and stockholders’ deficit, and cash flows for each of the threetwo years in the period ended December 31, 2014. 2017, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.
Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred net losses for each of the years ended December 31, 2017 and 2016 and has not yet generated any revenues from real estate activities. As of December 31, 2017, there is an accumulated deficit of $134,445. These conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for opinion
These financial statements are the responsibility of the Company'sCompany’s management. Our responsibility is to express an opinion on thesethe Company’s financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. Anmisstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit includesof its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An auditOur audits also includes assessingincluded evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement presentation.statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ FAHN KANNE & CO. GRANT THORNTON ISRAEL
We have served as the Company’s auditor since 2011.
Tel Aviv, Israel
April 2, 2018
FC GLOBAL REALTY INCORPORATED (FORMERLY: PHOTOMEDEX, INC.) AND SUBSIDIARIES
(In thousands, except share and per share amounts)
| December 31, | ||||||||
| 2014 | 2013 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 10,605 | $ | 45,388 | ||||
| Short term bank deposit | 87 | 14,113 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of $13,559 and $10,734, respectively | 21,977 | 27,218 | ||||||
| Inventories, net | 19,380 | 27,547 | ||||||
| Deferred tax asset, net | 762 | 13,041 | ||||||
| Prepaid expenses and other current assets | 8,347 | 12,597 | ||||||
| Assets held for sale, net | 70,855 | - | ||||||
| Total current assets | 132,013 | 139,904 | ||||||
| Property and equipment, net | 13,802 | 10,489 | ||||||
| Patents and licensed technologies, net | 8,811 | 10,832 | ||||||
| Other intangible assets, net | 8,337 | 9,701 | ||||||
| Goodwill, net | 24,048 | 24,930 | ||||||
| Deferred tax asset, net | 567 | 24,039 | ||||||
| Other assets, net | 185 | 213 | ||||||
| Total assets | $ | 187,763 | $ | 220,108 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Current portion of notes payable | $ | 704 | $ | 838 | ||||
| Current portion of long term debt | 38,732 | 10,000 | ||||||
| Accounts payable | 12,419 | 14,785 | ||||||
| Accrued compensation and related expenses | 2,622 | 3,230 | ||||||
| Other accrued liabilities | 13,022 | 22,032 | ||||||
| Current portion of deferred revenues | 4,480 | 5,961 | ||||||
| Liabilities held for sale | 34,497 | - | ||||||
| Total current liabilities | 106,476 | 56,846 | ||||||
| Long-term liabilities: | ||||||||
| Notes payable, net of current maturities | 25 | 82 | ||||||
| Long term debt, net of current maturities | 37,768 | - | ||||||
| Deferred revenues, net of current portion | 1,127 | 2,758 | ||||||
| Other liabilities | 102 | 61 | ||||||
| Total liabilities | 145,498 | 59,747 | ||||||
| Commitment and contingencies (Note 11) | ||||||||
| Stockholders' equity: | ||||||||
| Preferred Stock, $.01 par value, 5,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2014 and 2013 | - | - | ||||||
| Common Stock, $.01 par value, 50,000,000 shares authorized; 20,376,245 and 18,903,245 shares issued and outstanding, respectively | 204 | 189 | ||||||
| Additional paid-in capital | 110,391 | 104,954 | ||||||
| Retained earnings (accumulated deficit) | (67,817 | ) | 53,679 | |||||
| Accumulated other comprehensive (loss) income | (513 | ) | 1,539 | |||||
| Total stockholders' equity | 42,265 | 160,361 | ||||||
| Total liabilities and stockholders' equity | $ | 187,763 | $ | 220,108 | ||||
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 948 | $ | 2,335 | ||||
| Prepaid expenses and other current assets | 646 | 601 | ||||||
Assets held for sale (Note 2 and 4) | — | 15,565 | ||||||
| Total current assets | 1,594 | 18,501 | ||||||
| Non-current assets: | ||||||||
| Investment properties (Note 5) | 2,600 | — | ||||||
| Investment in other company (Note 5) | 1,806 | — | ||||||
| Property and equipment, net (Note 7) | 5 | — | ||||||
| Other assets, net | 334 | — | ||||||
| Total non-current assets | 4,745 | — | ||||||
| Total assets | $ | 6,339 | $ | 18,501 | ||||
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Notes payable | $ | 778 | $ | — | ||||
| Accounts payable | 612 | 6,648 | ||||||
| Accrued compensation and related expenses (Note 10) | 467 | 4,029 | ||||||
| Other accrued liabilities | 2,450 | 6,023 | ||||||
Liabilities related to assets held for sale | — | 3,209 | ||||||
| Total current liabilities | 4,307 | 19,909 | ||||||
| Non-current liabilities: | ||||||||
| Option to purchase Redeemable Convertible B Preferred Stock (Note 14) | 4,390 | — | ||||||
| Note payable, net of current portion (Note 12) | 454 | — | ||||||
| Total non-current liabilities | 4,844 | — | ||||||
| Total liabilities | 9,151 | 19,909 | ||||||
| Commitment and contingencies (Note 13) | ||||||||
| Redeemable Convertible Preferred Stock Series B, $.01 par value; 15,000,000 shares authorized at December 31, 2017; 1,500,000 issued and outstanding at December 31, 2017, net of amount allocated to option to purchase additional shares; Aggregate liquidation preference $1,503,000 at December 31, 2017 (Note 14) | 87 | — | ||||||
Stockholders’ deficit (Note 14): | ||||||||
| Common Stock, $.01 par value, 500,000,000 and 50,000,000 shares authorized at December 31, 2017 and 2016 respectively; 11,868,619 and 4,361,094 shares issued and outstanding at December 31, 2017 and 2016, respectively | 119 | 44 | ||||||
| Preferred stock, $.01 par value, 32,000,000 shares authorized at December 31, 2017; 0 shares issued and outstanding at December 31, 2017 | ||||||||
| Preferred A Stock $.01 par value, 3,000,000 shares authorized at December 31 ,2017; 123,668 issued and outstanding at December 31, 2017; | 1 | — | ||||||
| Additional paid-in capital | 132,446 | 118,762 | ||||||
| Accumulated deficit | (134,445 | ) | (115,635 | ) | ||||
| Accumulated other comprehensive loss | (1,162 | ) | (4,579 | ) | ||||
| Total stockholders’ deficit attributable to FC Global Realty Incorporate | (3,041 | ) | (1,408 | ) | ||||
| Noncontrolling interest (Note 5) | 142 | — | ||||||
| Total stockholders’ deficit | (2,899 | ) | (1,408 | ) | ||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ deficit | $ | 6,339 | $ | 18,501 | ||||
The accompanying notes are an integral part of these consolidated financial statements.
FC GLOABAL REALTY INCORPORATED (FORMERLY: PHOTOMEDEX, INC.) AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOMELOSS
(In thousands, except share and per share amounts)
| For the Year Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Revenues: | $ | — | $ | — | ||||
| Cost of revenues | — | — | ||||||
| Gross profit | — | — | ||||||
| Operating expenses: | ||||||||
| General and administrative | 10,817 | — | ||||||
Impairment of investment in other company (Note 5) | 862 | — | ||||||
| 11,679 | — | |||||||
| Operating loss | (11,679 | ) | — | |||||
| Revaluation of asset contribution related financial instruments, net (Note 5) | (1,392 | ) | — | |||||
| Revaluation of Option to purchase redeemable convertible B preferred stock (Note 14) | (3,018 | ) | — | |||||
| Interest and other financing expense, net | (267 | ) | — | |||||
| Loss from continuing operations | (16,356 | ) | — | |||||
| Discontinued operations: | ||||||||
| Loss from discontinued operations, net of taxes | (2,459 | ) | (13,264 | ) | ||||
| Net loss including portion attributable to noncontrolling interest | ( 18,815 | ) | (13,264 | ) | ||||
| Loss attributable to noncontrolling interest | 8 | — | ||||||
| Net loss attributable to FC Global Realty Incorporated | $ | (18,807 | ) | $ | (13,264 | ) | ||
| Basic and diluted net loss per share: | ||||||||
| Continuing operations | $ | (2.96 | ) | $ | — | |||
| Discontinued operations | (0.45 | ) | (3.18 | ) | ||||
| $ | (3.41 | ) | $ | (3.18 | ) | |||
| Shares used in computing basic and diluted net loss per share | 5,073,751 | 4,171,549 | ||||||
| Other comprehensive loss: | ||||||||
| Reclassification of cumulative translation adjustment | $ | 3,228 | $ | — | ||||
| Foreign currency translation adjustments | 189 | (2,810 | ) | |||||
| Total other comprehensive income (loss) | 3,417 | (2,810 | ) | |||||
| Comprehensive loss | $ | (15,390 | ) | $ | (16,074 | ) | ||
The accompanying notes are an integral part of these consolidated financial statements
FC GLOBAL REATLY INCORPORATED (FORMERLY: PHOTOMEDEX, INC.) AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)
(In thousands, except share and per share amounts)
| For the Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Revenues: | ||||||||||||
| Product sales | $ | 140,670 | $ | 209,175 | $ | 212,210 | ||||||
| Services | 22,871 | 15,489 | 8,441 | |||||||||
| 163,541 | 224,664 | 220,651 | ||||||||||
| Cost of revenues: | ||||||||||||
| Product sales | 31,400 | 38,229 | 41,558 | |||||||||
| Services | 7,219 | 6,806 | 5,084 | |||||||||
| 38,619 | 45,035 | 46,642 | ||||||||||
| Gross profit | 124,922 | 179,629 | 174,009 | |||||||||
| Operating expenses: | ||||||||||||
| Engineering and product development | 3,086 | 3,306 | 2,914 | |||||||||
| Selling and marketing | 107,169 | 127,528 | 116,487 | |||||||||
| General and administrative | 35,711 | 26,750 | 27,330 | |||||||||
| 145,966 | 157,584 | 146,731 | ||||||||||
| (Loss) income from continuing operations before interest and other financing income (expense), net | (21,044 | ) | 22,045 | 27,278 | ||||||||
| Interest and other financing income (expense), net | (4,387 | ) | 702 | (351 | ) | |||||||
| (Loss) income from continuing operations before income taxes | (25,431 | ) | 22,747 | 26,927 | ||||||||
| Income tax expense | (36,312 | ) | (4,370 | ) | (4,438 | ) | ||||||
| (Loss) profit from continuing operations | (61,743 | ) | 18,377 | 22,489 | ||||||||
| Discontinued operations: | ||||||||||||
| Loss from discontinued operations, net of taxes of $5,496 | (15,155 | ) | - | - | ||||||||
| Estimated loss on sale from discontinued operations | (44,598 | ) | - | - | ||||||||
| Net (loss) income | $ | (121,496 | ) | $ | 18,377 | $ | 22,489 | |||||
| Basic net (loss) income per share: | ||||||||||||
| Continuing operations | $ | (3.25 | ) | $ | 0.90 | $ | 1.10 | |||||
| Discontinued operations | (3.16 | ) | 0.00 | 0.00 | ||||||||
| $ | (6.41 | ) | $ | 0.90 | $ | 1.10 | ||||||
| Diluted net (loss) income per share: | ||||||||||||
| Continuing operations | $ | (3.25 | ) | $ | 0.89 | $ | 1.08 | |||||
| Discontinued operations | (3.16 | ) | 0.00 | 0.00 | ||||||||
| $ | (6.41 | ) | $ | 0.89 | $ | 1.08 | ||||||
| Shares used in computing net income (loss) per share: | ||||||||||||
| Basic | 18,940,355 | 20,454,970 | 20,355,520 | |||||||||
| Diluted | 18,940,355 | 20,657,240 | 20,764,354 | |||||||||
| Other comprehensive (loss) income: | ||||||||||||
| Foreign currency translation adjustments | $ | (2,052 | ) | $ | 678 | $ | 859 | |||||
| Comprehensive (loss) income | $ | (123,548 | ) | $ | 19,055 | $ | 23,348 | |||||
| Redeemable Convertible Preferred Stock | Stockholders’ deficit | |||||||||||||||||||||||||||||||||||||||||||
| Series B | Common Stock | Series A Preferred Stock | Additional Paid-In | Accumulated | Accumulated Other Comprehensive | Noncontrolling | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Loss | Interest | Total | ||||||||||||||||||||||||||||||||||
| BALANCE, DECEMBER 31, 2015 | — | — | 4,398,344 | $ | 44 | — | — | $ | 116,793 | ($102,371 | ) | ($1,769 | ) | — | $ | 12,697 | ||||||||||||||||||||||||||||
| Stock-based compensation related to stock options and restricted stock | — | — | — | — | — | — | 1,969 | — | — | — | 1,969 | |||||||||||||||||||||||||||||||||
| Restricted stock canceled | — | — | (37,250 | ) | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | — | — | — | — | — | — | — | — | (2,810 | ) | — | (2,810 | ) | |||||||||||||||||||||||||||||||
| Loss | — | — | — | — | — | — | — | (13,264 | ) | — | — | (13,264 | ) | |||||||||||||||||||||||||||||||
| BALANCE, DECEMBER 31, 2016 | — | — | 4,361,094 | $ | 44 | — | — | $ | 118,792 | ($115,635 | ) | ($4,579 | ) | — | ($1,408 | ) | ||||||||||||||||||||||||||||
| Stock-based compensation related to stock options and restricted stock | — | — | — | — | — | — | 1,466 | — | — | — | 1,466 | |||||||||||||||||||||||||||||||||
| Common shares issued for asset contribution (Note 5) | — | — | 879,234 | 9 | — | — | 1,266 | — | — | — | 1,275 | |||||||||||||||||||||||||||||||||
| Preferred A stock issued for asset contribution (Note 5 ) | — | — | — | — | 123,668 | 1 | 4,482 | — | — | — | 4,483 | |||||||||||||||||||||||||||||||||
| Common shares issued for Note Payout (Note 14) | 5,628,291 | 56 | — | 5,570 | — | 5,626 | ||||||||||||||||||||||||||||||||||||||
| Common shares issued for severance (Note 14) | — | — | 1,000,000 | 10 | — | — | 900 | — | — | — | 910 | |||||||||||||||||||||||||||||||||
| Issuance of series B redeemable convertible preferred stock and embedded option, net of stock issuance costs of $42 | 1,500,000 | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Amortization of discount related to written call option (Note14) | — | $ | 84 | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
| Accretion of dividend (Note 14) | — | $ | 3 | — | — | — | — | — | (3 | ) | — | — | (3 | ) | ||||||||||||||||||||||||||||||
| Noncontrolling interest from asset acquisition | — | — | — | — | — | — | — | — | — | 150 | 150 | |||||||||||||||||||||||||||||||||
| Reclassification of cumulative translation adjustment | — | — | — | — | — | — | — | — | 3,228 | — | 3,228 | |||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | — | 189 | — | 189 | ||||||||||||||||||||||||||||||||||||||||
| Net Loss | — | — | — | — | — | — | — | (18,807 | ) | — | (8 | ) | (18,815 | ) | ||||||||||||||||||||||||||||||
| BALANCE, DECEMBER 31, 2017 | 1,500,000 | $ | 87 | 11,868,619 | $ | 119 | 123,668 | $ | 1 | $ | 132,446 | ($134,445 | ) | ($1,162 | ) | $ | 142 | ($2,899 | ) | |||||||||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
FC GLOBAL REALTY INCORPORATED (FORMERLY: PHOTOMEDEX, INC.) AND SUBSIDIARIES
(In thousands)
| Common Stock | Additional Paid-In | Treasury | Retained Earnings (Accumulated | Accumulated Other Comprehensive | ||||||||||||||||||||||||
| Shares | Amount | Capital | stock | Deficit) | (Loss) Income | Total | ||||||||||||||||||||||
| BALANCE, DECEMBER 31, 2011 | 18,821,728 | $ | 188 | $ | 97,972 | $ | (250 | ) | $ | 12,813 | $ | 2 | $ | 110,725 | ||||||||||||||
| Issuance of warrants to consultants for services | - | - | 98 | - | - | - | 98 | |||||||||||||||||||||
| Stock-based compensation - grants of common stock | 30,000 | - | 405 | - | - | - | 405 | |||||||||||||||||||||
| Stock-based compensation related to stock options and restricted stock | - | - | 5,709 | - | - | - | 5,709 | |||||||||||||||||||||
| Stock options issued to consultants for services | - | - | 83 | - | - | - | 83 | |||||||||||||||||||||
| Issuance of common stock, net | 3,023,432 | 30 | 37,484 | - | - | - | 37,514 | |||||||||||||||||||||
| Repurchase and retirement of common stock | (842,961 | ) | (9 | ) | (10,747 | ) | - | - | - | (10,756 | ) | |||||||||||||||||
| Exercise of stock options | 10,048 | - | 67 | - | - | - | 67 | |||||||||||||||||||||
| Warrants exercised | 17,756 | 1 | 133 | - | - | - | 134 | |||||||||||||||||||||
| Retirement of treasury stock (16,056 shares) | (16,056 | ) | - | (250 | ) | 250 | - | - | - | |||||||||||||||||||
| Other comprehensive income | - | - | - | - | - | 859 | 859 | |||||||||||||||||||||
| Net income | - | - | - | - | 22,489 | - | 22,489 | |||||||||||||||||||||
| BALANCE, DECEMBER 31, 2012 | 21,043,947 | 210 | 130,954 | - | 35,302 | 861 | 167,327 | |||||||||||||||||||||
| Stock-based compensation related to stock options and restricted stock | - | - | 4,892 | - | - | - | 4,892 | |||||||||||||||||||||
| Stock options issued to consultants for services | - | - | 93 | - | - | - | 93 | |||||||||||||||||||||
| Repurchase and retirement of common stock | (2,144,452 | ) | (21 | ) | (31,008 | ) | - | - | - | (31,029 | ) | |||||||||||||||||
| Exercise of stock options | 3,750 | - | 23 | - | - | - | 23 | |||||||||||||||||||||
| Other comprehensive income | - | - | - | - | - | 678 | 678 | |||||||||||||||||||||
| Net income | - | - | - | - | 18,377 | - | 18,377 | |||||||||||||||||||||
| BALANCE, DECEMBER 31, 2013 | 18,903,245 | 189 | 104,954 | - | 53,679 | 1,539 | 160,361 | |||||||||||||||||||||
| Stock-based compensation related to stock options and restricted stock | - | - | 4,862 | - | - | - | 4,862 | |||||||||||||||||||||
| Stock options issued to consultants for services | 1,663 | - | 76 | - | - | - | 76 | |||||||||||||||||||||
| Issuance of common stock, net | 645,000 | 7 | 1,406 | - | - | - | 1,413 | |||||||||||||||||||||
| Restricted stock issued, net of payroll taxes paid | 826,337 | 8 | (988 | ) | - | - | - | (980 | ) | |||||||||||||||||||
| Issuance of warrants | - | - | 81 | - | - | - | 81 | |||||||||||||||||||||
| Other comprehensive loss | - | - | - | - | - | (2,052 | ) | (2,052 | ) | |||||||||||||||||||
| Net loss | - | - | - | - | (121,496 | ) | - | (121,496 | ) | |||||||||||||||||||
| BALANCE, DECEMBER 31, 2014 | 20,376,245 | $ | 204 | $ | 110,391 | $ | - | $ | (67,817 | ) | $ | (513 | ) | $ | 42,265 | |||||||||||||
| For the Year Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Cash Flows From Operating Activities: | ||||||||
| Net loss | ($16,966 | ) | $ | — | ||||
| Adjustments to reconcile loss to net cash provided by (used in) operating activities related to continuing operations: | ||||||||
| Depreciation and amortization | 297 | — | ||||||
| Impairment of investment in other company | 862 | — | ||||||
| Deferred income taxes | 66 | — | ||||||
| Stock-based compensation | 655 | — | ||||||
| Capital loss from sale of assets | 2,567 | — | ||||||
| Revaluation of asset contribution related financial instruments, net (Note 5) | 1,392 | — | ||||||
Revaluation of option to purchase redeemable convertible B preferred stock (Note 14) | 2,890 | — | ||||||
| Issuance costs allocated to Option to purchase redeemable convertible B preferred stock (Note 14) | 42 | — | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 1,518 | — | ||||||
| Prepaid expenses and other assets | 2,072 | — | ||||||
| Accounts payable | (2,134 | ) | — | |||||
| Accrued compensation and related expenses | 2,936 | — | ||||||
| Other accrued liabilities | (2,906 | ) | — | |||||
| Amortization of discount on mezzanine | 84 | |||||||
| Adjustments related to continuing operations | 10,341 | — | ||||||
| Adjustments related to discontinued operation | (2,673 | ) | 358 | |||||
Net cash provided by (used in) operating activities | (9,298 | ) | 358 | |||||
| Cash Flows From Investing Activities: | ||||||||
| Direct expenses related to asset acquisition (Note 5) | (283 | ) | — | |||||
| Purchases of property and equipment | (22 | ) | — | |||||
| Stock based compensation | 10 | |||||||
| Payment of note receivable | (159 | ) | — | |||||
| Net cash provided by investing activities – continuing operation | 454 | — | ||||||
| Net cash provided by investing activities – discontinued operations | 7,251 | 2,148 | ||||||
| Net cash provided by investing activities | 6,797 | 2,148 | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
PHOTOMEDEX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| For the Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Cash Flows From Operating Activities: | ||||||||||||
| Net (loss) income | $ | (121,496 | ) | $ | 18,377 | $ | 22,489 | |||||
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||||||||||||
| Depreciation and amortization | 6,912 | 6,119 | 5,611 | |||||||||
| Provision for doubtful accounts | 7,661 | 5,958 | 4,629 | |||||||||
| Deferred income taxes | 35,699 | 2,589 | (2,330 | ) | ||||||||
| Stock-based compensation | 4,938 | 4,985 | 6,197 | |||||||||
| Amortization of bank debt issue costs and discount | 2,358 | - | - | |||||||||
| Loss on disposal of property and equipment | (10 | ) | - | - | ||||||||
| Changes in operating assets and liabilities: | ||||||||||||
| Accounts receivable | (2,718 | ) | (13,944 | ) | (11,254 | ) | ||||||
| Inventories | 7,967 | (4,967 | ) | (3,195 | ) | |||||||
| Prepaid expenses and other assets | 2,378 | 843 | (8,583 | ) | ||||||||
| Accounts payable | (2,244 | ) | 4,658 | 1,787 | ||||||||
| Accrued compensation and related expenses | (588 | ) | 733 | (1,316 | ) | |||||||
| Other accrued liabilities (see Note 9) | (8,839 | ) | (444 | ) | 5,719 | |||||||
| Other liabilities | - | - | (1 | ) | ||||||||
| Deferred revenues | (3,083 | ) | 130 | 5,243 | ||||||||
| Net cash (used in) provided by operating activities – continuing operations | (71,065 | ) | 25,037 | 24,996 | ||||||||
| Net cash provided by operating activities – discontinued operations | 46,894 | - | - | |||||||||
| Net cash (used in) provided by operating activities | (24,171 | ) | 25,037 | 24,996 | ||||||||
| Cash Flows From Investing Activities: | ||||||||||||
| Purchases of property and equipment | (251 | ) | (943 | ) | (573 | ) | ||||||
| Lasers placed into service | (6,746 | ) | (5,476 | ) | (3,221 | ) | ||||||
| Proceeds from (investments in) short-term deposit | 14,026 | 3,887 | (18,000 | ) | ||||||||
| Proceeds on sale of property and equipment | 20 | - | - | |||||||||
| Acquisition, net of cash received | (77,510 | ) | 84 | - | ||||||||
| Net cash used in investing activities – continuing operations | (70,461 | ) | (2,448 | ) | (21,794 | ) | ||||||
| Net cash used in investing activities – discontinued operations | (5,218 | ) | - | - | ||||||||
| Net cash used in investing activities | (75,679 | ) | (2,448 | ) | (21,794 | ) | ||||||
| For the Year Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Cash Flows From Financing Activities: | ||||||||
| Proceeds from issuance of redeemable preferred B stock and embedded option, net of issuance cost of $42 (Note 14) | 1,458 | — | ||||||
| Proceeds from note payable | 111 | — | ||||||
| Net cash provided by financing activities –continuing operation | 1,569 | — | ||||||
Net cash provided by (used in) financing activities – discontinued operations | (663 | ) | (684 | ) | ||||
| Net cash provided by (used in) financing activities | 906 | (684 | ) | |||||
| Effect of exchange rate changes on cash | 208 | (2,789 | ) | |||||
| Change in cash and cash equivalents | (1,387 | ) | (967 | ) | ||||
| Cash and cash equivalents at the beginning of year | 2,335 | 3,302 | ||||||
| Cash and cash equivalents at the end of year | $ | 948 | $ | 2,335 | ||||
| Supplemental disclosure of non-cash activities: | ||||||||
| Cash paid for income taxes | $ | 36 | $ | 203 | ||||
| Cash paid for interest | $ | 126 | $ | 281 | ||||
| Contribution of investment property and investment in other company against stock issue, financial assets related to future mandatory asset contribution and financial liabilities for optional asset acquisition (Note 5) | $ | 4,836 | — | |||||
| Conversion of Payout Notes into shares of common stock | $ | 5,626 | — | |||||
The accompanying notes are an integral part of these consolidated financial statements.
FC GLOBAL REALTY INCORPORATED (FORMERLY: PHOTOMEDEX, INC. AND SUBSIDIARIES
(In thousands, except share and per share amounts.)
)
| For the Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Cash Flows From Financing Activities: | ||||||||||||
| Repurchase of common stock | - | (31,029 | ) | (10,756 | ) | |||||||
| Proceeds from issuance of common stock, net | 1,413 | - | 37,514 | |||||||||
| Issuance of warrants | 81 | - | 98 | |||||||||
| Issuance of restricted stock, net of taxes | (980 | ) | - | - | ||||||||
| Proceeds from option exercises | - | 23 | 67 | |||||||||
| Proceeds from warrant exercises | - | - | 134 | |||||||||
| Proceeds from issuance of debt | 85,000 | 10,000 | - | |||||||||
| Repayment of debt | (18,500 | ) | - | - | ||||||||
| Payments on notes payable | (838 | ) | (623 | ) | (465 | ) | ||||||
| Repayment of long-term debt | - | (43 | ) | (2,000 | ) | |||||||
| Net cash provided by (used in) financing activities – continuing operations | 66,176 | (21,672 | ) | 24,592 | ||||||||
| Net cash (used in) financing activities – discontinued operations | (523 | ) | - | - | ||||||||
| Net cash (used in) provided by financing activities | 65,653 | (21,672 | ) | 24,592 | ||||||||
| Effect of exchange rate changes on cash | (586 | ) | 123 | 5 | ||||||||
| Net (decrease) increase in cash and cash equivalents | (34,783 | ) | 1,040 | 27,799 | ||||||||
| Cash and cash equivalents, beginning of year | 45,388 | 44,348 | 16,549 | |||||||||
| Cash and cash equivalents, end of year | $ | 10,605 | $ | 45,388 | $ | 44,348 | ||||||
| Supplemental information: | ||||||||||||
| Cash paid for income taxes | $ | 1,041 | $ | 7,233 | $ | 12,976 | ||||||
| Cash paid for interest | $ | 2,216 | $ | 13 | $ | 79 | ||||||
Background:
FC Global Realty Incorporated (formerly PhotoMedex, Inc.) (and its subsidiaries) (the "Company"“Company” or “FCRE”), re-incorporated in Nevada on December 30, 2010, originally formed in Delaware in 1980, is, since earlier in 2017, a real estate development and asset management company concentrated primarily on investments in high quality income producing assets, hotel and resort developments, residential developments and other opportunistic commercial properties.
Under its previous name, PhotoMedex, Inc., the Company was, until the recent sale of the Company’s last significant business unit (its consumer products division which was sold to ICTV Brands, Inc. on January 23, 2017), as described below and in other sections of this report, a Global Skin Health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. The Company providesprovided proprietary products and services that addressaddressed skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain types of skin cancer), photo damage and unwanted hair.
Starting in August 2014, the Company closedbegan to restructure its operations and redirect its efforts in a manner that management expected would result in improved results of operations and address certain defaults in its commercial bank loan covenants. As part of such redirected efforts, management continued its comprehensive efforts to minimize the merger with Radiancy, Inc. Immediately following the reverse merger, the pre-reverse merger shareholders of PhotoMedex, Inc. ("Pre-merged PhotoMedex") collectively owned approximately 20% of the Company's outstanding common stock,Company’s operational costs and the former Radiancy, Inc. stockholders owned approximately 80% of the Company's outstanding common stock.
As a result of the Contribution Agreement (see also Note 5), the Company has primarily become a real estate asset management and servicesdevelopment company for the purpose of investing in a diversified portfolio of quality commercial and residential real estate properties and other real estate investments located both throughout the United States.
Resignation and Appointment of Officers and Directors:
Pursuant to patientsthe Contribution Agreement and consumersPurchase Agreement (see also Notes 5 and 14, respectively), there were changes to the Company’s named executive officers and its Board of Directors that were made on May 17, 2017 and December 22, 2017.
Expansion of Company’s Board of Directors quorum:
At the Initial Date of the First Contribution under the Contribution Agreement (see also Note 5), the Company’s Board of Directors was expanded, so that the Board of Directors consists of seven persons, of whom (i) three were designated by the Company’s departing board, (ii) three were designated by Contributor Parent; and (iii) one (the “Nonaffiliated Director”) was selected by the other six directors.
In March 2018, two members of the Company’s Board of Directors resigned from their position as directors and Opportunity Fund I-SS, LLC has notified the Company that it exercised its right under the Purchase Agreement (see also Note 14) to appoint two replacement directors to the Company’s Board of Directors (see also Note 17).
Special Meeting of Stockholders
Following the Initial Closing of the First Contribution under the Contribution Agreement (see also Note 5), the Company was required to file a proxy statement and hold a special meeting of its stockholders to authorize and approve the following matters:
| ■ | an increase in the number of authorized shares of common stock, $.01 par value per share, of the Company from 50,000,000 shares to 500,000,000 shares and increase the number of authorized shares of preferred stock, $.01 par value per share, of the Company from 5,000,000 shares to 50,000,000 shares; |
| ■ | the issuance to the Contributor or its designee or designees of the Company’s common and/or preferred shares in exchange for the contributed assets, and the issuance of the Warrant and, upon exercise of the Warrant, the underlying shares of the Company’s Common Stock in exchange for the contribution of the optional property interests, if any are made; |
| ■ | the amendment and restatement of the Articles of Incorporation of the Company; |
| ■ | the approval of the issuance of the Payout Notes and the issuance of the Company’s Common Stock upon conversion thereof; and |
| ■ | the election of a new Board of Directors as set forth above in Resignation and Appointment of Officers and Directors in this report. |
The Annual Meeting of Shareholders was convened on September 14, 2017, then adjourned and reconvened on October 12, 2017, at which meeting all of the proposals specified in selected marketsthe Company’s Definitive Proxy and further described in that region.
Liquidity and Going Concern:
As of December 31, 2017, the Company had an accumulated deficit of $134,445 and the Company incurred a wholly-owned subsidiary in India, PhotoMedex India Private Limited, through whichnet loss attributable to FC Global Realty Incorporated, for the year ended December 31, 2017 of $18,807. Subsequent to the sale of the Company’s last significant business unit, the consumer products division as described above, and to date, the Company has dedicated most of its financial resources to general and administrative expenses.
As of December 31, 2017, the Company’s cash and cash equivalents amounted to $948. While the Company is directly marketinga party to a Securities Purchase Agreement with Opportunity Fund I-SS, LLC, and has raised certain productsfunds under that agreement in both 2017 and services to patients and consumers in selected markets in that country.
At this time, there is no guarantee that the Company will be able to obtain an adequate level of financial resources required for the short and long-term support of its existing products from these centers.operations or that the Company will be able to obtain additional financing as needed, or meet the conditions of such financing, or that the costs of such financing may not be prohibitive.
These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The results of operations of LCA-Vision have been included from May 13, 2014 through December 31, 2014 in the Company'saccompanying consolidated financial statements as a discontinued operation. (See do not include any adjustments to reflect the possible future effects on recoverability of assets and classification of liabilities that may result from the outcome of this uncertainty.
As discussed in Note 3, Acquisition of LCA-Vision Inc.).
On July 12, 2017 the Company, realized net proceeds of approximately $36.5 million. The LCA-Vision assetsalong with its subsidiaries Radiancy, Inc. (“Radiancy”), Photo Therapeutics Ltd. (“PHMD UK”), and liabilities are considered to be held for sale as of December 31, 2014. For the statement of operations, the activity related to LCA is captured as discontinued operations.
Under the terms of the Release, the Asset Purchase Agreement among the Parties, dated October 4, 2016, as amended by the First Amendment to the CreditAsset Purchase Agreement, dated May 12, 2014,January 23, 2017 (as so amended, the “Purchase Agreement”), is terminated and of no further force and effect, except for certain surviving rights, obligations and covenants described in the Release. Pursuant to the Release, each of the Sellers, on one hand, and ICTV and ICTV Holdings, on the other hand, fully release, forever discharge and covenant not to sue any other Party, from and with JP Morgan Chase, as Administrative Agent forrespect to any and all past and present claims arising out of, based upon or relating to the Lenders.
Pursuant to the terms of the Second Amended Forbearance Agreement,Release, ICTV was required to pay to the LendersCompany, within 3 business days of the date of the Release, $2,000 in cash and in immediately available funds (the “Payment”). Subject to this Payment, neither ICTV nor ICTV Holdings shall have agreedany further royalty or other payment obligations under the Purchase Agreement. The Company received $2,000 on July 13, 2017.
As partial consideration for the releases provided by ICTV Holdings to forbearthe Sellers pursuant to the Release and in accordance with the terms therein, on July 12, 2017, the Sellers and ICTV Holdings entered into a Bill of Sale and Assignment (“Bill of Sale”), which provides that each Seller sell, assign, transfer, convey and deliver to ICTV Holdings, and ICTV Holdings purchase and accept from exercising their rightseach Seller, all of the right, title and remediesinterest, legal or equitable, of each such Seller in and to a deposit in the amount of $210 held by a consumer division vendor, Sigmatron International, Inc. (“Sigmatron”), pursuant to an arrangement between one or more of the Sellers and Sigmatron.
As the total selling price has been adjusted to an amount that was less than the aggregate carrying amount of the assets held for sale, the Company recorded a loss from sale of asset in an amount of $4,652 (net of a gain of $3,228 with respect to accumulative translation adjustment that was reclassified from accumulated other comprehensive income to earnings). This loss is included in discontinued operations for each period.
As discussed in Note 5, on March 31, 2017, the Specified EventsCompany entered into a Contribution Agreement with First Capital Real Estate Operating Partnership, L.P., and its parent, First Capital Real Estate Trust Incorporated, under which certain real estate investment properties were to be contributed to the Company in three stages in exchange for the issuance of Default from August 25, 2014 until April 1, 2016, or earlier if an eventCompany stock. The closing of default occurs (the "Forbearance Period"). Chasethe First Contribution under this transaction occurred on May 17, 2017, and consideration transferred consisted of shares of common and preferred stock.As of December 31, 2017, neither the Secondary nor the Optional Contribution were made and the Lenders agreedContribution Agreement was terminated at that date.
As discussed in Note 14, on December 22, 2017, the Company shall not be obligatedentered into a Purchase Agreement with Opportunity Fund I-SS, LLC, a Delaware limited liability company (the “Investor”), pursuant to paywhich the principal amounts set forthInvestor may invest up to $15 million ($1.5 million out of which, net of expenses was received on December 22, 2017) in the Credit AgreementCompany in a series of closings, in exchange for any date identified therein duringwhich the period beginning on February 28, 2015 and ending on the endInvestor will receive shares of the Forbearance Period (the "Effective Period"Company’s newly designated Series B Preferred Stock (“Convertible Redeemable Series B Preferred Stock” or “Series B Shares”), and that any failure to do so shall not constitute at a default or eventpurchase price of default. Instead, the Lenders and the Company agreed that the Company would make prepayments against the Term Loan of $250,000$1.00 per share.
As discussed in Note 17, on the first business day of each month during the Forbearance Period, which will be applied in direct order of maturity. The Company also agreed that, on or before the fifth calendar day of each month, the Company would pay against the Term Loan $125,000 to the extent that the cash-on-hand exceeds $5 million, and 100% of the cash-on-hand in excess of $7 million, also to be applied to the Term Loan in inverse order of maturity.
Note 2
Discontinued Operations:
As this business was a substantial business unit of the Company, and as such the sale brings a strategic shift in focus of management. The Company accordingly classified this former business as held for sale and discontinued operations in accordance with ASC Topic 360.
The accompanying consolidated financial statements as of and for the year ended December 31, 2016 have been retrospectively adjusted to reflect the operating results and balance sheet items of the Consumer business as discontinued operations separately from continuing operations. Also, as of December 31, 2016, balance sheet items related to the Lenders.Consumer business were presented as assets held for sale. The Company recognized a loss of $13,264, on the sale of the discontinued operations in the year ended December 31, 2016, which represents the difference between the adjusted net purchase price and the carrying value of the disposal group.
The following is a summary of assets and liabilities held for sale in the consolidated balance sheet as of December 31, 2016, which has been retrospectively adjusted to reflect the assets and liabilities of the skin health business as discontinued operations:
| December 31, 2016 | ||||
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | — | ||
| Restricted cash deposits | 342 | |||
| Accounts receivable, net of allowance for doubtful accounts of $1,192 | 4,125 | |||
| Prepaid expenses and other current assets | 2,652 | |||
| Assets held for sale (Note 4) | 8,362 | |||
| Total current assets | 15,481 | |||
| Non-current assets: | ||||
| Property and equipment, net (Note 7) | 77 | |||
| Other assets, net | 7 | |||
| Total non-current assets | 84 | |||
| Total assets | $ | 15,565 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||
| Current liabilities: | ||||
| Other accrued liabilities | 2,068 | |||
| Deferred revenues | 1,141 | |||
| Total current liabilities | $ | 3,209 | ||
| Total net assets of discontinued operation | $ | 12,356 | ||
The following is a summary of loss from discontinued operations for the year ended December 31, 2017 and 2016:
| For the Year Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Revenues: | $ | 3,880 | $ | 38,397 | ||||
| Cost of revenues | 100 | 8,086 | ||||||
| Gross profit | 3,780 | 30,311 | ||||||
| Operating expenses: | ||||||||
| Engineering and product development | 143 | 1,249 | ||||||
| Selling and marketing | 620 | 21,729 | ||||||
| General and administrative | 2,342 | 13,233 | ||||||
| Impairment loss | — | 3,518 | ||||||
| Other income, net | (1,504 | ) | — | |||||
| Loss on sale of assets | 4,652 | 2,574 | ||||||
| 6,253 | 42,303 | |||||||
| Loss before interest and other financing expense, net | (2,473 | ) | (11,992 | ) | ||||
| Interest and other financing expense, net | — | (385 | ) | |||||
| Loss before income taxes | (2,473 | ) | (12,377 | ) | ||||
| Income tax expense (benefit) | (14 | ) | 762 | |||||
| Loss from discontinuing operations | (2,459 | ) | (13,139 | ) | ||||
| Loss from discontinued operations, net of taxes | — | (125 | ) | |||||
| Loss | ($ | 2,459 | ) | ($ | 13,264 | ) | ||
Note 3
Summary of Significant Accounting Policies:
Accounting Principles
The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("(“US GAAP"GAAP”). Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have material impact on the Company'sCompany’s equity, net assets, results of operations or cash flows.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and the wholly and majority ownedmajority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Entities in which the Company directly or indirectly owns more than 50% of the outstanding voting securities, and for which other interest holders do not possess the right to affect significant management decisions, are generally accounted for under the voting interest consolidation method of accounting. Participation of other interest holders in the net assets and in the earnings or losses of a consolidated subsidiary is reflected in the line items “Noncontrolling Interest” in the Company’s consolidated balance sheets and “net income (loss) attributable to the noncontrolling interest” in the Company consolidated statements of comprehensive loss. Noncontrolling interest adjusts the Company’s consolidated results of operations to reflect only the Company’s share of the earnings or losses of the consolidated subsidiary.
Any changes in the Company’s ownership interest in a consolidated subsidiary, through additional equity issuances by the consolidated subsidiary or from the Company acquiring the shares from existing shareholders, in which the Company maintains control is recognized as an equity transaction, with appropriate adjustments to both the Company’s additional paid-in capital and the corresponding noncontrolling interest.
Held for Sale Classification and Discontinued Operations
Under ASC 205 “Presentation of Financial Statement - Discontinued Operations”, a disposal group is reported as held for sale when management has approved or received approval to sell and is committed to a formal plan, the disposal group is available for immediate sale, the business is being actively marketed, the sale is anticipated to occur during the next 12 months and certain other specified criteria are met. A disposal group classified as held for sale is recorded at the lower of its carrying amount or estimated fair value less cost to sell. If the carrying value of the business exceeds its estimated fair value less cost to sell, a loss is recognized. However, when a disposal group meets the held for sale criteria, the Company first evaluates whether the carrying amounts of the assets not covered by ASC 360-10 included in the disposal group (such as goodwill) are required to be adjusted in accordance with other applicable GAAP before measuring the disposal group at fair value less cost to sell.
Assets and liabilities related to a disposal group classified as held for sale are segregated in the consolidated balance sheet in the period in which the business is classified as held for sale.
Only disposal of a component of an entity or a group of components of an entity that represents a strategic shift that has or will have a major effect on an entity’s operations and cash flows of the business have been or willfinancial results shall be eliminated from our ongoing operationsreported as a result of a disposal transaction and we will not have any significant continuing involvement in the operations of the business after the disposal transaction. discontinued operations.
The results of discontinued operations are reported in discontinued operations in the consolidated statement of operationscomprehensive loss for current and prior periods commencing in the period in which the business meets the criteria of a discontinued operation, and include any gain or loss recognized on closing or adjustment of the carrying amount to fair value less cost to sell. Depreciation is not recorded on assets of a business while it is classified as held for sale.
Use of Estimates
The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States ("US GAAP")GAAP requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As part of December 31, 2014,these financial statements, the more significant estimates include (1) revenue recognition, including provision for sales returnstock-based compensation; (2) identification of and valuation allowancesmeasurement of accounts receivable; (2) valuation allowanceinstruments in equity transactions; (3) impairment of deferred tax assetsinvestment properties and uncertaintyinvestment in tax positions;other company; (4) evaluation of going concern; and (3) stock based compensation.(5) contingencies.
Functional Currency
The currency of the primary economic environment in which the operations of the Company its U.S. subsidiaries and Radiancy Ltd., its subsidiary in Israel, are conducted is the US dollar ("(“$"” or "dollars"“Dollars”).
In accordance with ASC 830,“Foreign Currency Matters”, Brazilian Real (BRL), Hong Kong Dollar (HKD), Columbian Peso (COP) and Indian Rupee (INR). Substantially all of the Group's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar
Assets and liabilities of foreign subsidiaries, whose functional currency is the local currency, are translated from its respective functional currency to U.S. dollars at the balance sheet date exchange rates. Income and expense items are translated at the average rates of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive income or loss. Deferred taxes are not provided on translation adjustments as the earnings of the subsidiaries are considered to be permanently reinvested
.
The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards CodificationASC 820 “Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820Value”, which defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1 - unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
Level 2 - pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
Level 3 - pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors.
This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
The fair value of cash and cash equivalents and short term bank deposits are based on its demand value, which is equal to its carrying value. The estimated fair values of notes payable, short-term and long-term debt which are based on borrowing rates that are available to the Company for loans with similar terms, collateral and maturity approximate the carrying values. Additionally, the carrying value of all other monetary assets (including long term receivables which bear interest) and liabilities (including the secured credit facilities) is estimated to be equal to their fair value due to the short-term nature of these instruments.
As of derivatives generally reflectsDecember 31, 2017, an option to purchase redeemable convertible preferred stock as embedded in the estimated amounts that the Group would receive or pay to terminate the contracts at the reporting dates, based on the prevailing currency prices and the relevant interest rates. Such measurement is classified within Level 2.
Cash and Cash Equivalents
The Company investsinvested its excess cash in highly liquid short-term investments. The Company considersconsidered short-term investments that arewere purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consisted of cash and money market accounts at December 31, 2014 and 2013.
Short-term Deposits
Short-term deposits are deposits with original maturities of more than three months but less than one year. Short-term deposits are presented at their costs including accrued interest.
Accounts Receivable
The majority of the Company'sCompany’s accounts receivable (other than LCA) arewere due from consumers, distributors (domestic and international), physicians and other entities in the medical field.field, divisions which are no longer operated by the Company. Accounts receivable arewere most often due within 30 to 90 days and are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms arewere considered past due. The Company determines its allowanceAllowance for doubtful accounts was determined by considering a number of factors, including the length of time trade accounts receivable are past due, the Company'sCompany’s previous loss history, the customer'scustomer’s current ability to pay its obligation to the Company and available information about their credit risk, and the condition of the general economy and the industry as a whole. The Company writeswrote off accounts receivable when they arewere considered uncollectible, and payments subsequently received on such receivables arewere credited to the allowance for doubtful accounts. The Company doesdid not recognize interest accruing on accounts receivable past due.
Inventories
Inventories arewere stated at the lower of cost or market. Cost is determined to be purchased cost for raw materials and the production cost (materials, labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods. For the Company'sCompany’s consumer and LHE products, cost iswas determined on the weighted-average method. For the pre-merged PhotoMedex'sPhotoMedex products, cost iswas determined on the first-in, first-out method. Throughout the laser manufacturing process, the related production costs are recorded within inventory. Work-in-process is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.
Reserves for slow moving and obsolete inventories arewere provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trend.
As of December 31, 2016, the inventory is included in the discontinued operation. As of December 31, 2017, there are no inventories.
Investment in Other Company
The investment in the other company is stated at cost, since the Company does not have the ability to exercise significant influence over operating and financial policies of those investees. The Company’s investments in the other company is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an investment may not be recoverable, in accordance with ASC 320 “Investments – Debt and Equity Securities”. As of December 31, 2017, based on managements’ most recent analyses, impairment losses have been identified in the amount of $862 (see also Notes 5 and 13).
Property, Equipment and Depreciation
Property and equipment are recorded at cost, net of accumulated depreciation. Excimer lasers-in-service are depreciated on a straight-line basis over the estimated useful life of five years. For other property and equipment, depreciationDepreciation is calculated on a straight-line basis over the estimated useful lives of the assets, primarily three to seven years for computer hardware and software, furniture and fixtures, and machinery and equipment. Leasehold improvements are amortized over the lesser of the useful lives or lease terms. Expenditures for major renewals and betterments to property and equipment are capitalized, while expenditures for maintenance and repairs are charged as an expense as incurred. Upon retirement or disposition, the applicable property amounts are deducted from the accounts and any gain or loss is recorded in the consolidated statements of comprehensive (loss) income.loss. Useful lives are determined based upon an estimate of either physical or economic obsolescence or both.
Realizability of property and equipment was based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows iswas less than the net book value of the asset, the asset iswas written down to fair value. As of December 31, 2014, no such write-down was requiredvalue (see alsoImpairment of Long-Lived Assetsand Intangibles).
Patent Costs and Licensed Technologies
Costs incurred to obtain or defend patents and licensed technologies arewere capitalized and amortized over the shorter of the remaining estimated useful lives or eight to 12 years. Core and product technology was also recorded in connection with the reverse acquisition on December 13, 2011 and iswas being amortized on a straight-line basis over ten years for core technology and five years for product technology. (See technology (see also Note 6, 8).
Patent and Licensed Technologies).
Other Intangible Assets
Other intangible assets were recorded in connection with the reverse acquisition on December 13, 2011 and in connection with the acquisition of LCA.2011. The assets which were determined to have definite useful lives are beingwere amortized on a straight-line basis over ten years. Such assets primarily includeincluded customer relationships and trademarks. (See Note 79).,
Goodwill and Other Intangible Assets).
The Company evaluates the carrying value of goodwill annually at the end of the calendar year and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. Goodwill impairment evaluation is performed subsequent to Impairment evaluation of long-lived assets and intangibles (see also Notes 6 and 7). Goodwill impairment testing involves a two-step process. Step 1 compares the fair value of the Group'sGroup’s reporting units to which goodwill was allocated to their carrying values. If the fair value of the reporting unit exceeds its carrying value, no further analysis is necessary. The reporting unit fair value is based upon consideration of various valuation methodologies, including guideline transaction multiples, multiples of current earnings, and projected future cash flows discounted at rates commensurate with the risk involved. If the carrying amount of the reporting unit exceeds its fair value, Step 2 must be completed to quantify the amount of impairment. Step 2 calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit, from the fair value of the reporting unit as determined in Step 1. The implied fair value of goodwill determined in this step is compared to the carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss, equal to the difference, is recognized. See Note 2, regarding As part of the purchase price allocation for the 2011 reverse acquisition, the Company recorded goodwill in the amount of $24,005 and definite-lived intangibles in the amount of $12,000. Goodwill reflected the value or premium of the acquisition price in excess of the fair values assigned to specific tangible and intangible assets. Goodwill had an indefinite useful life and therefore was not amortized as an expense but was reviewed annually for impairment of goodwill whichits fair value to the Company. The fair value of Goodwill associated with the operating and reporting units was allocatedestimated using a combination of Income and Market Approach methodologies to LCA.
As of December 31, 2016, the Company provides post-surgical enhancements freerecorded an impairment of charge should the patient not achieveentire remaining balance of goodwill (allocated to consumer segment) in the desired visual correction during the initial procedure. Under this pricing structure, the Company accounts for the acuity program similar to a warranty obligation. Accordingly, the Company accrues the costs expected to be incurred to satisfy the obligation as a liability and costamount of revenue at the point of sale given its ability to estimate reasonably such costs$2,257 which is included in discontinued operation. Such determination was based on historical trends and the satisfaction of all other revenue recognition criteria.
Accrued Warranty Costs
The Company offersoffered a standard warranty on product sales of its previous skin care business generally for a one to two-year period. In the case of domestic sales of XTRAC lasers, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company providesprovided for the expected cost of estimated future warranty claims on the date the product is sold. Total accrued warranty iswas included in other accrued liabilities on the balance sheet. The activity in the warranty accrual during the years ended December 31, 20142017 and 20132016 is summarized as follows:
| December 31, | ||||||||
| 2014 | 2013 | |||||||
| Accrual at beginning of year | $ | 1,151 | $ | 1,440 | ||||
| Additions charged to warranty expense | 808 | 1,206 | ||||||
| Expiring warranties | (341 | ) | (410 | ) | ||||
| Claims satisfied | (857 | ) | (1,085 | ) | ||||
| Total | 761 | 1,151 | ||||||
| Less: current portion | (665 | ) | (1,094 | ) | ||||
| Long term accrued warranty | $ | 96 | $ | 57 | ||||
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Accrual at beginning of year | $ | 241 | $ | 330 | ||||
| Additions charged to warranty expense | — | 56 | ||||||
| Expiring warranties | — | (145 | ) | |||||
| Sale of consumer segment (*) | (241 | ) | ||||||
Total (**) | — | 241 | ||||||
| Less: current portion | — | (241 | ) | |||||
| Long term accrued warranty | $ | — | $ | — | ||||
(*) The buyer of the remaining consumer products business assumed the warranty obligations.
(**) Included in liabilities related to assets held for sale.
For extended warranty on the consumer products, see alsoRevenue Recognition below. below.
Revenue Recognition
The Company through its subsidiary LCA-Vision (which is presented as a discontinued operations), maintains a captive insurance company to provide professional liability insurance coverage for claims brought against the Company and its optometrists. In addition, the captive insurance company's charter allows it to provide professional liability insurance for the Company's ophthalmologists, none of whom are currently insured by the captive. The Company uses the captive insurance company for both primary insurance and excess liability coverage. A number of claims are now pending with the captive insurance company. Since the captive insurance company is wholly-owned enterprise, it is included in the Company's consolidated financial statements. As of December 31, 2014, the insurance reserves were $6,044, which represented an actuarially determined estimate of future costs associated with claims filed as well as claims incurred but not yet reported. The actuaries determine loss reserves by comparing the Company's historical claim experience to comparable insurance industry experience.
The Company shipsshipped most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will be granted FOB destination terms. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured and included in deferred revenues until that time.
For revenue arrangements with multiple deliverables within a single, contractually binding arrangements (usually sales of products with separately priced extended warranty), each element of the contract is accounted for as a separate unit of accounting when it provides the customer value on a stand-alone basis and there is objective evidence of the fair value of the related unit.
With respect to sales arrangements under which the buyer hashad a right to return the related product, revenue iswas recognized only if all the following conditions are met: the price iswas fixed or determinable at the date of sale; the buyer has paid, or iswas obligated to pay and the obligation iswas not contingent on resale of the product; the buyer'sbuyer’s obligation would not be changed in the event of theft or physical destruction or damage of the product; the buyer hashad economic substance; the Company doesdid not have significant obligations for future performance to directly bring about resale of the product by the buyer; and the amount of future returns cancould be reasonably estimated.
The Company providesprovided a provision for product returns based on the experience with historical sales returns, in accordance with ASC Topic 605-15 with respect to sales of product when a right of return exists.
Deferred revenue includesincluded amounts received with respect to extended warranty maintenance, repairs and other billable services and amounts not yet recognized as revenues. Revenues with respect to such activities arewere deferred and recognized on a straight-line basis over the duration of the warranty period, the service period or when service iswas provided, as applicable to each service.
Shipping and Handling Costs
Shipping and handling fees billed to customers arewere reflected as revenues while the related shipping and handling costs arewere included in selling and marketing expense. To date, shippingShipping and handling costs have not been material.
Advertising Costs
Advertising costs arewere charged to expenses as incurred.
Concentrations of credit risk
Financial instruments which subject the Company to approximately $62,197, $71,992concentrations of credit risk consist primarily of cash and $60,651 for the years ended December 31, 2014, 2013 and 2012, respectively.
Concentrations of credit risk
Most of the Israeli subsidiary (Radiancy) denominatedCompany’s sales were generated in Israeli local currency (NIS) which is different than its functional currency.
Income Taxes
The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized.realized.
The Company or its subsidiaries may incur an additional tax liabilityliabilities in the event of an intercompany dividend distribution or a deemed dividend distribution under the U.S. income tax law and regulations. Prior to 2014, it was the Company'sCompany’s policy not to cause a distribution of dividends which would generate an additional tax liability to the Company. During the years ended December 31, 2014 and 2015, the CompanyCompany’s affiliates borrowed funds from itsthe subsidiary in Israel. These borrowings resulted in a large deemed distribution taxable in the U.S. Furthermore, Managementmanagement can no longer represent that the earnings of its non U.S. subsidiaries will remain permanently invested outside the U.S. Therefore, beginning in 2014, the Company has provided deferred taxes on the undistributed earnings of its non U.S. subsidiaries. Taxes, which wouldmay apply in the event of a disposal of investments in subsidiaries, have not been taken into accountincluded in computing the deferred taxes, as the Company anticipates it is the Company's policy to hold these investments, not to dispose of them.
The Company accounts for uncertain tax positions in accordance with an amendment to ASC Topic 740-10, “Income Taxes (Accounting for Uncertainty in Income Taxes), Taxes”which clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position can be recognized in the financial statements only if the position is "more-likely-than-not"“more-likely-than-not” to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard the likelihood that the tax position may be challenged. If an uncertain tax position meets the "more-likely-than-not"“more-likely-than-not” threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded.
During the yearyears ended December 31, 2014,2017 and 2016, the Company determined that the liability for unrecognized tax benefits could suitably be extinguished by application of net operating loss carryforwards and carrybacks, with any residual impact arising as a liability in 20142017 and 2016 that has been duly provided for.
Accounts receivableContingencies above).
The Company and its subsidiaries are involved in certain legal proceedings that arise from time to time in the ordinary course of its business. We account for business contingent liabilities in accordance with ASC 450 “Contingencies”. Except for income tax contingencies, the Company records accruals for contingencies to the extent that the management concludes that the occurrence is probable and that the related amounts of the loss can be reasonably estimated. A provision is recorded when it is both probable and when a liability has been incurred and the related amounts of the loss can be reasonably estimated. Legal expenses associated costs incurred in connection with the contingencycontingencies are expensed as incurred.
With respect to legal matters, provisions are computed by dividing net income by the weighted-average number of common shares outstanding during the period, net of the weighted average number of treasury shares. Diluted earnings (loss) per common share are computed similarreviewed and adjusted to basic earnings per share, except that the denominator is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the computation for a period in which a net loss is reported or if their effect is anti-dilutive. The Company's potential common shares consist of stock options, warrants and restricted stock awards issued under the Company's stock incentive plans and their potential dilutive effect is considered using the treasury method.
| December 31, | ||||||
| 2014 | 2013 | 2012 | ||||
| Weighted average number of common and common equivalent shares outstanding: | ||||||
| Basic number of common shares outstanding | 18,940,355 | 20,454,970 | 20,355,520 | |||
| Dilutive effect of stock options and warrants | - | 202,270 | 408,834 | |||
| Diluted number of common and common stock equivalent shares outstanding | 18,940,355 | 20,657,240 | 20,764,354 | |||
Impairment of Long-Lived Assets and Intangibles
Long-lived assets, such as property and equipment, and definite-lived intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or group of assets) may not be recoverable. Impairment test is applied at the lowest level where there are identifiable independent cash flows, which may involve a group of assets.
Recoverability of assets to be held and used (or group of assets) is measured by a comparison of the carrying amount of an asset to the fair value ofundiscounted cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds the fair value,is determined to be impaired, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. As of December 31, 2014, (other than the measurement of LCA net assets based on it estimated fair value less cost to sell- see Note 2) no such impairment exists. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and are no longer depreciated. The assets and liabilities of a disposed group classified as discontinued operations are presented separately in the appropriate asset and liability sections of the balance sheet.
Indefinite-life intangible assets are tested for impairment, on an annual basis or more often, when triggering events indicate that it is more likely than not that the asset is impaired, by comparing the fair value of the asset with its carrying amount. If the carrying amount of the intangible asset exceeds its fair value, an impairment loss is recognized in the amount of that excess. Subsequent reversal of a previously recognized impairment loss is prohibited.
Pursuant to ASC 360 the Company tested the long-lived assets and determined that changes in circumstances indicated that its carrying value may not be recoverable. The carrying amount of the assets is considered recoverable if it exceeds the sum of undiscounted cash flows expected from the use or eventual disposition of the asset. Upon completion of our goodwill impairment analysis in connection with the pending transaction with ICTV Brands, as of December 31, 2016, the Company recorded an impairment of the entire remaining balance of Consumer segment goodwill in the amount of $2,257. The Company recorded an impairment of the Consumer segment intangibles for its entire remaining Licensed Technology balance in the amount of $1,261. These impairment charges are included in discontinued operations.
Loss per Share
The Company computes net loss per share in accordance with ASC 260,“Earnings per share”. Basic loss per share are computed by dividing net loss by the weighted-average number of common shares outstanding during the period, net of the weighted average number of treasury shares (if any). Securities that may participate in dividends with the Common Stock (such as the convertible Preferred Stock Series A and Series B) are considered in the computation of basic income per share using the two-class method. However, in periods of net loss, participating securities are included only if the holders of such securities have a contractual obligation to share the losses of the Company. Accordingly, the outstanding Series A preferred shares were included in the computation, while the Series B preferred shares were not.
Diluted loss per common share is computed similar to basic earnings per share, except that the denominator is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the computation for a period in which a net loss is reported or if their effect is anti-dilutive. The Company’s potential common shares consist of stock options, stock warrants and restricted stock awards issued under the Company’s stock incentive plans and their potential dilutive effect is considered using the treasury method and of convertible Preferred Stock Series A and Series B which their potential dilutive effect is considered using the “if-converted method”.
The net loss from continuing operations and the weighted average number of shares used in computing basic and diluted net loss per share from continuing operations for the years ended December 31, 2017 and 2016, is as follows: (in thousands except share and per share amounts)
| Year ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Numerator: | ||||||||
| Net loss attributable to common stockholders | $ | 18,807 | $ | 13,264 | ||||
Net loss from discontinued operations attributable to common stockholders | (2,459 | ) | (13,264 | ) | ||||
| Accretion of dividend for the period (*) | 3 | — | ||||||
| Participation of stockholders of series A preferred stock in the net loss from continuing operations | (1,318 | ) | — | |||||
| Net loss from continuing operations attributable to common stockholders | $ | 15,033 | $ | — | ||||
| Denominator: | ||||||||
| Shares of common stock used in computing basic and diluted net loss per share | 5,073,751 | 4,171,549 | ||||||
Net loss per share of Ordinary Share from continuing operations, basic and diluted | $ | 2.96 | $ | — | ||||
| (*) | The net loss used for the computation of basic and diluted net loss per share for the year ended December 31, 2017, includes the dividend requirement of 8% per share per annum for the Series B preferred stock, compounded annually which shall be distributed to stockholders in case of distributable assets determined in the Company’s certificate of designation (the “Certificate of Designation”) under the liquidation preference right (see also Note 14). |
For the year ended December 31, 2017, diluted loss per share excludes the impact of stock options, stock warrants, series Preferred A Stock, series Preferred B Stock, common stock to be issued upon exercise of asset contribution financial instruments and common stock to be issued upon written call option totaling 43,053,913 shares, as the effect of their inclusion would be anti-dilutive. For the year ended December 31, 2016, diluted loss per share excludes the impact of stock options totaling 1,000 shares.
Convertible Redeemable Series B Preferred Stock
The Company classifies its Convertible Redeemable Series B Preferred Stock outside of Stockholders’ deficit because certain features of the Company’s Certificate of Designation could require redemption of some or all classes of Convertible Redeemable Series B Preferred Stock upon events not solely within the control of the Company (see also Note 14).
Option to purchase Convertible Redeemable Series B Preferred Stock:
The Company has classified the option to purchase additional shares of its Convertible Redeemable Series B Preferred Stock as a liability in accordance with ASC 480, “Distinguishing Liabilities from Equity” as the underlying Series B Preferred Shares are subject to redemption feature. The Company measures the option at fair value by using the Black Scholes Pricing Model in each reporting period until they are exercised or expired, with changes in the fair values being recognized in the Company’s statement of comprehensive loss (see also Note 14).
Stock-Based Compensation
The Company accounts for stock-based compensation in accordance with ASC Topic 718, “Compensation – Stock Compensation.Compensation. Under”, (“ASC 718”), which requires companies to estimate the fair value recognition provision, of this statement, share-basedshare-equity based compensation cost is measured at payment awards on the date of grant date based on the fair using an option pricing model. The value of the portion of the award that is ultimately expected to vest and is recognized as operating an expense over the applicable vesting period of requisite service periods in the stock award using Company’s consolidated statement of comprehensive loss.
The Company recognizes compensation expense for the value of its awards granted based on the graded vesting method.
The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing model which requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon historical daily stock price observations of its common stock. The expected option term represents the period that the Company’s stock options are expected to be outstanding and is determined based on the simplified method until sufficient historical exercise data will support using expected life assumptions. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
Recently Issued Accounting Standards
Recent Accounting Pronouncements adopted
On March 30, 2016, the FASB Emerging Issues Task Force)
Recent Accounting Pronouncements not adopted yet
In May 2014, the Company adoptedFinancial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2013-5(“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU 2014-09), Foreign Currency Matterswhich amends the existing accounting standards for revenue recognition. In August 2015, FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 830) Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity ("ASU 2013-5").
In February 2016, the FASB issued ASU 2016-02, “Leases”. This guidance will require that lease arrangements longer than 12 months result in an entity recognizing an asset and liability equal to the present value of the lease payments in the statement of financial position. This guidance is effective for annual periods beginning after December 15, 2018, and interim periods therein. This standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with calendar year ends.an option to use certain transition relief. Early adoption is permitted.
In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash” (ASU 2016-18), which requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period, however, the Company has not elected to early adopt ASU 2016-18. This new guidance is not expected to have a material impact on the Company'sCompany’s consolidated results of operations and financial condition.
In May 2014, TheJanuary 2017, the FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with CustomersASU 2017-01 Business Combinations (Topic 606) ("805): “Clarifying the Definition of a Business”. ASU 2014-09").
In May 2017, the FASB issued ASU 2017-09 “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting”, which includes guidance on changes to terms and conditions of share-based payment awards. The amendment provides guidance about which changes to terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance will be effective for the fiscal year beginning on January 1, 2018, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early application(early adoption is not permitted.permitted). The Company is incurrently evaluating the processpotential effect of assessing the impact, if any, of ASU 2014-09guidance on its consolidated financial statements.
Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern Note 4("ASU 2014-15"). ASU 2014-15 provide guidance on management's responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provide guidance related to the required disclosures as a result of management evaluation.
Discontinued Operations Assets Held for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early applicationSale:
A disposal group is permitted.
Assets and liabilities related to a disposal group classified as held for sale are segregated in the consolidated balance sheet in the period in which the disposal group is classified as held for sale.
Only disposal of a component of an entity or a group of components of an entity that represents a strategic shift that has or will have a major effect on an entity’s operations and financial results shall be reported as discontinued operations. The revised guidance did not change the criteria required to qualify for held for sale presentation.
In connection with the sale of the Consumer Division to ICTV Brands, Inc., announced on October 4, 2016 and subsequently completed on January 23, 2017, the assets related to this transaction were included as of December 31, 2014:
| December 31, 2014 | ||||
| Assets: | ||||
| Cash and cash equivalents | $ | 4,514 | ||
| Accounts receivable | 2,759 | |||
| Inventories | 119 | |||
| Deferred tax assets | 1,930 | |||
| Other current assets | 2,492 | |||
| Property & Equipment, net | 14,519 | |||
| Goodwill, net | 6,491 | |||
| Other intangible assets, net | 38,331 | |||
| Other assets | 1,207 | |||
| Assets held for sale | 72,362 | |||
| Less: Impairment | (1,507 | ) | ||
| Assets held for sale, net | $ | 70,855 | ||
| Liabilities: | ||||
| Accounts payable | $ | 5,518 | ||
| Other accrued liabilities | 5,933 | |||
| Deferred revenues | 97 | |||
| Long term debt: | 1,080 | |||
| Other liabilities | 6,870 | |||
| Deferred tax liability | 14,999 | |||
| Liabilities held for sale | 34,497 | |||
| Total net assets of discontinued operations | $ | 36,358 | ||
| Inventory | $ | 7,336 | ||
| Property and equipment | 911 | |||
| Other assets | 115 | |||
| Assets held for sale as of December 31, 2016 | $ | 8,362 |
Note 3
Acquisitions:
On March 31, 2017, the Company and its newly-formed subsidiary FC Global Realty Operating Partnership, LLC, a Delaware limited liability company (“Acquiror”) entered into an Interest Contribution Agreement (the “Contribution Agreement”) with First Capital Real Estate Operating Partnership, L.P., a Delaware limited partnership (“Contributor”), and First Capital Real Estate Trust Incorporated, a Maryland corporation, (the “Contributor Parent” and, together with Contributor, the “Contributor Parties”), under which the Contributor will contribute mostly certain real estate assets (the “Contributed Properties”) to the Company’s subsidiary. In exchange, the Contributor will receive shares of LCA-Vision Inc.:
The first installment of contributed assets (the “First Contribution”) closed on May 17, 2017 (the “Initial Closing”).
First Contribution
In the Initial Closing, the Contributor transferred certain assets comprising the Contributed Properties to the Company. On May 12, 2014, PhotoMedex Inc.,the Initial Closing date, the Contributor transferred to the Acquiror four vacant land sites set for development into gas stations, which are located in Atwater and Merced, Northern California, and which had an agreed upon value of approximately $2.6 million. One of these vacant land sites was contributed through the transfer of a 75% membership interest in a limited liability company that owns the vacant land site located in Northern California, in which profits and losses are allocated 75% to the Company and 25% to the noncontrolling member subject to a preferred equity split in which the noncontrolling member earns the first 10% of net profits and the balance of the 90% is to be paid along the terms of the 75% split to the Company and 25% to the noncontrolling member. The Contributor then completed the acquisitiontransfer to the Acquiror of its 17.9% passive interest in a limited liability company that is constructing a single family residential development located in Los Lunas, New Mexico (the “Avalon Property”) on June 26, 2017.
This residential development in New Mexico consisted of 251, non-contiguous, single family residential lots and a 10,000 square foot club house. 37 of the lots had been finished, and the remaining 214 were platted and engineered lots. The agreed upon value of its share of this property was approximately $7.4 million.
In return for the Contributed Properties, the Company issued to the Contributor 879,234 duly authorized, fully paid and non-assessable shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), which represented approximately 19.9% of the Company’s issued and outstanding Common Stock immediately prior to the Initial Closing, at an agreed upon Per Share Value (defined below) of $2.5183, or $2,214 in the aggregate. These shares of Common Stock are restricted and unregistered. The Company issued the remaining $7,786 of the approximately $10 million agreed upon consideration to the Contributor in the form of 123,668 shares of the Company’s newly designated non-voting Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Stock” or “Convertible Series A Preferred Stock”). Each share of the Series A Stock is convertible into 25 shares of the Company’s Common Stock, subject to the satisfaction of certain conditions, including stockholder approval in accordance with the rules of The Nasdaq Stock Market (“Nasdaq”), which was obtained on October 12, 2017. The shares of Series A Stock do not have voting rights and are restricted and unregistered. The number of shares of Common Stock issued to the Contributor and to be issued upon conversion of the Series A Stock was determined by dividing the $10 million agreed upon value of the Contributed Assets by $2.5183, a specified price per share value which represents a 7.5% premium above the volume-weighted average price (“VWAP”) of all on-exchange transactions in the Company’s Common Stock executed on Nasdaq during the forty-three trading days prior to the trading day immediately prior to the public announcement of the transaction by the Company and the Contributor Parent, as reported by Bloomberg L.P. (the “Per Share Value”). The shares of Common Stock both issued to the Contributor and issuable upon the conversion of the Series A Stock carry certain registration rights as specified in a Registration Rights Agreement dated May 17, 2017.
At the Initial Closing, the Company assumed the liabilities associated with the Contributed Properties, except that it did not assume any liabilities with respect to the Avalon Property until that property’s contribution was completed on June 26, 2017. The obligations that the Acquiror assumed at the Initial Closing include the following: Obligations of the Contributor and its affiliates under certain agreements covering the contributed properties, including an Operating Agreement of Central Valley Gas Station Development, LLC, a Delaware limited liability company, dated January 28, 2013, and all amendments thereto; and a Construction Contract dated November 19, 2014 between Central Valley Gas Stations Development, LLC, as owner and First Capital Builders, LLC, as Contractor, with respect to the project known commonly as Green Sands and Buhach Rd., Atwater, CA. Once the full interest in the Avalon Property was contributed to the Company, the Company also assumed the Operating Agreement of Avalon Jubilee, LLC, a New Mexico limited liability company dated as of May 16, 2012, and all amendments thereto; and a Development Services Agreement dated September 15, 2015 by and between UR-FC Contributed Assets, LLC, a Delaware limited liability company, as Owner, and Land Strategies, LLC, a Nevada limited liability company, as Developer, with respect to real property owned by Avalon Jubilee, LLC. As of the Initial Closing, the Company also assumed an installment note dated April 7, 2015 made by First Capital Real Estate Investments, LLC (“FCREI”) in favor of George Zambelli (“Zambelli”) in the original principal amount of $470 (the “Note”) and a Long Form Deed of Trust and Assignment of Rents dated April 7, 2015 between FCREI, as Trustor, Fidelity National Title Company, as Trustee (“Trustee”), and Zambelli, as Beneficiary (the “Deed of Trust”), which secures the Note (see also Note 12).
Second Contribution
Contributor Parent was also required to contribute two additional property interests valued at the agreed upon value amount of $20 million if certain conditions as set forth in the Contribution Agreement are satisfied by December 31, 2017. This second installment was mandatory under the original terms of the Contribution Agreement. As discussed below, the contribution Agreement was terminated and this second contribution did not take place.
The agreement stated that Contributor Parent must contribute to the Acquirer its 100% ownership interest in a private hotel that was currently undergoing renovations to convert to a Wyndham Garden Hotel. This 265 room full service hotel was located in Amarillo, Texas and had an agreed upon value of approximately $16 million and outstanding loans of approximately $10.11 million. Before contributing the property to the Acquiror, Contributor Parent was required to resolve a lawsuit concerning ownership of the property. Only when Contributor Parent had confirmed that it was the full and undisputed owner of the property was it able to contribute that interest to the Acquiror. If the contribution was made, the Company would have been required to account for this transaction as a business combination under ASC 805, Business Combinations.
On July 3, 2017, the Company and the Acquiror entered into an Agreement to Waive Second Closing Deliverables (the “Second Waiver”) with the Contributor Parties, amending the Contribution Agreement. The Contributor Parties had received an offer to purchase the Amarillo Hotel from a non-related third party. Under the Second Waiver, the Company and the Acquiror agreed to waive the requirement for the Contributor Parties to contribute to the Acquiror their 100% ownership interest in the Amarillo Hotel, and to accept in its place a contribution in cash of not less than $5.89 million from the Contributor Parties from the sale proceeds of the Amarillo Hotel, after the satisfaction of the outstanding loan, provided that the sale is completed and closed upon not later than August 31, 2017. In exchange the Contributor Parties would receive shares of stock in the Company, such amount to be calculated as set forth in the Second Waiver and Contribution Agreement. The sale of the Amarillo Hotel was not completed and closed by August 31, 2017, therefore the waiver of the requirement for the contribution of the interest in the Amarillo Hotel lapsed.
On September 22, 2017, the Company and Acquiror entered into a Second Agreement to Waive Closing Deliverables (the “Second Agreement”) with the Contributor Parties, amending the Contribution Agreement. Pursuant to the terms of the Second Agreement, the Company and the Acquiror agreed to extend the date for the closing of the sale of the Amarillo Hotel until October 18, 2017, with the contribution of the funds from the sale to be made not later than October 23, 2017. In exchange the Contributor Parties would receive shares of stock in the Company, such amount to be calculated as set forth in the Contribution Agreement, as amended by the Second Waiver and the Second Agreement. If the sale of the Amarillo Hotel was not completed and closed by October 18, 2017, the waiver of the requirement for the contribution of the interest in the Amarillo Hotel would lapse. The sale was not completed.
In addition, the agreement stated that Contributor Parent must contribute to the Acquiror its interest in Dutchman’s Bay and Serenity Bay (referred to as the “Antigua Resort Developments”), two planned full service resort hotel developments located in Antigua and Barbuda in which Contributor Parent would contribute a 75% interest in coordination with the Antigua government. Serenity Bay is a planned five star resort comprised of five contiguous parcels (28.33 acres) zoned for hotel and residential use that are planned for 246 units and 80 one, two and three bedroom condo units. Dutchman’s Bay is a planned four star condo hotel with 180 guestrooms, 102 two bedroom condos, and 14 three bedroom villas. For the property in Antigua, Contributor Parent was required to obtain an amendment to its agreement with the government to extend the time for development of these properties and confirm that all development conditions in the original agreement with the government had been either satisfied or waived.
In exchange for each of these properties, the agreement stated the Company would issue to Contributor a number of duly authorized, fully paid and non-assessable shares of the Company’s Common Stock or Series A Convertible Preferred Stock, determined by dividing the $20 million agreed upon value of that contribution by the Per Share Value. The agreement stated that shares would be comprised entirely of shares of Common Stock if the issuance had been approved by the Company’s stockholders prior to the issuance thereof and would be comprised entirely of shares of Series A Convertible Preferred Stock if such approval had not yet been obtained.
The Company had determined in accordance with the updated guidance of ASU 2017-01,Business Combinations (Topic 805) Clarifying the Definition of a Businessthat the Amarillo property (an operating hotel) represented a business as it included an organized workforce with the necessary skills, knowledge and experience to perform the acquired process and an input that the workforce could develop or convert into output. However, it was determined that the Antigua property did not represent a business. Based on the above conclusion it was determined that the Amarillo property component was not required to be analyzed under the provisions of ASC 815-10 “Derivatives and Hedging”since such contract between an acquirer and a seller to enter into a business combination are scoped out from its provisions. As for the Antigua property it was determined that such future transaction did not constitute a derivative instrument in accordance with ASC 815-10 -Derivatives and Hedging as the net settlement criteria was not met. Further, the Company considered the provisions of Subtopic ASC 815-40 “Contracts in the Entity’s Own Equity” and determined that such contractual obligations cannot be considered as indexed to an entity’s own stock, as its settlement provisions are not based on a fixed monetary amount or a fixed amount of a debt instrument issued by the entity but rather on the fair value of the Antigua property which represents a real estate asset. Based on the terms of this component, (i.e. the fair value of the Antigua property and the fair value of the shares that the Company is obligated to issue for this asset), it was determined that such freestanding financial instrument represented a financial asset required to be measured upon initial recognition of LCA-Vision,at fair value. Subsequent to initial recognition the financial instrument (which might be a previously publicly-traded Delaware corporation.
Optional Contribution
Contributor Parent had the option to contribute either or both of two additional property interests valued at the agreed upon value of $66.5 million if certain conditions as set forth in the Contribution Agreement were satisfied by December 31, 2017. This third installment was optional in Contributor Parent’s sole discretion. As discussed below, the contribution Agreement was terminated and this optional contribution did not take place.
The agreement stated that the Contributor Parent may contribute to the Acquiror its interest in a providerresort development project on an island just south of fixed-site laser vision corrections servicesHilton Head, South Carolina (“Melrose”). Contributor Parent had the property under a Letter of Intent and expected to close on the property by December 31, 2017. Melrose was valued by Contributor Parent at its LasikPlus® vision centers. an agreed upon value of $22.5 million, based upon a senior lending position that Contributor Parent held under the Letter of Intent on this property.
The vision centers provideagreement stated that the staff, facilities, equipmentContributor Parent also may contribute to the Acquiror a golf and support servicessurf club development project on the Baja Peninsula in Mexico (“Punta Brava”). Contributor Parent also had this property under a Letter of Intent and expected to close by December 31, 2017. Punta Brava was valued at the agreed upon value by Contributor Parent at $44 million based on Contributor Parent’s commitment of $5 million upon closing on this property, plus a commitment for performing laser vision correctionan additional $5 million and a second commitment of $34 million for construction of the project.
In exchange for each of these properties, the Company would issue to Contributor a number of duly authorized, fully paid and non-assessable shares of the Company’s Common Stock or Series A Convertible Preferred Stock, determined by dividing an agreed upon value of $86,450 (130% of the value of the agreed upon value of $66,500) by the Per Share Value. The shares would be comprised entirely of shares of Common Stock if the issuance had been approved by the Company’s stockholders prior to the issuance thereof and would be comprised entirely of shares of Series A Convertible Preferred Stock if such approval had not yet been obtained. In addition, the Company would issue to Contributor a five year warrant (the “Warrant”) to purchase up to 25,000,000 shares of the Company’s Common Stock at an exercise price of $3.00 per share that employs advanced laser technologieswould vest with respect to help correct nearsightedness, farsightednessthe number of underlying shares upon the achievement of the milestone specified in the Contribution Agreement. The number of warrant shares and astigmatism.the exercise price would be equitably adjusted in the event of a stock split, stock combination, recapitalization or similar transaction. These optional contributions represented a potential liability to the Company as the number of shares and warrants to be issued is fixed but the market value of the shares fluctuates. It is possible that the share price could have risen to a level that upon contribution of the properties causing the Company to give consideration that exceeded the fair value of the assets acquired. This would represent a potential liability to the Company and to quantify the liability the Company has used the Black Scholes formula. The vision centers are supported by independent ophthalmologists and credentialed optometrists,warrants also represented a potential liability in that the Company may be required to issues shares at $3 when the share price was significantly higher.
To estimate the fair value of the liability associated with optionality granted to the Contributor as well as other healthcare professionals. Substantially all of LCA's revenues are derived from the delivery of laser vision correction procedures performedwarrant liability, Management has used the Black Scholes option pricing formula. The key input in the vision centers.
The Company has determined that the Company’s contractual obligations under the optional contributions does not constitute a derivative instrument in accordance with ASC 815-10 -Derivatives and Hedging as the net settlement criteria is not met. Further, the Company considered the provisions of Subtopic ASC 815-40Contracts in the Entity’s Own Equity and determined that such contractual obligations cannot be considered as indexed to an entity’s own stock, as its settlement provisions are not based on a fixed monetary amount or a fixed amount of a debt instrument issued by the entity but rather on the fair value of certain real estate assets. Thus, such freestanding financial instrument were classified as financial liabilities and were measured upon initial recognition at fair value. Subsequent to initial recognition the financial liabilities are remeasured at fair value, with changes in fair value reported in earnings (within the line item “Revaluation of asset contribution related financial instruments, net”).
The Company elected to early adopt ASU 2017-01 Business Combinations (Topic 805)Clarifying the Definition of a Business.Accordingly, the determination whether the asset contribution transaction represents a business combination was evaluated by applying the ASU 2017-01 guidance. The Company has determined that the group of assets assumed in the First Contribution does not (and also, none of them on a stand-alone basis) include, an input and a substantive process that together significantly contribute to the ability to create output and thus it was determined that the First Contribution represents an acquisition of assets rather than a business combination. Accordingly, the total sum of the fair value of consideration given (i.e. the fair value of the equity interests issued) together with the transaction costs and the fair value of financial assets was allocated to the individual assets acquired and liabilities assumed in the first contribution based on their relative fair values at the date of acquisition. Such allocation did not give rise to goodwill.
| Fair value LCA-Vision stock (A) | $ | 103,896 | ||
| Fair value of LCA-Vision restricted stock units, including payroll taxes (B) | 2,656 | |||
| Total purchase price | $ | 106,552 |
The consideration for the assets acquisition as of the Initial Date consists of the following:
| Fair value 879,234 shares of FC Global common stock (*) | $ | 1,275 | ||
| Fair value 123,668 shares of FC Global Series A preferred stock (*) | 4,483 | |||
| Fair value of financial liability related to Optional contribution (**) | 857 | |||
| Fair value of Warrant (***) | 1,925 | |||
| Fair value of asset related to future mandatory asset contribution (***) | (4,175 | ) | ||
| Fair value of assumed note payable on acquired asset | 470 | |||
| Transaction costs | 283 | |||
| Total consideration | $ | 5,118 |
| Fair value of Common shares based on | ||
| (**) | Related to Optional Contribution |
| (***) | Related to Second Contribution |
The fair value of the assets acquired, and liabilities assumed were based on management estimates and values, derived from an outside independent appraisal. The Company expected thatincluding estimates based on historical sales of similar parcels. Adjustments were applied to such historical sales and assumptions were applied to other attributes of the allocation would be finalized within twelve months after the merger. However, LCA was soldassets in January 2015 and it is presented as a discontinued operations, see Note 2. Accordingly management has determinedorder to retain the provisional amounts. Based on the purchase price allocation, theestimate market value. The following table summarizes the provisional fair value amountsallocation of the consideration to the assets acquired in the transaction.
The allocation of aforesaid total consideration is as follows:
| Investment properties | $ | 2,600 | ||
| Investment in other company | 2,668 | |||
| Less: Noncontrolling interest (***) | (150 | ) | ||
| Total assets acquired at fair value | $ | 5,118 | ||
| Impairment of investment in other company (*) | (862 | ) | ||
| Total asset value as of December 31, 2017 | $ | 4,256 |
(*) Loss from impairment was recorded amounting to $862 as part of operating expenses in the Company’s consolidated statement of comprehensive loss during the year ended December 31, 2017 (see also Note 13).
(***) Attributable to the 25% noncontrolling membership interest in a limited liability company that owns a vacant land site located in Northern California
The fair value of options, warrants and liabilities assumedasset related to future mandatory asset contribution granted was estimated at the dateInitial Date by using the Black-Scholes option pricing model. The following are the data and assumptions used:
Options Value:
| May 17, 2017 | ||||
| Dividend yield (%) | 0 | |||
| Expected volatility (%) | 39.45 | |||
| Risk free interest rate (%) | 1.25 | |||
| Strike price | 1.93 | |||
| Stock price | 1.45 | |||
| Probability (%) | 50 | |||
| Expected term of options (years) | 0.62 | |||
Warrants Value:
| May 17, 2017 | ||||
| Dividend yield (%) | 0 | |||
| Expected volatility (%) | 39.45 | |||
| Risk free interest rate (%) | 1.25 | |||
| Strike price | 3 | |||
| Stock price | 1.45 | |||
| Probability (%) | 50 | |||
| Expected term of options (years) | 5 | |||
Asset related to future mandatory asset contribution:
| May 17, 2017 | ||||
| Dividend yield (%) | 0 | |||
| Stock price | 1.45 | |||
| Probability (%) | 70 | |||
As of acquisition:
| Cash and cash equivalents | $ | 29,042 | ||
| Current assets, excluding cash and cash equivalents | 6,114 | |||
| Deferred tax asset, current | 1,124 | |||
| Property, plant and equipment | 17,269 | |||
| Identifiable intangible assets | 39,050 | |||
| Other assets | 1,518 | |||
| Total assets acquired at fair value | 94,117 | |||
| Current liabilities | (19,009 | ) | ||
| Long-term debt | (1,603 | ) | ||
| Deferred tax liability, long-term | (9,138 | ) | ||
| Other long-term liabilities | (7,397 | ) | ||
| Total liabilities assumed | (37,147 | ) | ||
| Net assets acquired | $ | 56,970 |
Note 6
Inventories, net:
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Raw materials and work-in-process | $ | — | $ | 1,968 | ||||
| Finished goods | — | 5,368 | ||||||
| Total inventories | $ | — | $ | 7,336 | ||||
| Less assets held for sale (*) | — | (7,336 | ) | |||||
| Total inventory | $ | — | $ | — | ||||
(*) Inventory was classified as part of the assets acquired by $49,582, whichheld for sale as of December 31, 2016. In January 2017, all of the consumer inventory was recorded as goodwill. The goodwillsold to ICTV (see also Note 2 and 4).
Note 7
Property and Equipment, net:
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Equipment, computer hardware and software | $ | 320 | $ | 5,005 | ||||
| Furniture and fixtures | 350 | 433 | ||||||
| Leasehold improvements | 112 | 438 | ||||||
| 782 | 5,876 | |||||||
| Accumulated depreciation and amortization | (777 | ) | (4,888 | ) | ||||
| Total property and equipment, net | $ | 5 | $ | 988 | ||||
| Less Assets held for sale (*) | — | (911 | ) | |||||
| Total property and equipment, net | $ | 5 | $ | 77 | ||||
(*) In January 2017, the consumer division property and equipment was recognized at that time as a new reportable segmentsold to ICTV (see also Note 2 and allocated to the activities of LCA.4).
During the years ended December 31, 20142017 and 2013 are not provided as required under ASC Topic 805 since LCA is presented as a discontinued operation for the periods presented.
Note 4
| December 31, | ||||||||
| 2014 | 2013 | |||||||
| Raw materials and work-in-process | $ | 7,483 | $ | 12,631 | ||||
| Finished goods | 11,897 | 14,916 | ||||||
| Total inventories | $ | 19,380 | $ | 27,547 | ||||
| December 31, | ||||||||
| 2014 | 2013 | |||||||
| Lasers-in-service | $ | 18,974 | $ | 12,599 | ||||
| Equipment, computer hardware and software | 4,870 | 4,730 | ||||||
| Furniture and fixtures | 767 | 705 | ||||||
| Leasehold improvements | 481 | 534 | ||||||
| 25,092 | 18,568 | |||||||
| Accumulated depreciation and amortization | (11,290 | ) | (8,079 | ) | ||||
| Total property and equipment, net | $ | 13,802 | $ | 10,489 | ||||
Patents and Licensed Technologies, net:
| December 31, | ||||||||
| 2014 | 2013 | |||||||
| Gross Amount beginning of period | $ | 15,648 | $ | 15,411 | ||||
| Additions | 168 | 171 | ||||||
| Translation differences | (190 | ) | 66 | |||||
| Gross Amount end of period | 15,626 | 15,648 | ||||||
| Accumulated amortization | (6,815 | ) | (4,816 | ) | ||||
| Net Book Value | $ | 8,811 | $ | 10,832 | ||||
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Gross Amount beginning of period | $ | — | $ | 3,376 | ||||
| Disposals | — | (177 | ) | |||||
| Translation differences | — | 36 | ||||||
| Gross Amount end of period | — | 3,235 | ||||||
| Accumulated amortization | — | (1,974 | ) | |||||
| Impairment of assets (see Note 9 below) | — | (1,261 | ) | |||||
| Total patents and licensed technology | $ | — | $ | — | ||||
During the years ended December 31, 2014, 20132017 and 2012,2016, amortization expenses were $0 and $230, respectively. An amount of $13,500, included in gross amount related to Patents represents product and core technologies recorded as part of the purchase price allocation done in connection with the reverse acquisition of the Pre-merged PhotoMedex.
| 2015 | $ | 2,056 | ||
| 2016 | 2,019 | |||
| 2017 | 903 | |||
| 2018 | 906 | |||
| 2019 | 892 | |||
| Thereafter | 2,035 | |||
| Total | $ | 8,811 |
Note 7
Goodwill and Other Intangible Assets:
As part of the purchase price allocation for thea reverse acquisition transaction in 2011, the Company recorded goodwill in the amount of $24,005 and definite-lived intangibles in the amount of $12,000. Goodwill reflects the value or premium of the acquisition price in excess of the fair values assigned to specific tangible and intangible assets. Goodwill has an indefinite useful life and therefore is not amortized as an expense but is reviewed annually for impairment of its fair value to the Company. Activity in goodwill during the year ended December 31, 2016 was as follows:
| Balance at January 1, 2016 | $ | 3,581 | ||
| Disposal on sale of assets | (1,039 | ) | ||
| Impairment of goodwill | (2,257 | ) | ||
| Translation differences | (285 | ) | ||
| Balance at December 31, 2016 | $ | — |
The purchase price intrinsicallyfair value of Goodwill associated with the operating and reporting units were estimated using a combination of Income and Market Approach methodologies to valuation. The Income method of valuation explicitly recognizes the current value of future economic benefits developed by discounting future net cash flows to their present value at a rate that reflects both the current return requirements of the broadened depthmarket and the risks inherent in the market. The Market approach measures the value of an asset through the analysis of recent sales or offerings of comparable property.
The Company’s business was organized into three operating and reporting units which are defined as Consumer, Physician Recurring, and Professional Equipment.
During the third quarter of 2016, we recorded goodwill and other intangible asset impairment charges of $3,518, as we determined that a portion of the management team and the addition of a sizeable direct sales force creating greater access to the physician community with branded products and technologies. Furthermore, the purchase price paid by Radiancy, Inc., a private company includes, among other things, other benefits such as the intrinsic value of being a Nasdaq-listed issuer post mergerthe Company’s goodwill and now having access to capital markets and stockholder liquidity.
| Balance at January 1, 2014 | $ | 24,930 | ||
| Additions to goodwill | - | |||
| Translation differences | (882 | ) | ||
| Balance at December 31, 2014 | $ | 24,048 | ||
Note 10
Accrued Compensation and related expenses:
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Accrued payroll and related taxes | $ | 453 | $ | 262 | ||||
| Accrued vacation | 14 | 66 | ||||||
| Accrued commissions and bonuses (*) | — | 3,701 | ||||||
| Total accrued compensation and related expense | $ | 467 | $ | 4,029 | ||||
| (*) | The amount related to the obligation the Company had in connection with the Payout Notes Holders as of December 31, 2016. On December 22, 2017, the then outstanding payout notes were converted into shares of common stock of the Company (see also Note 14). |
Note 11
Other Accrued Liabilities:
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Accrued taxes, including liability for unrecognized tax benefit, (see also Note 15) | $ | 1,549 | $ | 1,606 | ||||
| Other accrued liabilities | 901 | 4,417 | ||||||
| Total other accrued liabilities | $ | 2,450 | $ | 6,023 | ||||
Note 12
Note payable:
Following the Initial Closing of the Interest Contribution Agreement (see also Note 5), the Company assumed an installment note dated April 7, 2015 made by the Contributor in favor of George Zambelli (“Zambelli”) in the original principal amount of $470 (the “Note”) and a Long Form Deed of Trust and Assignment of Rents dated April 7, 2015 between FCREI, as Trustor, Fidelity National Title Company, as Trustee (“Trustee”), and Zambelli, as Beneficiary (the “Deed of Trust”), which secures the Note. The Note carries a per annum interest rate of 8% which is payable on a monthly basis from the Initial Closing. As of December 31, 2014. See 2017, the Note 2 regarding impairmentamounted to $459 ($454 out of goodwill allocated to the discontinued operations.
which is classified as non-current note payable) and has a maturity date of April 10, 2020.
Note 13
Commitments and Contingencies:
Leases
The goodwill was allocated among the reportable segments as ofCompany has entered into a non-cancelable operating lease agreement for real property which expires on December 31, 2014 in accordance with the provisions of ASC Topic 350-20 Intangibles-Goodwill and consisted of the following:
| December 31, 2014 | ||||
| Consumer segment | $ | 19,968 | ||
| Physician Recurring segment | 4,080 | |||
| Total goodwill | $ | 24,048 | ||
| December 31, 2014 | December 31, 2013 | |||||||||||||||||||||||
| Trademarks | Customer Relationships | Total | Trademarks | Customer Relationships | Total | |||||||||||||||||||
| Gross Amount beginning of period | $ | 5,772 | $ | 6,417 | $ | 12,189 | $ | 5,744 | $ | 6,372 | $ | 12,116 | ||||||||||||
| Translation differences | (80 | ) | (128 | ) | (208 | ) | 28 | 45 | 73 | |||||||||||||||
| Gross Amount end of period | 5,692 | 6,289 | 11,981 | 5,772 | 6,417 | 12,189 | ||||||||||||||||||
| Accumulated amortization | (1,731 | ) | (1,913 | ) | (3,644 | ) | (1,178 | ) | (1,310 | ) | (2,488 | ) | ||||||||||||
| Net Book Value | $ | 3,961 | $ | 4,376 | $ | 8,337 | $ | 4,594 | $ | 5,107 | $ | 9,701 | ||||||||||||
| 2015 | $ | 1,200 | ||
| 2016 | 1,200 | |||
| 2017 | 1,200 | |||
| 2018 | 1,200 | |||
| 2019 | 1,200 | |||
| Thereafter | 2,337 | |||
| Total | $ | 8,337 |
| Year Ending December 31, | ||||
| 2018 | $ | 70 | ||
| December 31, | ||||||||
| 2014 | 2013 | |||||||
| Accrued payroll and related taxes | $ | 513 | $ | 707 | ||||
| Accrued vacation | 211 | 290 | ||||||
| Accrued commissions and bonuses | 1,898 | 2,233 | ||||||
| Total accrued compensation and related expense | $ | 2,622 | $ | 3,230 | ||||
| December 31, | ||||||||
| 2014 | 2013 | |||||||
Accrued warranty, current, see Note 1 | $ | 665 | $ | 1,094 | ||||
Accrued taxes, including liability for unrecognized tax benefit, see Note 13 | 1,362 | 1,023 | ||||||
| Accrued sales return (1) | 7,651 | 16,046 | ||||||
| Other accrued liabilities | 3,344 | 3,869 | ||||||
| Total other accrued liabilities | $ | 13,022 | $ | 22,032 | ||||
| December 31, | ||||||||
| 2014 | 2013 | |||||||
| Balance at beginning of year | $ | 16,046 | $ | 11,901 | ||||
| Additions that reduce net sales | 35,771 | 47,916 | ||||||
| Actual returns | (44,166 | ) | (43,771 | ) | ||||
| Balance at end of year | $ | 7,651 | $ | 16,046 | ||||
As a summaryresult of the Company's long-term debt:
| December 31, | ||||||||
| 2014 | 2013 | |||||||
| Senior-secured credit facilities | $ | 76,500 | $ | - | ||||
| Term note | - | 10,000 | ||||||
| Sub-total | 76,500 | 10,000 | ||||||
| Less: current portion | 38,732 | 10,000 | ||||||
| Long-term debt | $ | 37,768 | $ | - | ||||
Litigations
JFURTI
The Company also agreed that, on or before the fifth calendar day of each month, the Company would pay against the Term Loan $125,000is a party to the extent that the cash-on-hand exceeds $5 million, and 100% of the cash-on-hand in excess of $7 million, also to be applied to the Term Loan in inverse order of maturity.
| 2015 | $ | 38,732 | ||
| 2016 | 37,768 | |||
| $ | 76,500 |
| Year Ending December 31, | ||||
| 2015 | $ | 814 | ||
| 2016 | 472 | |||
| 2017 | 176 | |||
| Thereafter | 366 | |||
| Total | $ | 1,828 | ||
The suit is the ninth filed by Jacob Frydman and/or JFURTI, LLC in a dispute between the plaintiffs and the First Capital group of companies, which entered into a series of agreements with Mr. Frydman beginning in September 2015. Mr. Frydman had founded, sponsored, and taken public United Realty Trust Incorporated, a Real Estate Investment Trust (“REIT”). Mr. Frydman was the CEO and Chairman of the REIT as well as the owner of various other United Realty branded companies affiliated with the REIT business. In September 2015, Mr. Frydman and Mr. Singal negotiated and agreed to a transaction between various First Capital branded companies, on the one hand, and the United Realty branded companies affiliated with the REIT business, on the other hand, as a result of which the REIT was rebranded as the Contributor Parent.
After the September 2015 transaction was concluded, several disputes arose between the parties. This suit is the ninth action brought by Mr. Frydman in state and federal courts relating to these disputes, and the second attempt by Mr. Frydman and JFURTI to bring federal claims derivatively in this Court against First Capital entities and other parties. The first action, titled JFURTI, LLC and Jacob Frydman v. Forum Partners Investment Management LLC et al., No. 16 Civ. 8633 (the “Prior Action”), commenced on November 7, 2016 and asserted, inter alia, derivative RICO and securities fraud claims. The Court dismissed the action in a decision and order dated April 27, 2017.
Following dismissal of the Prior Action, Mr. Frydman sent letters to each member of the Contributor Parent’s Board of Directors (the “Demand Letter”) demanding that the Board investigate and remediate the dissipation of assets as alleged by plaintiffs. In particular, the Demand Letter questioned (i) a letter of intent with Presidential Realty Corporation, or Presidential, announced in an 8K filed by First Capital REIT on or about July 18, 2016; (ii) First Capital REIT’s use of funds raised between September 15, 2015 and February 28, 2016; (iii) an interest contribution agreement with Presidential entered into on or about December 16, 2016; (iv) the Contributor Parent’s failure to file quarterly and annual reports; (iv) an interest contribution agreement entered into on March 31, 2017 with PhotoMedex; and (v) other purportedly fraudulent acts such as publishing an artificially inflated NAV, defaulting on certain mortgage loans, misrepresentations by Singal with respect to certain properties contributed to the REIT through the Master Agreement executed on September 15, 2015, and various loan agreements with Forum Partners Investment Management LLC, or Forum. The Demand Letter also demanded inspection of certain corporate documents pursuant to Md. Code § 2-512.
The Contributor Parent commenced such an investigation, and offered such an inspection, but Mr. Frydman and JFURTI failed to wait for the results of the investigation or make any inspection, and instead brought suit in the same court as the Prior Action. The suit alleges, among other claims, violations of the Federal securities laws between November 7, 2012 and November 14, 2013. A mediation on possible settlement of this action was held on November 10, 2014; the parties including the Company's insurance carrier have agreed on a possible settlement. The Company has paid its own legal fees up to the deductible cap on its insurance policy, and all amounts to be paid to plaintiffs and plaintiff's counsel will be paid by the carrier§ 10(b) of the insurance policy. This settlement is subject to reviewExchange Act and approval by the District Court, which has not yet rendered its opinion.
The parties have reachedsubmitted a possible settlementmotion for an order (i) staying all proceedings in these suits,this action for 60 days, or until the end of 2017, and (ii) extending the defendants time to respond to the complaint, or to make a motion with respect to the complaint, until 45 days after First Capital REIT’s response to the Demand Letter. The Court granted that motion on October 31, 2017. Upon completion of their investigation, the Contributor Parent provided a response to the Demand Letter, denying all claims made in the letter. A Motion to Dismiss this action has now been filed with the Company contributing less than $100,000 to the settlement, plus the paymentCourt on behalf of its legal fees, and the remainder of the settlement being covered by the insurance carriers. This settlement is subject to review and approval by the state court, which has not yet rendered its opinion.
The Company has filed a motionintends to dismiss this case; that motion is pending before the Court. A mediation was scheduled in this matter for November 24, 2014, but no settlement was reached. Radiancy and its officers intend todefend itself vigorously defend themselves against this lawsuit.suit. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case has only been initiated and no discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters.
DSKX
On February 19, 2016, the Company and its subsidiaries entered into Agreements and Plans of Merger and Reorganization with DS Healthcare Group, Inc. and its subsidiaries (“DSKX”), under which DSKX would acquire the Company’s subsidiaries Radiancy, Inc. and PhotoMedex Technology, Inc. in exchange for shares of stock in DSKX as well as cash payments and notes for future cash payments. Subsequent to the signing of those Agreements, on March 23, 2016, after discussion with its independent registered public accounting firm, DSKX concluded that the unaudited condensed consolidated financial statements of DSKX for the two fiscal quarters ended June 30, 2015 and September 30, 2015 should no longer be relied upon because of certain errors in such financial statements. Also, DSKX reported that its audit committee, consisting of all members of its board of directors other than Daniel Khesin (at the time DSKX’s President and Chairman of the Board and a member of its board of directors), had engaged independent counsel to conduct an investigation regarding certain transactions involving Mr. Khesin and other individuals; the committee’s investigation had begun earlier in February. The board also reported that it had terminated the employment of Mr. Khesin as DSKX’s president and as an employee of DSKX, and also terminated Mr. Khesin’s employment agreement, dated December 16, 2013, for cause.
The Company was not advised of this investigation during its negotiations with DSKX or after signing the Merger Agreements until the evening of March 21, 2016. On April 12, 2016, the Company sent a Reservation of Rights letter to DSKX. The Notice states that, based upon the disclosures set forth in DSKX’s Current Report on Form 8-K filed on March 23, 2016 and subsequent press releases and filings by DSKX with the United States Securities and Exchange Commission (collectively, the “DSKX Public Disclosure”), DSKX is in material breach of various representations, warranties, covenants and agreements set forth in the Agreements; had failed to provide to the Company the information contained in the DSKX Public Disclosures during the discussions relating to the negotiation and execution of the Agreements; and continues to be in material breach under the Agreements. As a result, the conditions precedent to the closing of these transactions as set forth in the Agreements may not be able to occur. The Notice also declares that the Company reserves all its rights and remedies under the Agreements, including, without limitation, the right to terminate the Agreements and collect a termination fee from DSKX of $3 million. The Notice further asserts that the Company regards certain provisions of the Agreements to have been waived by DSKX and to no longer be in effect, including the non-solicitation and no-shop provisions, negative covenants, and termination events, as applicable solely to the PHMD Group, as well as the payment of any termination fee by PHMD to DSKX. Finally, the Notice provided that the Company has the right to terminate the Agreements to pursue, consider and enter into any acquisition proposal or other transaction without the payment of fees and expenses to DSKX.
On May 27, 2016, the Company and its subsidiaries Radiancy, Inc., an indirectly wholly-owned subsidiary of the Company (“Radiancy”), and PhotoMedex Technology, Inc., a wholly-owned subsidiary of the Company (“P-Tech”), terminated: (a) the Agreement and Plan of Merger and Reorganization, dated as of February 19, 2016 (the “Radiancy Merger Agreement”), among the Company, Radiancy, DS Healthcare Group, Inc. (“DSKX”) and PHMD Consumer Acquisition Corp., a wholly-owned subsidiary of DSKX (“Merger Sub A”), and (b) the Agreement and Plan of Merger and Reorganization, dated as of February 19, 2016 (the “P-Tech Merger Agreement” and together with the Radiancy Merger Agreement, the “Merger Agreements”), among the Company, P-Tech, DSKX, and PHMD Professional Acquisition Corp., a wholly-owned subsidiary of DSKX (“Merger Sub B”). Pursuant to the Merger Agreements, Radiancy was to merge with Merger Sub A, with Radiancy as the surviving corporation in such merger, P-Tech was to merge with Merger Sub B, with P-Tech as the surviving corporation in such merger, and DSKX was to become the holding company for Radiancy and P-Tech.
Given the material breaches identified in the Company’s notice to DSKX, and other disclosures and communications by DSKX, in connection with the Company’s termination of the Merger Agreements and pursuant to their terms, the Company sought to recover a termination fee of $3.0 million, an expense reimbursement of up to $750, and its liabilities and damages suffered as a result of DSKX’s failures and breaches in connection with each of the Merger Agreements. On May 27, 2016, the Company, Radiancy and P-Tech filed a complaint in the U.S. District Court for the Southern District of New York alleging breaches of the Merger Agreements by DSKX and seeking the damages described in the foregoing sentence. On August 1, 2016, DSKX filed its answer to the complaint, denying the allegations stated in the complaint and alleging its own counterclaims including, among others, the Company’s alleged failure to disclose the Mouzon and Cantley cases filed against Radiancy.
On June 30, 2014,23, 2017, the Company'sCompany and its subsidiaries, Radiancy, Inc. (“Radiancy”) and PhotoMedex Technology, Inc. (“P-Tech”), entered into a Confidential Settlement and Mutual Release Agreement (the “DS Settlement Agreement”) with DS Healthcare Group, Inc. (“DSKX”) and its subsidiaries, PHMD Consumer Acquisition Corp. and PHMD Professional Acquisition Corp.
The terms of the DS Settlement Agreement are confidential. According to the DS Settlement Agreement the parties dismissed the suit between them with prejudice on June 23, 2017. The amount under this settlement agreement was recorded under discontinued operation.
Linda Andrews
During 2016, Linda Andrews, an alleged user of the no!no! Hair device, filed a product liability claim against the Company, its subsidiary Radiancy, Inc., was served with a class action lawsuit filedand Dr. Dolev Rafaeli, in the SuperiorUnited States District Court infor the StateMiddle District of California, County of Kern. The suit was filed by April Cantley, who purchased Radiancy's no!no! Hair products. It alleges various violations of state business and consumer protection codes including false and misleading advertising, breach of express and implied warranties and breachFlorida, Orlando Division, alleging that use of the California Legal Remedies Act.device had caused a relapse of and complication to a pre-existing medical condition resulting from her treatment for cancer. The complaint seeks certificationalleged, among other claims, that Radiancy failed to provide adequate warnings regarding the operation of the class, which consists of customers indevice. The Company and Dr. Rafaeli filed a motion to dismiss the State of California who purchased the no!no! Hair devices. The complaint also seeks an unspecified amount of monetary damages, pre-and post-judgment interest and attorneys' fees, expert witness fees and other costs.claims against them; Radiancy has filed an Answeranswer to this Complaint;the Complaint. Ms. Doe then sought leave to amend her complaint to clarify the claims; the Company, Radiancy and Dr. Rafaeli filed appropriate responses and renewed the motion to dismiss the claims against the Company and Dr. Rafaeli.
On June 22, 2017, the United States District Court for the Middle District of Florida, Orlando Division, dismissed the Company and Dr. Dolev Rafaeli, its former Chief Executive Officer, from the case is now in the discovery phase.of Linda Andrew v. Radiancy, and its officers intend to vigorously defend themselves against this lawsuit. Discovery has now commenced in this action. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case has only been initiated and no discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore,Inc.; the Company has not recorded any reserve or contingent(under the name PhotoMedex, Inc.); and Dr. Rafaeli. Ms. Andrew had filed a product liability related to these particular legal matters. However, in the future, as the cases progress,suit alleging damages from her use of a no!no! hair device. The claims against the Company may be required to recordand Dr. Rafaeli were dismissed without prejudice. The Company’s subsidiary, Radiancy, Inc., entered into a contingentsettlement with Ms. Andrews in 2017; the terms of the settlement are confidential.
Other litigation
The Company and certain subsidiaries are, and have been, involved in other miscellaneous litigation and legal actions, including product liability, or reserve for these matters.
Avalon
On January 12, 2018, we received a copy of a complaint, dated November 17, 2017, that was filed by Alpha Alpha, LLC in the Thirteenth Judicial District Court in the County of Valencia in the State of New Mexico against Avalon Jubilee, LLC, the holding company that owns the property in Los Lunas, New Mexico, HiTex, LLC, MCBB, LLC, Land Strategies, LLC, Ronald R. Cobb and John Does 1–5. The suit asks the court to, among other things, determine whether there have been unauthorized transfers of interest in Avalon Jubilee LLC; and declare who are the holders of interests in Avalon Jubilee LLC. Although the complaint does not name the Company or any of its subsidiaries or specifically question the Company’s interest in Avalon Jubilee LLC, it raises questions about whether the transfers of interest leading to our acquisition of our interest in Avalon Jubilee LLC (under the Contribution Agreement described in Note 5) were properly made in accordance with the Avalon Jubilee operating agreement. The Company has severance agreementsbegun an internal investigation into this matter and will disclose the results of that investigation once it has been completed. Although neither our company nor any of its subsidiaries is a party to litigation regarding this matter, we recognized an impairment expense of $862 to account for our estimate of the impact that such litigation may have on the operations and fair value of the underlying asset.
Registration Rights Agreement with certain key executivesParty to the Purchase Agreement
As discussed in Note 14, as a condition to the first closing under the Purchase Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor, pursuant to which the Company agreed to register all shares of Common Stock that may be issued upon conversion of the Series B Preferred Stock (the “Registrable Securities”) under the Securities Act of 1933, as amended (the “Securities Act”). The Company agreed to file a registration statement covering the resale of such Registrable Securities within 30 days of the first closing and employeescause such registration statement to be declared effective under the Securities Act as soon as possible but, in any event, no later than 120 days following the filing date if such registration statement is filed on Form S-3 or 150 days if such registration statement is filed on Form S-1. If such registration statement is not filed or declared effective by the Securities and Exchange Commission on or prior to such dates, or if after such registration statement is declared effective, without regard for the reason thereunder or efforts therefor, such registration statement ceases for any reason to be effective for more than an aggregate of 30 trading days during any 12-month period, which need not be consecutive, then in addition to any other rights the holders of Series B Preferred Stock may have under the Registration Rights Agreement or under applicable law, the Company shall pay to each holder an amount in cash, as partial liquidated damages and not as a penalty, equal to 1% of the product obtained by multiplying (x) the Series B Original Issue Price by (y) the number of shares of Registrable Securities held by the holder (such product being the “Investment Amount”); provided that, create certain liabilitiesin no event will the Company be liable for liquidated damages in excess of 1% of the Investment Amount in any single month and that the maximum aggregate liquidated damages payable to the holders under the Registration Rights Agreement shall be 10% of the Investment Amount. On January 23, 2018, the Company filed a registration statement on Form S-3 to register the shares issued to OFI in the first closing. OFI waived its right to liquidated damages in connection with the late filing of such registration statement.
Registration Rights Agreements with Payout Note Holders
As discussed in Note 14, the Payout Notes were convertible into shares of common stock and the Company agreed to register the shares underlying the Payout Notes within thirty (30) days of issuance with best efforts to cause the registration statement covering such shares to become effective within one-hundred twenty (120) days of issuance. On November 14, 2017, the Company filed a registration statement on Form S-3 (the “First Registration Statement”) to register all shares that may be issued upon conversion of the Payout Notes, which was subsequently amended to include the Payout Shares issued under the Stock Grant Agreement. In connection with the Stock Grant Agreement, the Company entered into a registration rights agreement (the “Payout Registration Rights Agreement”) with the Note Holders, pursuant to which the Company agreed to register the shares of common stock under the Additional Shares under the Securities Act. The Company agreed to file a registration statement covering the resale of the Additional Shares within 30 days of the Stock Grant Agreement and cause such registration statement to be declared effective under the Securities Act as soon as possible but, in any event, of their termination of employmentno later than 120 days following the filing date if such registration statement is filed on Form S-3 or 150 days if such registration statement is filed on Form S-1. If such registration statement is not filed or declared effective by the companySecurities and Exchange Commission on or prior to such dates, or if after such registration statement is declared effective, without cause,regard for the reason thereunder or followingefforts therefor, such registration statement ceases for any reason to be effective for more than an aggregate of 30 trading days during any 12-month period, which need not be consecutive, then in addition to any other rights the Note Holders may have under the Payout Registration Rights Agreement or under applicable law, the Company shall pay to each Note Holder an amount in cash, as partial liquidated damages and not as a change in controlpenalty, equal to 1% of the Company.product obtained by multiplying (x) $1.00 by (y) the number of shares of Common Stock held by the Note Holder included in the registration statement (such product being the “Payout Investment Amount”); provided that, in no event will the Company be liable for liquidated damages in excess of 1% of the Payout Investment Amount in any single month and that the maximum aggregate liquidated damages payable to the Note Holders under the Payout Registration Rights Agreement shall be 10% of the Payout Investment Amount. The aggregate commitment under these executive severance agreements, shouldregistration rights provision contained in the Payout Notes was incorporated by reference into the Payout Registration Rights Agreement, except that the Note Holders waived the breach by the Company for failure to timely file the First Registration Statement and agreed that they are not entitled to liquidated damages as a result of such failure. Under the Payout Registration Rights Agreement, the Note Holders are entitled to liquidated damages if the First Registration Statement is not declared effective within 120 days following the date of the Payout Notes, but the Note Holders subsequently agreed to waive their rights to such liquidated damages until April 20, 2018. On January 23, 2018, the Company filed a registration statement on Form S-3 for the Additional Shares. The Note Holders waived their rights to liquidated damages in connection with the late filing of such registration statement and in connection with the effectiveness deadline for such registration statement until April 20, 2018.
Note 14
Stockholders’ Equity:
Common Stock
The Company’s common stock confer upon their holders the following rights:
| ■ | The right to participate and vote in the Company’s stockholder meetings, whether annual or special. Each share will entitle its holder, when attending and participating in the voting in person or via agent or letter, to one vote; |
| ■ | The right to a share in the distribution of dividends, whether in cash or in the form of bonus shares, the distribution of assets or any other distribution pro rata to the par value of the shares held by them; |
| ■ | The right to a share in the distribution of the Company’s excess assets upon liquidation pro rata to the par value of the shares held by them. |
Convertible Series A Preferred Stock
The terms of the Convertible Series A Preferred Stock are governed by a certificate of designation, or the Series A Certificate of Designation, filed by the Company with the Nevada Secretary of State on May 15, 2017. Pursuant to the Series A Certificate of Designation, the Company designated 3,000,000 shares of the Company’s preferred stock as Series A Convertible Preferred Stock. As more fully described in Note 5, the Company issued 123,668 share of Convertible Series A Preferred Stock in connection with the Contribution Agreement. Following is a summary of the material terms of the Series A Convertible Preferred Stock:
| ■ | Liquidation -Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation, after the Redeemable Convertible Series B Preferred Stockholder’s liquidation preference, the same amount that a holder of Common Stock would receive if the Convertible Series A Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder) to Common Stock which amounts shall be paid pari passu with all holders of Common Stock. |
| ■ | Voting -Except as otherwise provided in the Series A Certificate of Designation or as otherwise required by law, the Convertible Series A Preferred Stock shall have no voting rights. However, as long as any shares of Convertible Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Convertible Series A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Convertible Series A Preferred Stock or alter or amend the Series A Certificate of Designation, (b) amend the Company’s articles of incorporation or other charter documents in any manner that adversely affects any rights of the holders, (c) increase the number of authorized shares of Convertible Series A Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing. |
| ■ | Conversion - Each share of Convertible Series A Preferred Stock shall be convertible, at any time and from time to time from at the option of the holder thereof, into that number of shares of common stock determined by dividing $62.9575 by the Conversion Price. The Conversion Price for the Series A Convertible Preferred Stock is equal to $2.5183, subject to adjustment as described in the Series A Certificate of Designation. |
| ■ | Dividends- Except for stock dividends or distributions for which adjustments are to be made, holders shall be entitled to receive, and the Company shall pay, dividends on shares of Convertible Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends shall be paid on shares of Convertible Series A Preferred Stock. |
Redeemable Convertible Series B Preferred Stock
Convertible Series B preferred stock confer upon their holders all covered executivesthe rights of Common Stock. As more fully described below, the Company issued 1,500,000 shares of Redeemable Convertible series B Preferred Stock in connection with the Securities Purchase Agreement. In addition, based on the Company’s Certificate of Designation, the Series B Shares bear the following rights and employees be terminated other than for cause, was approximately $10,073privileges:
| ■ | Liquidation Preference -Holders of the Series B Shares shall receive cumulative dividends, pro rata among such holders, prior to and in preference to any dividend on the Company’s outstanding Common Stock and Series A Convertible Preferred Stock, at the per annum rate of 8% of the Series B Original Issue Price ($1.00). Dividends on each Series B Share will accrue daily and be cumulative from the original issued date of December 22, 2017 and shall be payable upon the occurrence of any voluntary or involuntary liquidation, dissolution or winding up of the, a conversion or a redemption. The redemption price shall be $1.00 per share, subject to appropriate adjustment. Holders shall also be entitled to receive dividends on the Series B Shares (on an as-if-converted-to-Common-Stock basis) as dividends actually paid on shares of the Company’s Common Stock when, as and if such dividends are paid on shares of the Common Stock. |
As of December 31, 2014, based on 2014 salary levels. Should all covered executives and certain key employees be terminated following a change in control of the Company,2017, the aggregate commitment under these executive severance agreements at December 31, 2014 was approximately $9,820, based on 2014 salary levels.
| ■ | Voting -Each holder of the Series B Shares shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series B Shares held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter subject to certain conversion limitations. |
| ■ | Conversion -Each Series B Share shall be convertible at the option of the holder thereof, at any time after the date of issuance of such share, into such number of fully paid and non-assessable Common Stock as is determined by dividing the original issue price plus accrued, but unpaid, dividends by the applicable conversion price at that time in effect for such Series B Share. The Series B Shares are automatically converted to Common Stock on May 31, 2018 should voluntary conversion or redemption not occur prior to that time. |
| ■ | Redemption – Under certain conditions beyond the Company’s control, the Series B shareholders may require redemption of the Series B Shares at a price per share equal to $1.33, plus accrued, but unpaid, dividends through and including the date of such redemption. |
Reverse Split and Retroactive Adjustment of Shares and Per Share Information
On September 7, 2016, the issuance from time to time of one or more classes of preferred stock with one or more series within any class thereof, with such voting powers, full or limited, or without voting powers and with such designations, preferences and relative, participating, optional or special rights and qualifications, limitations or restrictions thereon as shall be set forth in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such preferred shares. At December 31, 2014 and 2013, no shares of preferred stock were issued or outstanding.
All common stock, stock warrants, stock options and per share amounts set forth herein are presented to give retroactive effect to the 2016 Reverse Split for all periods presented.
Change of Authorized Shares
On October 19, 2017, the Company filed Amended and Restated Articles of Incorporation to among the other things, increase in the number of authorized shares of common stock, $.01 par value per share, of the Company from 50,000,000 shares to 500,000,000 million shares and increase the number of authorized shares of preferred stock, $.01 par value per share, of the Company from 5,000,000 shares to 50,000,000 shares.
Contribution Agreement
As discussed in Note 5, upon the Initial Closing of the First Contribution, the Company issued to the Contributor 879,234 duly authorized, fully paid and non-assessable shares of the Company’s common stock, par value $0.01 per share and 123,668 shares of the Company’s newly designated non-voting Series A Convertible Preferred Stock, par value $0.01 per share for certain Contributed Properties.
Payout Notes
Following the Initial Closing of the First Contribution under the Contribution Agreement (see also Note 5), amounts due to Dr. Dolev Rafaeli, the Company’s former Chief Executive Officer and Dennis McGrath, the Company’s former Chief Financial Officer under their employment agreements, as well as amounts due to Dr. Yoav Ben-Dror for his services as a maximumboard member of $25 million.the Company’s foreign subsidiaries, were to be converted to convertible secured notes (the “Payout Notes”) after approval from the Company’s stockholders. The Payout Notes would be due one year after the stockholder approval and carry a 10% interest rate. The principal would convert to shares of the Company’s Common Stock at the lower of (i) the Per Share Value or (ii) the VWAP with respect to on-exchange transactions in the Company’s Common Stock executed on the NASDAQ during the 30 trading days prior to the maturity date as reported by Bloomberg L.P.; provided, however, that the value of the Company’s Common Stock should in no event be less than $1.75 per share. The Payout Notes would be secured by a security interest in all assets of the Company; provided, however, that such security interest would be subordinated to any (i) claims or liens to the holders of any debt (including mortgage debt) being assumed by the Company as a result of the transaction contemplated by the Agreement, and (ii) all post-closing indebtedness incurred by the Company or its subsidiaries. The holders of the Payout Notes would have registration rights which would require the filing of a re-sale registration statement on appropriate form that registers for re-sale the shares of Common Stock underlying the Payout Notes within thirty (30) days of issuance with best efforts to cause the same to become effective within 120 days of issuance. The form of those Payout Notes was agreed to at the time of signing of the Contribution Agreement and was attached as an exhibit thereto. In August 2013,connection with the Payout Notes, the parties also agreed to a form of security agreement (the “Security Agreement”), which was also attached as an exhibit to the Contribution Agreement.
On October 12, 2017, following approval by the Company’s stockholders, the Company issued a secured convertible promissory notes (the “Payout Notes”) to Dr. Dolev Rafaeli, the Company’s former Chief Executive Officer, Dennis M. McGrath, the Company’s former President and Chief Financial Officer, and Dr. Yoav Ben-Dror, the former director of the Company’s foreign subsidiaries (collectively, the “Note Holders”) in the principal amounts of $3,134, $978 and $1,515, respectively. The Payout Notes were due on October 12, 2018, carried a 10% interest rate, payable monthly in arrears commencing on December 1, 2017 (each such payment, a “Monthly Interest Payment” and each date of such payment, an “Interest Payment Date”), and were convertible into shares of the Company’s Common Stock at maturity. The Payout Notes were secured by a security interest in all of the properties, assets and personal property of the Company (the “Security Agreement”).
On December 22, 2017, the Company and the Note Holders entered into a stock grant agreement (the “Stock Grant Agreement”) to cause the early conversion of the Payout Notes into an aggregate of 5,628,291 shares of the Company’s Common Stock (the “Payout Shares”), valued at $5,626 based on the quoted share price in the market for our common stock on December 22, 2017, and to effectuate the release of all security interests associated with the Payout Notes.
Pursuant to the Stock Grant Agreement, the Company also agreed to provide for the issuance of an aggregate of 1,857,336 additional shares of Common Stock to the Note Holders as consideration for the various agreements of the Note Holders contained in the Stock Grant Agreement (the “Additional Shares”), subject to stockholder approval. In addition, as promptly as possible following entry into the Stock Grant Agreement, the Company is required to file a proxy statement and hold a special meeting of its stockholders to authorize and approve the issuance of the Additional Shares. As of December 31, 2017, a proxy statement was not filed, and special meeting of the stockholders has not been held. Therefore, during the year ended December 31, 2017, no expenses have been recorded in connection with the Additional Shares.
Pursuant to the Stock Grant Agreement, the Company also agreed to make 12 monthly payments on the first of each month commencing on January 1, 2018 in the amounts of $21, $7 and $10 to Messrs. Rafaeli, McGrath, and Ben-Dror, respectively (collectively, the “Cash Payments”). The Cash Payments equal to the interest payments that would have been made to the Note Holders absent the conversion of the Payout Notes and are consideration for certain consulting services provided by the Note Holders specified in the Stock Grant Agreement.
In addition, Dr. Dolev Rafaeli and Dennis M. McGrath resigned from the Board of Directors has authorized an additional $30 million share re-purchase program of its common sharesthe Company effective upon the last to occur of (i) receipt of all of the Payout Shares and all of the Additional Shares, (ii) receipt of all of the Cash Payments (either in accordance with the schedule provided in the open market overStock Grant Agreement or, at the next twelve months, at such timesCompany’s option, in one lump sum on an accelerated basis), and prices as determined appropriate by(ii) the Company's managementdate that the Payout Shares and the Additional Shares have been registered for re-sale in collaborationaccordance with the BoardPayout Registration Rights Agreement.
In connection with the Stock Grant Agreement, the Security Agreement was automatically terminated.
Shares to former Chief Executive Officer
On December 22, 2017, Mr. Suneet Singal resigned from his position as Chief Executive Officer of Directors. To date,the Company, effective as of January 2, 2018. In connection with such resignation, on December 22, 2017, the Company and Mr. Singal entered into a separation agreement (the “Agreement”), pursuant to which Mr. Singal agreed to resign and the Company agreed to issue to Mr. Singal 1,000,000 shares of the Company’s Common Stock, 333,333 shares of which will vest immediately, 333,333 shares of which will vest upon the first anniversary of the Agreement, and 333,334 shares of which will vest upon the second anniversary of the Agreement.
Since the aforesaid shares of common stock were agreed to have been granted to Mr. Singal as a result of his resignation from the Chief Executive Officer position and Mr. Singal has no obligation to render service in the future with respect to the additional Shares, the Company has repurchased 2,987,413recognized an amount of $910 as part of the general and administrative expenses in the consolidated statement of comprehensive loss. The amount was determined based on the quoted share price in the market as of the December 22, 2017.
Securities Purchase Agreement
On December 22, 2017, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Opportunity Fund I-SS, LLC, a Delaware limited liability company (the “Investor”), under which the Investor may, but is not obligated to, invest up to $15 million in the Company in a series of closings over a period prior to December 31, 2018, in exchange for which the Investor will receive shares of the Company’s newly designated Redeemable Convertible Series B Preferred Stock (“Series B Shares) at a purchase price of $1.00 per share (the “Option”).
On December 22, 2017 (the “Initial Date”), the Company and the Investor completed the first closing under the Purchase Agreement, pursuant to which the Investor exercised a portion of the Option and provided $1,500 to the Company in exchange for 1,500,000 shares of Series B Shares.
Proceeds from any subsequent closings must be used to invest in Income Generating Properties (as that term is defined in the Purchase Agreement) that have been approved by the Company’s Board of Directors or as otherwise agreed to between the Company and the Investor in writing prior to such subsequent closings.
Under ASC 480, “Distinguishing Liabilities from Equity” preferred stock that is not redeemable or is redeemable solely at the option of the issuer shall be included in stockholders’ equity. If the instrument meets any of the following criteria, mezzanine classification between liabilities and stockholders’ equity would be required:
| ■ | it is redeemable at a fixed or determinable price on a fixed or determinable date or dates |
| ■ | it is redeemable at the option of the holder; or |
| ■ | It has conditions for redemption which are not solely within the control of the issuer, such as stocks which must be redeemed out of future earnings |
In addition, per ASC 480, deemed liquidation events that require (or permit at the holders options) the redemption of only one or more of a particular class of equity instrument for cash or other assets cause those instruments to be considered contingently redeemable and therefore, subject to mezzanine classification.
Since the Series B Shares have conditional redemption provisions which are outside of the control of the Company and also contain a deemed liquidation preference, the Series B Shares were classified as mezzanine financing at their initial fair value at the Initial Date. Subsequent measurement is unnecessary if it is not probable that the instrument will become redeemable. If it is probable that the equity instrument will become redeemable the following measurement methods shall be applied in accordance with either of the following methods and shall be applied in a consistent manner:
| ■ | Accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument using an appropriate methodology, usually the interest method. Changes in the redemption value are considered to be changes in accounting estimates. |
| ■ | Recognize changes in the redemption value (for example, fair value) immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the instrument. |
Under ASC 480, the aforementioned written call Option is considered freestanding, as the Company believes it is legally detachable and separately exercisable. As the option is exercisable for shares subject to possible redemption at the option of the holder, as of the Initial Date, the Option was measured at fair value in total amount of $5,584 and recorded as a non-current financial liability on the consolidated balance sheet as of December 31, 2017. Excess of the initial value of the option liability over the proceeds received, amounting to $4,084, was charged immediately into the consolidated statement of comprehensive loss as financing expenses. As such, there were no residual proceeds to allocate to the Series B preferred shares at an average pricethe Initial Date.
The Option is marked to market in each reporting period when changes in the fair value of $13.98 per share for a totalthe Option are charged into statement of $41,757.
In addition, the Company has incurred direct and incremental issuance costs amounting to $42 which it sold an aggregatewere charged immediately into the consolidated statement of 3,023,432comprehensive loss as finance expenses, as the Option was presented at fair value at the Initial Date.
On December 22, 2017, each Series B Share was convertible into 1.24789 shares of its common stock valued at an offering price of $13.23$1.00 per share. The sale resulted in net proceedsAs a result, Beneficial Conversion Feature (the “BCF”) amounting to approximately $372 was measured assuming full conversion. However, the conversion of approximately $37.8 million. The netthe Preferred Stock is subject to certain contingencies, which impact the timing and amount of the BCF. As of December 31, 2017, the Company should record a BCF for the Preferred Stock for any shares convertible at that time without requiring stockholder approval through the planned proxy statement. However, as no residual proceeds were usedallocable to the Series B Shares, no BCF was recognized at December 31, 2017.
The fair value of the Option was based on management estimates and values derived from a calculation to provide an approximate indication of value. The fair value of Option was estimated at the Initial Date and December 31, 2017 by using hybrid method that includes scenario of conversion and scenario liquidation and the Black-Scholes option pricing model. In the first scenario, the Series B Preferred Stock price applied in the model was assumed based on the as-converted price on the date of estimation. Expected volatility was estimated by using a group of peers in the real estate development, homebuilding and income-producing properties sectors, and applying a 75% percentile ranking based on the total capitalization of the Company. In the second scenario, the option was estimated based on the value of the option in a proposed liquidation scenario. A probability weighting was applied to determine the expected value of the option.
The following are the key underlying assumptions that were used:
Option Value:
| December 22, 2017 | December 31, 2017 | |||||||
| Dividend yield (%) | 0 | 0 | ||||||
| Expected volatility (%) | 36.9 | 36.9 | ||||||
| Risk free interest rate (%) | 1.72 | 1.74 | ||||||
| Strike price | 1.00 | 1.00 | ||||||
| Series B Preferred Stock price | 1.24 | 1.13 | ||||||
| Probability of if-converted scenario (%) | 90 | 90 | ||||||
| Probability assumed liquidation scenario (%) | 10 | 10 | ||||||
| Expected term of Option (years) | 1.0 | 1.0 | ||||||
In the absence of voluntary conversion and assuming no breaches as described above under “Redemption”, the Series B Shares automatically convert on May 31, 2018. As such, accretion adjustments to the carrying amount of the Series B Shares to the automatic conversion date of May 31, 2018 are recorded as deemed dividends.
The table below summarizes the change in the mezzanine financing during the year ended December 31, 2017:
December 31, 2017 | ||||
| Opening balance | $ | — | ||
| Proceeds from issuance of Series B Shares | 1,500 | |||
| Recognition of written call Option as a discount of Series B Shares | (1,500 | ) | ||
| Amortization of discount | 84 | |||
| Accretion of cumulative dividend | 3 | |||
| Closing balance | $ | 87 | ||
In addition, upon the Purchase Agreement, the Company agreed the following:
| ■ | To nominate two directors to the Company’s Board of Directors upon request of the Investor (see also Note 17). |
| ■ | So long as the shares of Series B Shares purchased by the Investor are outstanding, the Company’s debt (as defined by U.S. generally accepted accounting principles) shall not exceed 45% of its fixed assets without the prior written consent of the Requisite Holders. As of December 31, 2017, the covenant has been met by the Company. |
| ■ | Subject to stockholder approval, to amend the Certificate of Designation for the Company’s Series A Shares to change the conversion price from $2.5183 to $1.12024 such that each share of Series A Share will be initially convertible into 56.2 shares of Common Stock instead of 25 shares of Common Stock. |
The above inducement is considered as modification for general corporate purposes, including capital expenditures, continued product development, sales and marketing initiatives and working capital.
As of December 31, 2017, the stockholders’ approval has not been taken place.
Common Stock Options
The Company has a Non-Employee Director Stock Option Plan. This plan has authorized 370,00074,000 shares; of which 7,0002,135 shares had been issued or were reserved for issuance as awards of shares of common stock, and 14,57812,079 shares were reserved for outstanding stock options. The directors, who were electedAs of December 31, 2017 the number of shares available for future issuance pursuant to our Board in connection with the reverse merger, each received a one-time stock award of 5,000 shares of the Company's common stock in January 2012.
In addition, the Company has a 2005 Equity Compensation Plan ("(“2005 Equity Plan"Plan”). The 2005 Equity Plan which has authorized 6,000,0001,200,000 shares, of which 1,576,095467,328 shares had been issued or were reserved for issuance as awards of shares of common stock, and 1,144,976143,815 shares were reserved for outstanding options.
A summary of stock option transactions for all ofunder the Company's stock optionsNon-Employee Director Stock Option Plan and the 2005 Equity Plan during the years ended December 31, 2014, 20132017 and 2012 follows:
| Number of Stock Options | Weighted Average Exercise Price | |
| Outstanding at December 31, 2011 | 180,718 | $ 19.54 |
| Granted | 739,000 | 15.87 |
| Exercised | (10,048) | 6.67 |
| Expired/cancelled | (11,129) | 20.25 |
| Outstanding at December 31, 2012 | 898,541 | 16.65 |
| Granted | 259,625 | 16.59 |
| Exercised | (3,750) | 6.24 |
| Expired/cancelled | (21,738) | 31.36 |
| Outstanding at December 31, 2013 | 1,132,678 | 16.51 |
| Granted | 181,500 | 14.10 |
| Exercised | - | - |
| Expired/cancelled | (154,624) | 15.73 |
| Outstanding at December 31, 2014 | 1,159,554 | $16.23 |
| Exercisable at December 31, 2014 | 510,954 | $16.47 |
| Number of Stock Options | Weighted Average Exercise Price | ||||||||
| Outstanding at December 31, 2015 | 150,138 | 67.99 | |||||||
| Granted | — | — | |||||||
| Exercised | — | — | |||||||
| Expired/cancelled | (15,988 | ) | 82.26 | ||||||
| Outstanding at December 31, 2016 | 134,150 | $ | 85.22 | ||||||
| Granted | — | — | |||||||
| Exercised | — | — | |||||||
| Expired/cancelled | (133,150 | ) | 91.43 | ||||||
| Outstanding at December 31, 2017 | 1,000 | $ | 75.00 | ||||||
| Exercisable at December 31, 2017 | 800 | $ | 75.00 | ||||||
Options Range of Exercise Prices | Outstanding Number of Shares | Weighted Average Remaining Contractual Life (years) | Weighted Average Exercise Price | Exercisable Number of Shares | Exercisable Weighted Avg. Exercise Price |
| $0 - $7.50 | 21,584 | 4.58 | $ 6.12 | 21,584 | $ 6.11 |
| $7.51 - $15.00 | 699,622 | 7.85 | $ 14.11 | 255,022 | $ 13.93 |
| $15.01 - $22.50 | 427,900 | 7.32 | $ 19.02 | 223,900 | $ 18.13 |
| $22.51- up | 10,448 | 1.56 | $ 64.42 | 10,448 | $ 64.42 |
| Total | 1,159,554 | 7.54 | $ 16.23 | 510,954 | $ 16.47 |
| Year Ending | Number of Shares | Weighted Average Exercise Price | Exercise Price |
| 2015 | 2,499 | $102.90 | $102.90 |
| 2016 | 2,634 | $ 69.48 | $48.72 - $93.66 |
| 2017 | 3,146 | $ 46.85 | $46.62 - $47.88 |
| 2018 | 2,169 | $ 39.41 | $37.80 - $39.90 |
| 2019 and later | 1,149,106 | $ 15.79 | $5.70 - $20.00 |
| 1,159,554 | $ 16.23 | $5.70 - $102.90 |
A summary of December 31, 2014 was $1.53, the aggregate intrinsic value for options outstanding and exercisable was immaterial.
| Year Ended December 31, | |||||
| 2014 | 2013 | 2012 | |||
| Risk-free interest rate | 2.17% | 1.3% | N/A | ||
| Volatility | 78.41% | 85.25% | N/A | ||
| Expected dividend yield | 0% | 0% | N/A | ||
| Expected life | 5.5 years | 5.5 years | N/A | ||
| Estimated forfeiture rate | 0% | 0% | N/A | ||
| Shares of restricted stock | Weighted Average Grant-Date Fair Value | ||||||||
| Non-vested at December 31, 2015 | 258,572 | 10.57 | |||||||
| Granted | — | — | |||||||
| Vested/cancelled | (129,211 | ) | 10.04 | ||||||
| Non-vested at December 31, 2016 | 129,361 | 11.11 | |||||||
| Granted | — | — | |||||||
| Vested/cancelled | (122,861 | ) | 14.69 | ||||||
| Non-vested at December 31, 2017 | 6,500 | 9.25 | |||||||
The Company has used historical data to estimate expected employee behaviorstotal equity-based compensation expense related to option exercises and forfeitures and included these expected forfeitures as a partall of the estimate of expense as of the grant date
At December 31, 2014,2017, there was $7,644$35 of total unrecognized compensation cost related to non-vested stock awards that isbased on their original vesting terms was expected to be recognized over a weighted-average period of 3.14.17 years.
F-39
Note 15
Income Taxes:
On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, reducing the U.S. federal corporate tax rate from 35 percent to 21 percent; eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized; creating a new limitation on deductible interest expense; changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 12, 2014,31, 2017; limitations on the deductibility of certain executive compensation.
In December 2017, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”), which addresses situations where the accounting is incomplete for the income tax effects of the Act. SAB 118 directs taxpayers to consider the impact of the Act as “provisional” when the Company issued separately detachable warrants to the shareholders participating in the raise at 0.50 per share acquired. The warrantsdoes not have the following principal terms: (i)necessary information available, prepared or analyzed (including computations) to finalize the accounting for the change in tax law. Companies are provided a warrant exercise price of $2.25 per share of common stock, (ii) an exercisemeasurement period of December 12, 2015 through December 12, 2017. The underlying warrants were registered via registration statement.
Number of Warrants | Weighted Average Exercise Price | |
| Outstanding at January 1, 2012 | 1,067,240 | $ 19.98 |
| Issued | 25,000 | 20.00 |
| Exercised | (17,756) | 7.50 |
| Expired/cancelled | (11,216) | 47.04 |
| Outstanding at December 31, 2012 | 1,063,268 | 19.91 |
| Issued | - | - |
| Exercised | - | - |
| Expired/cancelled | (4,589) | 18.48 |
| Outstanding at December 31, 2013 | 1,058,679 | 19.91 |
| Issued | 322,500 | 2.25 |
| Exercised | - | - |
| Expired/cancelled | - | - |
| Outstanding at December 31, 2014 | 1,381,179 | $ 15.79 |
With regards to the aggregate intrinsic value for warrants outstanding and exercisable was immaterial.
Year Ending December 31, | Number of Warrants | Weighted Average Exercise Price |
| 2015 | 32,250 | $ 17.19 |
| 2016 | 1,026,429 | 20.00 |
| 2017 | 322,500 | 2.25 |
| 1,381,179 | $15.79 |
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.
A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible. The benefit of tax positions taken or expected to be taken in the Company'sCompany’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained.
For the years ended December 31, 2014, 2013,2016, and 2012,2015, the following table summarizes the components of income before income taxes from continuing operations and the provision for income taxes:
Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Income (loss) before income tax: | ||||||||||||
| U.S. | $ | (25,398 | ) | $ | 7,700 | $ | 3,152 | |||||
| Israel | 1,780 | 14,279 | 20,410 | |||||||||
| Other Foreign | (1,813 | ) | 768 | 3,365 | ||||||||
| Income (loss) before income taxes | $ | (25,431 | ) | $ | 22,747 | $ | 26,927 | |||||
| Income tax expense (benefit): | ||||||||||||
| United States - Federal tax: | ||||||||||||
| Current | $ | (1,030 | ) | $ | (1,253 | ) | $ | 2,752 | ||||
| Deferred | 34,117 | 1,795 | (1,572 | ) | ||||||||
| United States - State tax: | ||||||||||||
| Current | 195 | 180 | 315 | |||||||||
| Deferred: | 245 | 850 | (2,074 | ) | ||||||||
| Israel: | ||||||||||||
| Current | 1,431 | 2,781 | 4,034 | |||||||||
| Deferred | (190 | ) | (237 | ) | (50 | ) | ||||||
| Other foreign: | ||||||||||||
| Current | 81 | 54 | 1371 | |||||||||
| Deferred: | 1,463 | 200 | (338 | ) | ||||||||
| Income tax expense | $ | 36,312 | $ | 4,370 | $ | 4,438 | ||||||
| Year Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Loss from continuing operations before income tax: | ||||||||
| U.S. | $ | (15,684 | ) | $ | — | |||
| Israel | (453 | ) | — | |||||
| UK | (219 | ) | — | |||||
Loss from continuing operations before income taxes | $ | (16,356 | ) | $ | — | |||
| Income tax expense (benefit): | ||||||||
| United States - Federal tax: | ||||||||
| Current | $ | — | $ | — | ||||
| Deferred | — | — | ||||||
| United States - State tax: | ||||||||
| Current | — | — | ||||||
| Deferred: | — | — | ||||||
| Israel: | ||||||||
| Current | — | — | ||||||
| Deferred | — | |||||||
| UK: | ||||||||
| Current | — | — | ||||||
| Deferred | — | — | ||||||
| Other foreign: | ||||||||
| Current | — | — | ||||||
| Deferred: | — | — | ||||||
| Income tax expense (benefit) | $ | — | $ | — | ||||
For the years ended December 31, 2014, 20132017 and 2012,2016, the following table reconciles the federal
| Year Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Federal Tax rate | 34 | % | 34 | % | ||||
| Federal tax expense (benefit) at 34% | $ | (5,562 | ) | $ | — | |||
| State and local income tax, net of Federal benefit | (271 | ) | — | |||||
| Foreign rate differential | 519 | — | ||||||
| Increase in taxes from permanent differences in stock-based compensation | 333 | — | ||||||
| Increase in taxes from permanent difference in Intangible asset impairment | — | — | ||||||
| US taxation of foreign earnings – Subpart F | — | — | ||||||
| Return to provision and other adjustments | 289 | — | ||||||
| Impact of deferred tax adjustments | — | — | ||||||
| Federal Tax reform | 17,192 | — | ||||||
| Change in valuation allowance | (12,500 | ) | — | |||||
| Income tax expense (benefit) | $ | — | $ | |||||
Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| Federal Tax rate | 34 | % | 34 | % | 34 | % | ||||||
| Federal tax expense (benefit) at 34% | $ | (9,349 | ) | $ | 7,733 | $ | 9,157 | |||||
| State and local income tax, net of Federal benefit | 373 | 958 | 286 | |||||||||
| Foreign rate differential | (483 | ) | (2,404 | ) | (3,962 | ) | ||||||
| Increase in taxes from permanent differences in stock-based compensation | 330 | 420 | 618 | |||||||||
| US taxation of foreign earnings – Subpart F | 11,571 | 357 | 403 | |||||||||
| Increase (decrease) in uncertain tax positions | - | 269 | (2,325 | ) | ||||||||
| Return to provision and other adjustments | 301 | (1,963 | ) | - | ||||||||
| Impact of tax rate change on deferred taxes | 724 | (942 | ) | - | ||||||||
| Foreign tax credits | (7,041 | ) | (341 | ) | - | |||||||
| Tax on foreign exchange | 1,578 | - | - | |||||||||
| Tax on undistributed earnings | 3,333 | - | - | |||||||||
| Change in valuation allowance | 34,695 | 116 | - | |||||||||
| Other, net | 280 | 167 | 261 | |||||||||
| Income tax expense | $ | 36,312 | $ | 4,370 | $ | 4,438 | ||||||
As of December 31, 2014,2017, the Company had approximately $48$125 million of Federal net operating loss carryforwards in the United States. Other tax attributes in the United States and their approximate amounts include: State NOLs - $3.2 million; foreign tax credits -$7.1 million; and, AMT tax credits – $0.1 million. A 100% valuation allowance has been recorded against these tax attributes and the net deferred tax assets of the U.S. group of companies. The net deferred tax assets – liabilities of the U.S. companies is reduced to zero (0). Based on current operating conditions and the availability of projected future sources of taxable income, the Company determined that it was not more likely than not that the net deferred tax assets of the U.S. companies would be realized in the future. The StateFederal NOLs expire generally from 20172022 to 2034.
After conversion to U.S. dollars, Photo Therapeutics Limited had approximately $11$12.8 million of net operating loss carryforwards in the U.K. A 100% valuation allowance of approximately $7 million has been applied against these losses. Additionally, NOLs have been recorded in Brazil, Colombia, India, and Korea. The Brazilian NOL is approximately $1.7 million. The individual NOLs of the other companies are less than $0. 1 million. All these NOLs have a 100% valuation allowance recorded.
The following table summarizes the components of deferred income tax assets and (liabilities):
| December 31, | ||||||||
| 2014 | 2013 | |||||||
| Loss carryforwards | $ | 39,217 | $ | 21,092 | ||||
| AMT credits | 112 | 112 | ||||||
| Foreign tax credits | 7,066 | - | ||||||
| Accrued employment expenses | 1,785 | 1,256 | ||||||
| Amortization and write-offs | 9,480 | 8,883 | ||||||
| Capitalized R&D costs | 2,663 | 2,933 | ||||||
| Deferred revenues | - | 84 | ||||||
| Depreciation | 2,022 | 4,360 | ||||||
| Doubtful accounts | 4,177 | 3,499 | ||||||
| Inventory reserves | 1,030 | 822 | ||||||
| Tax on undistributed earnings | (3,333 | ) | - | |||||
| Other accruals and reserves | 324 | 228 | ||||||
| Return allowances | 2,787 | 5,660 | ||||||
| Translation adjustments | (44) | 61 | ||||||
| Gross deferred tax asset | 67,286 | 48,990 | ||||||
| Less: valuation allowance | (65,957 | ) | (11,910 | ) | ||||
| Net deferred tax asset | $ | 1,329 | $ | 37,080 | ||||
| Among current assets | $ | 762 | $ | 13,041 | ||||
| Among other non-current assets | 567 | 24,039 | ||||||
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Loss carryforwards | $ | 29,693 | $ | 30,770 | ||||
| AMT credits | 112 | 112 | ||||||
| Foreign tax credits | 12,308 | 12,308 | ||||||
| Accrued employment expenses | 11 | 2,652 | ||||||
| Amortization and write-offs | 875 | 1,299 | ||||||
| Capitalized R&D costs | 1,013 | 1,342 | ||||||
| Deferred revenues | — | 6,263 | ||||||
| Depreciation | 635 | 1,224 | ||||||
| Doubtful accounts | — | 225 | ||||||
| Inventory reserves | — | 459 | ||||||
| Tax on undistributed earnings | (517 | ) | (517 | ) | ||||
| Other accruals and reserves | 1,571 | 602 | ||||||
| Return allowances | — | 456 | ||||||
| Gross deferred tax asset | 45,701 | 57,195 | ||||||
| Less: valuation allowance | (45,701 | ) | (57,195 | ) | ||||
| Net deferred tax asset | $ | — | $ | — | ||||
| Among other non-current liabilities | — | — | ||||||
Taxes, which may apply in the event of a disposal of investments in subsidiaries, have not been included in computing the deferred taxes, as the Company anticipates it would liquidate those subsidiaries that can be closed on a tax free basis
FC Global Realty Inc. (formerly PhotoMedex, Inc.) files corporate income tax returns in the United States, both in the Federal jurisdiction and in various State jurisdictions. The Company is subject to Federal income tax examination for calendar years 20112014 through 20132017 and is also generally subject to various State income tax examinations for calendar years 20062014 through 2013.2017. Photo Therapeutics Limited files in the United Kingdom. Radiancy (Israel) Limited files in Israel. The Israeli subsidiary is subject to tax examination for calendar years 20112013 through 2013.
The Israeli subsidiary is entitled to reduced tax rates regarding income that is subject to tax pursuant to the "approved enterprise"“approved enterprise” until end of year 2012 and "preferred enterprise"“preferred enterprise” from year 2013. Other income is subject to the regular corporate income tax rate. For the year 20142015 and thereafter, all income isin Israel was taxed at the regular corporate income tax rate.
Change in Israel rates. Effective for tax periods beginning 1 January 2014, the standard corporate income tax rate was increased from 25% to 26.5% and preferred income tax rate (for preferred enterprise located in an area which is not development zone A) was increased to 16%.
Change in U.K. rates.In addition, effective for tax periods beginning on April 1, 2013,2014, the United Kingdom tax rate was reduced from 24% to 23%. A reduction from 23% to 21% was effective on April 1, 2014.. A further enacted decrease in the tax rate to 21% and 20% will taketook effect on April 1, 2015. The rate further reduced to 19% effective April 1, 2017. These changes in rate will affect the tax provision with regard to the tax attributes of Photo Therapeutics Limited, the United Kingdom subsidiary.
Unrecognized Tax Benefits.The Company is subject to income taxation in the U.S., Israel, the U.K., Brazil, Colombia, Hong Kong, India and The Republic of Korea. Colombia. Unrecognized tax benefits reflect the difference between positions taken or expected to be taken on income tax returns and the amounts recognized in the financial statements. Resolution of the related tax positions through negotiations with the relevant tax authorities or through litigation could take years to complete. It is difficult predict the timing of resolution for tax positions since such timing is not entirely within the control of the Company. It is reasonably possible that the total amount of unrecognized tax benefits could both increase and decrease in the next 12 months, with no material impact on earnings.
The Company and its subsidiaries file income tax returns in all of the countries listed above.
Management conducted an analysis of the facts and law surrounding the then existing income tax uncertainties, and found that such liability as may have arisen was of a much lesser magnitude and is able to be extinguished by loss carryforwards and carrybacks,
Reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
| Balance at January 1, 2012 | $ | 2,700 | ||
| Additions / Settlements during 2012 | (2,325 | ) | ||
| Balance December 31, 2012 | 375 | |||
| Additions/ Settlements due 2013 | 269 | |||
| Balance at December 31, 2013 | 644 | |||
| Additions / Settlements due 2014 | - | |||
| Balance at December 31, 2014 | $ | 644 | ||
| Balance at December 31, 2015 | $ | 1,921 | ||
| Additions / Settlements due 2016 | — | |||
| Balance at December 31, 2016 | $ | 1,921 | ||
| Additions / Settlements due 2017 | — | |||
| Balance at December 31, 2017 | $ | 1,921 |
Note 14
Significant Customer Concentration:
No single customer accounted for more than 10% of total company revenues of discontinued operations for the years ended December 31, 2014, 20132017 and 2012.
| CONSUMER | PHYSICIAN RECURRING | PROFESSIONAL | TOTAL | |||||||||||||
| Revenues | $ | 120,931 | $ | 34,240 | $ | 8,370 | $ | 163,541 | ||||||||
| Costs of revenues | 20,307 | 12,718 | 5,594 | 38,619 | ||||||||||||
| Gross profit | 100,624 | 21,522 | 2,776 | 124,922 | ||||||||||||
| Gross profit % | 83.2 | % | 62.9 | % | 33.2 | % | 76.4 | % | ||||||||
| Allocated operating expenses: | ||||||||||||||||
| Engineering and product development | 1,105 | 1,177 | 804 | 3,086 | ||||||||||||
| Selling and marketing expenses | 89,637 | 16,347 | 1,185 | 107,169 | ||||||||||||
| Unallocated operating expenses | - | - | - | 35,711 | ||||||||||||
| 90,742 | 17,524 | 1,989 | 145,966 | |||||||||||||
| Income (loss) from continuing operations | 9,882 | 3,998 | 787 | (21,044 | ) | |||||||||||
| Interest and other financing expense, net | - | - | - | (4,387 | ) | |||||||||||
| Income (loss) from continuing operations before taxes | $ | 9,882 | $ | 3,998 | $ | 787 | $ | (25,431 | ) | |||||||
| CONSUMER | PHYSICIAN RECURRING | PROFESSIONAL | TOTAL | |||||||||||||
| Revenues | $ | 188,259 | $ | 28,548 | $ | 7,857 | $ | 224,664 | ||||||||
| Costs of revenues | 26,794 | 13,022 | 5,219 | 45,035 | ||||||||||||
| Gross profit | 161,465 | 15,526 | 2,638 | 179,629 | ||||||||||||
| Gross profit % | 85.8 | % | 54.4 | % | 33.6 | % | 80.0 | % | ||||||||
| Allocated operating expenses: | ||||||||||||||||
| Engineering and product development | 1,100 | 1,371 | 835 | 3,306 | ||||||||||||
| Selling and marketing expenses | 112,898 | 12,681 | 1,949 | 127,528 | ||||||||||||
| Unallocated operating expenses | - | - | - | 26,750 | ||||||||||||
| 113,998 | 14,052 | 2,784 | 157,584 | |||||||||||||
| Income (loss) from operations | 47,467 | 1,474 | (146 | ) | 22,045 | |||||||||||
| Interest and other financing income, net | - | - | - | 702 | ||||||||||||
| Net income (loss) before taxes | $ | 47,467 | $ | 1,474 | $ | (146 | ) | $ | 22,747 | |||||||
| CONSUMER | PHYSICIAN RECURRING | PROFESSIONAL | TOTAL | |||||||||||||
| Revenues | $ | 188,425 | $ | 21,284 | $ | 10,942 | $ | 220,651 | ||||||||
| Costs of revenues | 28,965 | 11,512 | 6,165 | 46,642 | ||||||||||||
| Gross profit | 159,460 | 9,772 | 4,777 | 174,009 | ||||||||||||
| Gross profit % | 84.6 | % | 45.9 | % | 43.7 | % | 78.9 | % | ||||||||
| Allocated operating expenses: | ||||||||||||||||
| Engineering and product development | 876 | 1,201 | 837 | 2,914 | ||||||||||||
| Selling and marketing expenses | 102,736 | 10,203 | 3,548 | 116,487 | ||||||||||||
| Unallocated operating expenses | - | - | - | 27,330 | ||||||||||||
| 103,612 | 11,404 | 4,385 | 146,731 | |||||||||||||
| Income (loss) from operations | 55,848 | (1,632 | ) | 392 | 27,278 | |||||||||||
| Interest and other financing expense, net | - | - | - | (351 | ) | |||||||||||
| Net income (loss) before taxes | $ | 55,848 | $ | (1,632 | ) | $ | 392 | $ | 26,927 | |||||||
| Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
North America 1 | $ | 123,161 | $ | 174,850 | $ | 163,973 | ||||||
Asia Pacific 2 | 9,870 | 19,081 | 28,031 | |||||||||
| Europe (including Israel) | 29,227 | 27,849 | 25,521 | |||||||||
| South America | 1,283 | 2,884 | 3,126 | |||||||||
| $ | 163,541 | $ | 224,664 | $ | 220,651 | |||||||
1 United States | $ | 109,203 | $ | 149,713 | $ | 135,950 | ||||||
1 Canada | $ | 13,953 | $ | 25,137 | $ | 28,023 | ||||||
2 Japan | $ | 1,750 | $ | 12,226 | $ | 21,134 | ||||||
| Year Ended December 31, | ||||||||||||
| 2014 | 2013 | 2012 | ||||||||||
| North America | $ | 12,385 | $ | 9,119 | $ | 5,772 | ||||||
| Asia Pacific | 286 | - | - | |||||||||
| Europe (including Israel) | 1,127 | 1,370 | 987 | |||||||||
| South America | 4 | - | - | |||||||||
| $ | 13,802 | $ | 10,489 | $ | 6,759 | |||||||
| For the Quarter Ended | ||||||||||||||||
| 2014 | Mar. 31 | Jun. 30* | Sep. 30* | Dec. 31 | ||||||||||||
| Revenues | $ | 50,075 | $ | 38,977 | $ | 35,611 | $ | 38,878 | ||||||||
| Gross profit | 39,730 | 30,208 | 26,896 | 28,088 | ||||||||||||
| Net loss | (345 | ) | (7,480 | ) | (14,943 | ) | (98,726 | ) | ||||||||
| Net loss per share: | ||||||||||||||||
| Basic | $ | (0.02 | ) | $ | (0.40 | ) | $ | (0.80 | ) | $ | (5.20 | ) | ||||
| Diluted | $ | (0.02 | ) | $ | (0.40 | ) | $ | (0.80 | ) | $ | (5.20 | ) | ||||
| Shares used in computing net loss per share: | ||||||||||||||||
| Basic | 18,719,419 | 18,723,484 | 18,724,419 | 19,041,451 | ||||||||||||
| Diluted | 18,719,419 | 18,723,484 | 18,724,419 | 19,041,451 | ||||||||||||
| 2013 | Mar. 31 | Jun. 30 | Sep. 30 | Dec. 31 | ||||||||||||
| Revenues | $ | 57,216 | $ | 58,065 | $ | 45,893 | $ | 63,490 | ||||||||
| Gross profit | 45,350 | 46,675 | 36,827 | 50,777 | ||||||||||||
| Net income | 7,212 | 7,094 | 886 | 3,185 | ||||||||||||
| Net income per share: | ||||||||||||||||
| Basic | $ | 0.35 | $ | 0.34 | $ | 0.04 | $ | 0.16 | ||||||||
| Diluted | $ | 0.34 | $ | 0.34 | $ | 0.04 | $ | 0.16 | ||||||||
| Shares used in computing net income per share: | ||||||||||||||||
| Basic | 20,678,023 | 20,573,048 | 19,982,967 | 19,400,341 | ||||||||||||
| Diluted | 21,147,583 | 21,033,349 | 20,441,262 | 19,602,611 | ||||||||||||
| 2012 | Mar. 31 | Jun. 30 | Sep. 30 | Dec. 31 | ||||||||||||
| Revenues | $ | 50,273 | $ | 58,906 | $ | 56,681 | $ | 54,791 | ||||||||
| Gross profit | 39,039 | 46,551 | 45,400 | 43,019 | ||||||||||||
| Net income | 4,857 | 4,213 | 7,525 | 5,894 | ||||||||||||
| Net income per share: | ||||||||||||||||
| Basic | $ | 0.26 | $ | 0.20 | $ | 0.35 | $ | 0.28 | ||||||||
| Diluted | $ | 0.26 | $ | 0.20 | $ | 0.35 | $ | 0.27 | ||||||||
| Shares used in computing net income per share: | ||||||||||||||||
| Basic | 18,339,977 | 20,547,244 | 21,205,675 | 20,947,985 | ||||||||||||
| Diluted | 18,876,163 | 21,034,814 | 21,752,845 | 21,356,819 | ||||||||||||
Note 17
| Additions Charged to | ||||||||||||||||||||
Description | Balance at Beginning of Period | Cost and Expenses | Other Accounts | Deductions (1) | Balance at End of Period | |||||||||||||||
For The Year Ended December 31, 2014: | ||||||||||||||||||||
| Allowance for Doubtful Accounts | $ | 10,734 | $ | 7,661 | $ | - | $ | (4,836 | ) | $ | 13,559 | |||||||||
| Allowance for Sales Returns | $ | 16,046 | $ | 35,771 | $ | - | $ | (44,166 | ) | $ | 7,651 | |||||||||
For The Year Ended December 31, 2013: | ||||||||||||||||||||
| Allowance for Doubtful Accounts | $ | 6,917 | $ | 5,958 | $ | - | $ | (2,141 | ) | $ | 10,734 | |||||||||
| Allowance for Sales Returns | $ | 11,901 | $ | 47,916 | $ | - | $ | (43,771 | ) | $ | 16,046 | |||||||||
For The Year Ended December 31, 2012: | ||||||||||||||||||||
| Allowance for Doubtful Accounts | $ | 3,196 | $ | 4,629 | $ | - | $ | (908 | ) | $ | 6,917 | |||||||||
| Allowance for Sales Returns | $ | 6,143 | $ | 43,284 | $ | - | $ | (37,526 | ) | $ | 11,901 | |||||||||
Subsequent Events:
Second Closing under Securities Purchase Agreement
On January 31, 2015,24, 2018, the Company and its subsidiary LCA-Vision Inc. ("LCA")the Investor, as discussed in Note 13, completed a second closing under the Purchase Agreement, pursuant to which the Investor provided $2,225 to the Company in exchange for 2,225,000 shares of the Company’s Series B Preferred Stock. The issuance of these securities was made in reliance upon an exemption from the registration requirements of Section 5 of the Securities Act of 1933, as amended. The proceeds from this closing shall be used to perform due diligence and invest in Income Generating Properties (as defined in the Purchase Agreement) that have been approved by the Company’s Board of Directors.
Amended and Restated Separation Agreement
On February 12, 2018, the Company entered into a Stock Purchasean Amended and Restated Separation Agreement (the "Stock Purchase Agreement") with Vision Acquisition, LLC ("Vision"“Restated Agreement”), pursuant to which the Company has agreed to pay Mr. Stephen Johnson, its former Chief Financial officer, an amount of $123 in 11 installments as follows: the first 6 installments of $10 each, and the following five installments of $12.5 each. The first payment was made on February 15, 2018, and subsequent payments are to be made on or before the 15th day of each succeeding month, with the final installment to be paid on or before December 15, 2018. The Company will also provide a health (medical, dental and/or vision) insurance reimbursement payment for Mr. Johnson and his family, for a period of 11 months, in the agreed upon amount of $3 per month.
In addition, the Company has agreed to issue to Mr. Johnson 271,000 shares of the Company’s common stock, subject to appropriate adjustment for any stock splits, stock or business combinations, recapitalizations or similar events occurring after the date of the Restated Agreement. Those shares will be issued on any business day during the period commencing on the date that is six months after the date of the Restated Agreement and ending on the date that is three business days after such six-month anniversary.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
On February 20, 2018, the Company received written notification (the “Notice”) from Nasdaq that the closing bid price of its common stock had been below the minimum $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the requirements for continued listing on Nasdaq under which Vision acquired LCA andNasdaq Marketplace Rule 5550(a)(2). The Notice provides the Company with an initial period of 180 calendar days, or until August 19, 2018, to regain compliance with the listing rules. The Company will regain compliance if the closing bid price of its subsidiariescommon stock is $1.00 per share or higher for a minimum period of ten consecutive business days during this compliance period, as confirmed by written notification from Nasdaq.
If the Company does not achieve compliance by August 19, 2018, the Company expects that Nasdaq would provide notice that its securities are subject to delisting from the Company for a total purchase priceCapital Market.
Departure and Election of $40 million in cash (the "Purchase Price"). After giving effect to working capital and indebtedness adjustments andcertain Directors
Effective March 4, 2018, Suneet Singal, the paymentCompany’s former Chief Executive Officer, has resigned from the Company’s Board of professional fees,Directors. In addition, effective March 5, 2018, Darrel Menthe has also resigned from the Company realized net proceedsCompany’s Board of approximately $36.5 million from this sale, of which $2 million was placed in escrow. The Company had originally purchased LCA in a stock-for- cash transaction which closed on May 12, 2014. Pursuant to the Termination of Joinder, dated as of January 31, 2015, LCA has been released from all of its obligations, including its guarantee and collateral obligations,Directors. Their resignations were not in connection with the Company's Credit Agreement, dated as of May 12, 2014 (as amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), by and betweenany known disagreement with the Company JPMorgan Chase Bank, N.A., as Administrative Agent, First Niagara Bank, N.A. and PNC Bank, National Association, each as Co-Syndication Agents, J.P. Morgan Securities LLC, as Lead Arranger and Bookrunner, and the other Lenders party thereto. The Company has used the proceeds from this transaction to pay down portions of its outstanding revolving line of credit and term loan under the Credit Agreement.
Under the termsprovisions of the Stock Purchase Agreement LCA anddated December 22, 2017 (see also Note 14), Opportunity Fund I-SS, LLC has notified the Company must obtain consentsthat it may exercise its right to appoint two replacement directors to the transactionCompany’s Board of Directors.
Letter Agreement with OFI
Under the Purchase Agreement, the proceeds from certainthe first closing were to be used for working capital and general corporate purposes, the proceeds from the second closing were to be used to perform due diligence and invest in Income Generating Properties (as defined in the Purchase Agreement) that have been approved by the Board of LCA's vendors; a designated portionDirectors of the Escrow Amount will be released to the Company upon the receipt of each consent. If a consent is not obtained, a designated portion of the Escrow Amount may be released to Vision.
On March 16, 2018, the Company and OFI entered into a letter agreement, pursuant to payment of deferred bonuseswhich OFI agreed that the Company may use all proceeds for the purposes and uses described in a budget agreed to between the Company and OFI at the time the letter agreement was signed. In connection with such letter agreement, the terminationCompany agreed to provide OFI, on a quarterly basis, on or prior to 15 days after the end of their employment.each quarter, a report that describes, in reasonable detail, the actual expenses incurred, and payments made during such period compared to the expenses and payments specified in the budget for such period, certified by the Chief Financial Officer of the Company.
SIGNATURES
Pursuant to the requirements of section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: April 2, 2018 | FC GLOBAL REALTY INCORPORATED |
| /s/ Vineet P. Bedi | |
| Name: Vineet P. Bedi | |
| Title: Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date | ||
| /s/ Vineet P. Bedi | Chief Executive Officer (Principal Executive Officer) | April 2, 2018 | ||
| Vineet P. Bedi | ||||
| /s/ Matthew Stolzar | Chief Financial Officer (Principal Financial and Accounting Officer) | April 2, 2018 | ||
| Matthew Stolzar | ||||
| /s/ Dr. Bob Froehlich | Chairman of the Board of Directors | April 2, 2018 | ||
| Dr. Bob Froehlich | ||||
| /s/ Richard J. Leider | Director | April 2, 2018 | ||
| Richard J. Leider | ||||
| /s/ Dennis M. McGrath | Director | April 2, 2018 | ||
| Dennis M. McGrath | ||||
| /s/ Dr. Dolev Rafaeli | Director | April 2, 2018 | ||
| Dr. Dolev Rafaeli | ||||
| /s/ Michael R. Stewart | Director | April 2, 2018 | ||
| Michael R. Stewart |
F-47